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Abbreviations 
αSMA alpha smooth muscle actin 
Ab antibody 
AHA American Heart Association 
ApoE-/- apolipoprotein E knockout 
BMP bone morphogenic protein 
BSA bovine serum albumin 
CD40L CD40 ligand 
cDNA complimentary DNA 
CHX cycloheximide 
DAPI 4’,6-diamidino-2-phenylindole 
DiI 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate 
DNA deoxyribonucleic acid 
EC endothelial cell 
ECM extracellular matrix 
ELISA enzyme-linked immunosorbent assay 
EST expressed sequence tag  
FACS fluorescence-activated cell sorting 
FasL Fas ligand 
FGF fibroblast growth factor 
HDL high density lipoprotein 
HE hematoxylin and eosin 
HMGB1 high mobility group box 1 
IFNγ interferon gamma 
IL interleukin 
IVUS intravascular ultrasound 
LDL low density lipoprotein 
LDLR-/- low density lipoprotein receptor knockout 
mAb monoclonal antibody 
MAPP microarray pathway profiles 
MCP monocyte chemoattractant protein 
MGP matrix Gla protein 
MI myocardial infarction 
MMP matrix metalloproteinase 
MRI magnetic resonance imaging 
MSB martius, scarlet and blue 
NC normal chow 
NFκB nuclear factor kappa B 
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OC osteocalcin 
ON osteonectin 
OPG osteoprotegerin 
OPGL osteoprotegerin ligand 
OPN osteopontin 
oxLDL oxidized low density lipoprotein 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
RANTES regulated on activation normal T cell expressed and secreted 
RNA ribonucleic acid 
RT-PCR reverse transcriptase polymerase chain reaction 
SMC smooth muscle cell 
SR-BI scavenger receptor class B type I 
TGFβ transforming growth factor beta 
TIMP tissue inhibitor of matrix metalloproteinase 
TNF tumour necrosis factor 
TPLSM two-photon laser scanning microscopy 
TRAF TNF receptor-associated factor 
TUNEL terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling 
TWEAK tumour necrosis factor-like weak inducer of apoptosis 
VCAM vascular cell adhesion molecule 
VEGF vascular endothelial growth factor 
VLA very late antigen 
WD western-type diet 
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Clinical Relevance 
Cardiovascular disease is the leading cause of death and disability in western soci‐
ety and is increasing rapidly in the developing world.1 An underlying cause of car‐
diovascular disease  is atherosclerosis, a disease of  the  large and medium‐sized ar‐
teries characterized by  fatty deposits  that develop  in  the  inner  lining of  the vessel 
wall. Atherosclerosis  is  a progressive disease  that  begins  as  early  as  infancy  and 
becomes clinically relevant in the adult affecting different organ systems depending 
on  the artery affected.2 Luminal narrowing of an artery due  to  lesion progression 
can  impair blood flow  to  target organs, especially during exertion when metabolic 
activity and oxygen demand are increased. In the coronary and cerebral circulation 
this can lead to angina pectoris or transient ischemic attack, respectively. The renal 
arteries,  lower  extremities  and  abdominal  aorta  are  also  frequently  affected  by 
atherosclerosis  resulting  in  renal  failure,  claudication, and  limb‐threatening  ische‐
mia.3 Common acute manifestations of atherosclerosis are myocardial  infarction or 
stroke as a result of complete vessel occlusion caused by the formation of a throm‐
bus over an underlying atherosclerotic plaque. 
Pathogenesis of Atherosclerosis 
A widely accepted hypothesis of  the  initiation of atherosclerosis  is the response  to 
injury  theory,  which  proposes  that  endothelial  dysfunction  in  the  arterial  wall 
causes  an  inflammatory  and  fibroproliferative  response.4  Endothelial  dysfunction 
can be caused by various factors such as hyperlipidemia, hyperglycemia, infectious 
agents,  and  toxins.5  The  injured  site  is  characterized  by  increased  adhesion  and 
permeability of endothelial cells (EC) leading to an accumulation of lipoproteins in 
the  intima of  the vascular wall. An  inflammatory  response  ensues as  chemokines 
released by ECs recruit circulating monocytes and T lymphocytes that infiltrate the 
intima.6  Extravasated monocytes  differentiate  into macrophages  as  they  take  up 
modified  lipids such as oxidized  low density  lipoprotein (oxLDL) thereby forming 
the characteristic foam cells of early lesions.  The inflammatory response is perpetu‐
ated  as macrophages  release  cytokines  and  growth  factors  that  activate  vascular 
smooth muscle cells  (SMC) residing  in  the media  to proliferate and migrate  to  the 
intima. SMCs synthesize components of extracellular matrix (ECM) such as collagen 
resulting in the formation of a fibrous cap that covers the lesion. Progression to ad‐
vanced  lesions occurs as macrophage  foam cells release  their  lipid content  leading 
to  the development of a necrotic core. When  lesions are disrupted and  the  fibrous 
cap loses its integrity, the highly thrombogenic necrotic core is exposed and comes 
in  contact with  blood  prompting  the  formation  of  a  thrombus  that  overlies  the 
plaque. If the thrombus  is  large enough, this can  lead to complete occlusion of the 
vessel  resulting  in an acute clinical event. Fibrotic  lesions or  those with a  thick  fi‐
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brous cap are generally considered stable, whereas those with a thin fibrous cap, 
large lipid core, and inflammation in the shoulder region are considered unstable 
and at risk for thrombus formation.7 
Hypothesis 
Because atherosclerosis is a complex multifactorial disease, identification of poten-
tial mediators at various stages is key in gaining insight into the atherogenic process. 
Once mediators are identified, they can be manipulated in animal models of athero-
sclerosis such that their effects are either inhibited or enhanced in an attempt to 
promote stability in lesions. We hypothesized that in a mouse model of atheroscle-
rosis, the apolipoprotein E-deficient mouse (ApoE-/-), the various stages of athero-
genesis are accompanied by a specific expression patterns of genes. To test this hy-
pothesis, we used microarray technology to analyze gene expression in the various 
stages of atherosclerosis in ApoE-/- mice. The gene expression profile during plaque 
progression revealed upregulation of genes involved in inflammation, namely the 
small inducible cytokines, as well as genes involved in matrix degradation. We fur-
ther hypothesized that inhibition of the small inducible cytokines would reduce 
atherosclerosis and lead to a stable plaque phenotype. 
 Besides gene expression profiling using microarray technology, novel mediators 
involved in atherosclerosis as well as new potential targets of intervention may be 
found in the literature. Examples are very late antigen-1 (VLA-1) and tumour necro-
sis factor-like weak inducer of apoptosis (TWEAK), which have previously been 
shown to play a role in fibrosis and inflammation. Given that atherosclerosis is an 
inflammatory disease, the role of VLA-1 and TWEAK was investigated in the pre-
sent thesis in ApoE-/- mice. We hypothesized that inhibition of VLA-1 and TWEAK 
would reduce atherosclerosis and induce a stable plaque phenotype. 
 Processes that promote atherosclerotic development and progression such as 
angiogenesis may also be targeted in an attempt to induce stable lesions. We hy-
pothesized that inhibiting angiogenesis would reduce atherosclerosis in an ApoE-/- 
mouse model. 
Outline of this Thesis 
In this thesis, we identify and describe the role of several mediators of atherosclero-
sis in ApoE-/- mice. First, in chapter 2, the various animal models of atherosclerosis, 
particularly those used in the study of unstable lesions are reviewed and evaluated. 
In chapter 3, we identify the gene expression profile during atherosclerotic plaque 
progression in ApoE-/- mice and reveal a role for small inducible cytokines such as 
monocyte chemoattractant protein-1 (MCP-1). In chapter 4, we describe the effects of 
Chapter 1 
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treatment with the angiogenesis inhibitors anginex and endostatin on atheroscle-
rotic plaque development in the ApoE-/- mouse model of collar-induced atheroscle-
rosis. In chapter 5, the role of VLA-1 is described in atherosclerotic development in 
ApoE-/- mice. Similarly, in chapter 6, the role of the multifactorial cytokine TWEAK 
is described in atherosclerotic development in ApoE-/- mice. Lastly, in chapter 7, the 
findings in this thesis are discussed and future directions are given. 
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Abstract 
The need to identify and characterize vulnerable atherosclerotic lesions in humans 
has lead to the development of various animal models of plaque vulnerability. In 
this review, current concepts of the vulnerable plaque as it leads to an acute coro-
nary event are described, such as plaque rupture, erosion, intraplaque hemorrhage, 
and neovascularization. Recently developed animal models that have attempted to 
reproduce these concepts are described and evaluated based on their suitability in 
the study of vulnerable plaques. Although certain features of plaque vulnerability 
have been reported in animal models, a model encompassing all aspects of the vul-
nerable plaque is lacking. 
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Definition of a Vulnerable Plaque 
The definition of a “vulnerable” plaque varies among literature and is constantly 
being revised as clinicians and investigators gain more insight into the pathobiology 
of atherosclerosis and the conditions that lead to acute coronary events and stroke. 
Until about 10 years ago it was thought that atherosclerosis was a process in which 
lesions progressed to the point of complete arterial stenosis thereby leading to an 
acute coronary event.1 It is now accepted that most clinical manifestations of athero-
sclerosis such as acute myocardial infarction (MI), unstable angina, and sudden car-
diac death result from the development of an occlusive thrombus over an underly-
ing plaque.2 Vulnerable plaques are most often described as prone to thrombus 
formation and have a high probability of progressing rapidly to the point of becom-
ing culprit lesions.3 
 There are various ways in which plaques can lead to thrombus formation, the 
most common being plaque rupture.4 Virmani et al.5 defined plaque rupture as a 
fibroatheroma with a disruption in the cap where the overlying thrombus is con-
tinuous with the lipid core. Until recently it was thought that all acute coronary 
events were the result of plaque rupture, however an occlusive thrombus can also 
be caused by plaque erosion.6 This term defines plaques with a thrombus in which 
there is no evidence of rupture and the endothelium is absent at the site of erosion.5 
A less common, but documented cause of atherothrombosis is the calcific nodule, 
which is described as erupting through the fibrous cap into the lumen resulting in 
the formation of a thrombus.5 
 Because the etiology of coronary thrombi is diverse, it is important to character-
ize vulnerable plaques. When plaques prone to rupture were first defined as vul-
nerable, they were described as having thin fibrous caps, large lipid cores, and 
macrophage accumulation.7 In a comprehensive classification scheme for athero-
sclerotic lesions, Virmani et al. referred to lesions that are most likely to rupture as 
thin fibrous cap atheromas.5 Such plaques are characterized by a thin fibrous cap, a 
large lipid core, and an inflammatory infiltrate. However, it is important to empha-
size that not all plaques responsible for acute coronary syndromes possess this phe-
notype, as demonstrated by post-mortem studies.5,8,9 It also appears necessary to 
take into consideration the coagulability of the patient’s blood as well as the suscep-
tibility of the myocardium to develop fatal arrhythmia since these factors contribute 
to acute coronary syndromes.3 
 Several recent reviews have argued that the concept of the “vulnerable plaque” 
is overly simplistic and implies that such plaques can predict future clinical 
events.3,10-13 Characterization of vulnerable plaques has been based on retrospective 
histological studies of plaques containing a thrombus and, therefore, do not de-
scribe plaques just prior to thrombus formation. Currently, the life of a lesion and 
the circumstances that ultimately lead to acute clinical events are unknown simply 
because of the inability to recognize lesions that become clinically relevant. Imaging 
Chapter 2 
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techniques have been able  to  identify  features of atherosclerotic plaques, however 
longitudinal studies following the life of a plaque are limited. One recent study did 
however, follow subjects over an 18‐month period using magnetic resonance imag‐
ing  (MRI)  to  investigate whether  intraplaque hemorrhage  in carotid artery  lesions 
stimulates plaque progression.14 Indeed, it was found that hemorrhage into carotid 
lesions was  associated with  atherosclerotic  plaque  progression. Another  imaging 
technique, intravascular ultrasound (IVUS), has shown promise as it can distinguish 
between stable and unstable  lesions.15  In a  two‐year  follow‐up study,  the progres‐
sion  of  non‐stenotic  atheromatous  ruptured  plaques  in  patients  presenting with 
acute coronary syndromes was assessed using IVUS. It was found that 50% of rup‐
tures healed spontaneously within the two years of follow‐up.16 This study provides 
useful  information  for  the  treatment  of  patients with  acute  coronary  syndromes, 
however  serial  prospective  studies  using  IVUS  on  the  natural  history  of  plaques 
leading to rupture and thrombosis have not yet been published. 
  In  this  review,  the  term  vulnerable plaque will  refer  to  the  “concept  of  such 
plaques and not their histologic basis”, as recommended by Schaar et al.,13 and will 
be used synonymously with “unstable plaque”, “high‐risk plaque”, and “thrombus‐
prone plaque”. 
Mechanisms of Plaque Vulnerability 
When a plaque  ruptures,  the  fibrous  cap  is disrupted  exposing  the  thrombogenic 
lipid core, which comes  in contact with circulating blood  leading  to  thrombus for‐
mation and ultimately  to an acute  clinical  event. Thin  fibrous  caps are associated 
with a reduced smooth muscle cell (SMC) and extracellular matrix (ECM) content.5 
Because  SMCs  produce  collagen,  a  major  ECM  component  of  atherosclerotic 
plaques, one of  the mechanisms proposed  to  contribute  to plaque vulnerability  is 
fibrous cap thinning as a result of SMC apoptosis.17,18 The death of SMCs was shown 
to be induced by their direct interaction with macrophages.19 It has been suggested 
that SMCs in human atherosclerotic plaques exhibit reduced proliferation, undergo 
earlier  senescence,  and  demonstrate  higher  levels  of  apoptosis.20  It  has  also  been 
proposed  that  activated mast  cells may  contribute  to plaque  rupture  through  the 
secretion of mediators such as chymase, which inhibit SMC‐mediated collagen syn‐
thesis.21 
  In addition  to collagen  synthesis,  the  stability of an atherosclerotic plaque de‐
pends  on  collagen  degradation.22  Expression  of matrix  degrading  enzymes  have 
been  shown  in atherosclerotic plaques  such as matrix metalloproteinases  (MMP)23 
and cathepsins K and S,24,25 and contribute  to plaque vulnerability by reducing  the 
collagen content  in plaques and degrading  the fibrous cap.23 In addition,  tissue  in‐
hibitors of MMPs (TIMP) and cystatin C (an endogenous inhibitor of cathepsins) are 
also expressed in atherosclerotic lesions and mediate plaque stability by regulating 
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their respective proteinases.26-28 The factors contributing to fibrous cap thinning, as 
well as other mechanisms of plaque vulnerability discussed below, are summarized 
in table 1. 
 
 
 
Table 1. Factors contributing to plaque vulnerability. 
Fibrous cap thinning 
     SMC apoptosis 
     Reduced SMC proliferation 
     Reduced collagen synthesis 
          Mast cells 
     Matrix degradation 
          MMPs 
          Cathepsins 
 
Inflammation 
     Macrophage accumulation 
     T lymphocyte accumulation 
     Macrophage apoptosis 
     Cytokine regulation 
 
Necrotic Core 
     Size 
     Neovascularization 
 
Intraplaque Hemorrhage 
     Neovascularization 
 
Shear Stress 
 
 
 
Primary sources of matrix degrading enzymes and their inhibitors are monocyte-
derived macrophages.29 An inflamed plaque with a high macrophage infiltrate may 
contribute to plaque instability by synthesis and secretion of MMPs.  In addition, 
macrophages release cytokines and chemotactic factors that attract more macro-
phages and T lymphocytes into the lesion, thereby increasing inflammation.30 
Macrophage-derived foam cells, which take up extracellular lipids that have accu-
mulated in the intima ultimately die, release their contents and lead to the devel-
opment of the necrotic core. An influx of inflammatory cells such as macrophages 
and T lymphocytes has been shown to increase at sites of plaque rupture in hu-
mans.31 Besides the accumulation of inflammatory cells, apoptosis of macrophages 
has also been shown to contribute to plaque vulnerability. In advanced lesions, 
apoptotic macrophages are more abundant than in early lesions, which has been 
attributed to defective clearance by phagocytes.32 Defective phagocytosis of apop-
Chapter 2 
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totic macrophages promotes secondary necrosis of these cells and enhances the in-
flammatory response, in turn contributing to plaque instability.32 
 The initiation of atherosclerotic lesion formation involving the accumulation of 
macrophages and lipids often occurs at bifurcations and the inner curvature of ves-
sels where there is disturbed blood flow or low shear stress.33 Low shear stress pro-
motes the accumulation of lipids and stimulates the expression of leukocyte adhe-
sion molecules, cytokines, and growth factors that induce the proliferation of mono-
cyte-derived macrophages.34 Local shear stress conditions may not only induce 
plaque initiation, but is thought to play a role in plaque progression and vulnerabil-
ity. As plaques develop, the local shear stress environment is altered such that the 
disturbed blood flow becomes exacerbated downstream of the plaque, in turn pro-
moting the progression of the plaque.35 In addition, shear stress surrounding a 
growing plaque increases the tensile stress in the shoulder region making it prone to 
fissures and thrombosis.36 
 Another factor that may contribute to plaque vulnerability is intraplaque hem-
orrhage (figure 1A and B), which has been shown to occur in vulnerable plaques 
and is thought to mediate the progression of asymptomatic plaques into unstable 
lesions.37 Intraplaque hemorrhage involves the rapid accumulation of erythrocytes 
in the plaque, accompanied by macrophage infiltration. Erythrocyte membranes are 
a rich source of free cholesterol, which contributes to the enlargement of the necrotic 
core.37 Recently, it was suggested that a likely source of erythrocytes in lesions are 
leaky, immature vessels within the plaque.38 The role of neovascularization in 
plaque progression has previously been described39 and shown to be increased in 
lesions of patients with acute coronary syndromes.40 Microvessels in atherosclerotic 
plaques are thought to arise from hypoxic conditions that may occur when the ves-
sel wall exceeds a critical thickness beyond which the supply of oxygen and nutri-
ents from the lumen are restricted.41 Microvessels may therefore extend from the 
adventitial vasa vasorum through the media into the base of a lesion, or from the 
lumen through the fibrous cap.40  
 Rupture in itself may contribute to plaque vulnerability in that ruptures associ-
ated with non-occlusive thrombi as shown in figure 1C and D are known to occur at 
the subclinical level, which are thought to play a role in plaque progression.42 
Analysis of human atherosclerotic plaques has revealed previously healed ruptures, 
suggesting that plaques may rupture without resulting in acute coronary syn-
dromes.43 A detailed pathological study provided further evidence that silent rup-
tures may be a form of wound healing and plaque progression.42 It was also re-
ported in this study that previous plaque ruptures were common in arteries with an 
acute rupture suggesting that silent ruptures are a marker of plaque vulnerability. A 
recent study demonstrated that previous successive thrombotic events appear to 
occur in patients with acute coronary occlusion.44 In this study, the composition of 
thrombi in patients presenting with acute MI were analyzed. It was found that in 
over half of the cases, thrombi were days or even weeks old and had a layered com-
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position  suggesting  episodic growth of  thrombi prior  to  their becoming occlusive 
and symptomatic. 
Animal Models to Study Vulnerable Plaques 
The quest  to better understand  the mechanisms  leading  to human  atherosclerotic 
plaque rupture and thrombus formation have lead to the emergence of a variety of 
animal models of plaque vulnerability. Models have been developed primarily  in 
mice, rats, and rabbits  in which plaque rupture was either  induced45‐49 or occurred 
spontaneously.50‐54  These  models  have  been  described  extensively  in  recent  re‐
views55‐58 and will therefore not be repeated in the present review. 
  In the past few years, several reports of new models of plaque rupture and vul‐
nerability have been published, most of which have made use of apolipoprotein E 
Figure 1. Human atherosclerotic lesions with intraplaque hemorrhage or non‐occlusive luminal 
thrombus.  (A) Hematoxylin  and  eosin  (HE)‐stained  section of  a  carotid  artery  atherosclerotic 
plaque with intraplaque hemorrhage. (B) Martius, scarlet and blue (MSB)‐stained section of the 
same plaque as  in A, with  fibrin deposition shown  in red.  (C) HE‐stained section of a carotid 
artery atherosclerotic plaque associated with a nonocclusive luminal thrombus. (D) MSB‐stained 
section  of  the  same  plaque  as  in C  showing  fibrin  deposits  in  red  and  components  of  fresh
thrombus (erythrocytes) shown in yellow. For full colour figure see page 129. 
 
A B
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knockout  (ApoE‐/‐) mice. Frequent occurrences of  acutely  ruptured plaques were 
observed  in the brachiocephalic artery of ApoE‐/‐ mice after short periods of high‐
fat  feeding.59  It was  found  that  the  incidence of  ruptured plaques  significantly  in‐
creased after 8 weeks. Ruptures were defined as disruptions  in the fibrous cap ac‐
companied by hemorrhage  intruding  into  the  lesion. An earlier study by  the same 
group reported similar ruptures in plaques located in the brachiocephalic artery of 
ApoE‐/‐ mice after prolonged periods  (up  to 14 months) of  fat  feeding,53 however 
this extended time period does not make intervention studies in such a model feasi‐
ble.  Ruptured  plaques were  also  reported  in  aortic  root  lesions  of ApoE‐/‐ mice 
treated with  biphosphonates,60 which  reduce  bone  resorption  and  inhibit  arterial 
calcification, lipid accumulation, and fibrosis.61 Ruptures were observed in inflamed 
plaques in the aortic root and were associated with mural thrombosis, however the 
definition of plaque rupture was not given in this study. 
  Another model  tested  the  contribution of  angiotensin  II  to plaque vulnerabil‐
ity.62 Hypertensive ApoE‐/‐ mice were generated in which angiotensin II production 
was  either  endogenously  increased  (2K1C  renovascular  hypertension  model)  or 
remained normal. It was found that high angiotensin II production resulted in vul‐
nerable plaques characterized by a thin fibrous cap, large lipid core, and increased 
macrophage  content. Another  study  unexpectedly  observed  intralaminar  hemor‐
rhage  in  upper  aortic  regions  in  ApoE‐/‐  mice  that  received  angiotensin  II  and 
which were also naturally deficient in macrophage colony stimulating factor.63 An‐
giotensin II administration  in ApoE‐/‐ and low density lipoprotein receptor knock‐
out  (LDLR‐/‐) mice  has  been  associated with  abdominal  aortic  aneurysm  forma‐
tion.64,65 Rupture  and  thrombosis  of  aortic  aneurysms  has  been  reported  in  these 
mice, which involves weakening of the media and adventitia.66 
  Although evidence of plaque rupture in mouse models is sparse, atherosclerotic 
lesions in mice do develop intraplaque hemorrhage, an example of which is shown 
in figure 2. ApoE‐/‐ mice in which atherosclerotic lesions develop rapidly in carotid 
arteries by placement of a perivascular collar were employed in two recent studies 
of plaque vulnerability  in which  intraplaque hemorrhage was observed.  In one of 
the studies, the proinflammatory cytokine interleukin (IL)‐18 was overexpressed by 
intravenous  injection of an adenoviral vector carrying  the  IL‐18  transgene  in mice 
with  advanced  collar‐induced  lesions.67  Plaque morphology was  analyzed  and  it 
was found that IL‐18 overexpression resulted in a reduced intimal collagen content, 
thinner  fibrous  caps,  and  the  cap/core  ratio  significantly  decreased.  Intralesional 
bleeding as detected by iron deposition was reported in 19% of the plaques exhibit‐
ing  this  vulnerable  phenotype,  however  plaque  rupture  or  erosion were  not  ob‐
served. In the other collar‐induced lesion model, Fas ligand (FasL) was transferred 
directly to fibrous caps by transluminal injection of recombinant adenovirus carry‐
ing  FasL.68  Because  the  Fas/FasL  pathway  of  apoptosis  has  been  implicated  in 
plaque  vulnerability,  this  study  investigated whether  FasL  overexpression  could 
induce rupture‐related events. As quickly as one day after gene  transfer, a signifi‐
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cant increase in apoptosis in the fibrous cap was found. After two weeks, 35% of 
plaques exhibited intraplaque hemorrhage, as detected by the presence of iron de-
posits, and plaque ruptures that were not associated with thrombus formation. In a 
similar model, an extravascular device resembling a tapered collar was placed 
around carotid arteries in ApoE-/-mice so as to induce vulnerable lesions (thin fi-
brous cap, large lipid core) upstream and stable lesions downstream of the device.69 
Mice were treated with angiotensin II and were shown to have intraplaque hemor-
rhage in 75% of lesions. 
 A recent study investigated the effects of radiation on atherosclerotic develop-
ment in ApoE-/- mice and found intraplaque hemorrhage in carotid artery lesions.70 
Intraplaque hemorrhage was common in irradiated mice, especially 34 weeks after 
irradiation (∼85% of mice), and these lesions were associated with a vulnerable in-
flammatory phenotype. Plaque neovascularization was, however, not determined. 
The use of radiation to induce vulnerable plaques has previously been applied in a 
rabbit model.71  Plaque development was induced in iliac arteries by balloon denu-
dation followed by placement on a hypercholesterolemic diet. Animals were then 
irradiated so as to induce a vulnerable phenotype consisting of macrophage-rich, 
SMC-poor lesions that expressed MMPs. Intraplaque hemorrhage was, however, 
not reported in this model. 
 Small animal models of atherosclerosis associated with typical end-stage events 
such as MI, cardiac dysfunction, or premature death are limited. Rat models such as 
atherosclerosis-prone JCR:LA-corpulent rats72 and Dahl salt-sensitive hypertensive 
rats that overexpress human cholesteryl ester transfer protein52 have been shown to 
develop MI. Recently, a murine model exhibiting end-stage features of cardiovascu-
lar disease has been generated in ApoE-/- mice in which the gene for the high den-
Figure 2. Mouse atherosclerotic lesion with intraplaque hemorrhage. (A) HE-stained section of 
an aortic arch atherosclerotic plaque with intraplaque hemorrhage. (B) MSB-stained section of 
the same plaque as in A showing fibrin deposition in red. For full colour figure see page 130. 
A B
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sity lipoprotein (HDL) receptor SR-BI (scavenger receptor class B, type I) was de-
leted.73 When fed a normal chow diet, these mice become hypercholesterolemic and 
develop atherosclerotic lesions, coronary artery occlusions, MI, cardiac dysfunction, 
and spontaneous death. The same group later developed a similar model in which 
the features of cardiovascular disease observed in ApoE/SR-BI double knockout 
mice was induced with a high-fat diet in SR-BI-deficient, hypomorphic ApoER61 
mice.74 In addition to events related to coronary artery occlusion, these mice also 
developed intraplaque hemorrhage in aortic root lesions. 
 Recent models of plaque vulnerability continue to make use of small animals, 
particularly mice, however most do not result in features of human end-stage 
atherosclerosis. Characteristics of human vulnerable plaque such as plaque disrup-
tion, neovascularization, intraplaque hemorrhage, and occlusive thrombus forma-
tion occur rather infrequently in mouse models. 
Do Animal Models of Plaque Vulnerability Exist? 
The first commonly used animal models of atherosclerosis were cholesterol-fed rab-
bits, pigs, and non-human primates. Rabbits are beneficial in that they are easy to 
manipulate and develop lesions in a relatively short period of time on a high choles-
terol diet.75 Their disadvantages lie in the development of exceptionally high plasma 
cholesterol levels that differ from humans, and lesions do not develop beyond 
macrophage-rich lesions resembling human fatty streaks.76 Pigs and primates de-
velop lesions that are more similar to those in humans,76 however their size, rate of 
reproduction, and the time required for the formation of lesions make them costly 
models. The development of genetically engineered mice that lack genes crucial to 
lipid metabolism, such as ApoE and the LDL receptor has therefore been a major 
advancement in animal models of atherosclerosis. The ApoE-/- mouse in particular 
develops lesions of all stages of atherosclerosis throughout the arterial tree in a re-
producible manner.77 Lesions in ApoE-/- mice resemble those in humans if only in 
that they progress from fatty streaks to advanced fibroinflammatory lesions con-
taining a thick fibrous cap and often develop necrotic cores, cholesterol clefts, and 
calcification.78 
 These animal models have been instrumental in studying atherogenesis and 
elucidating the role of a multitude of mediators involved in the process. Where they 
fall short is their lack of resemblance to human end-stage atherosclerosis. Until re-
cently, the accepted paradigm for human end-stage atherosclerosis focused on a 
“big bang” scenario in which acute clinical events result from acute occlusive 
thrombus formation associated with disruptions in an underlying plaque. Occlusive 
thrombi leading to acute events were attributed to either plaque rupture, endothe-
lial erosion, or the presence of protruding calcified nodules. Vulnerable plaques 
considered to be at high risk for rupture have often been characterized as having a 
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thin fibrous cap, a large lipid core, and an inflammatory infiltrate, however, it is 
now known that not all plaques associated with occlusive thrombi possess this phe-
notype. Recent studies suggest a more subtle manner of occlusive thrombus forma-
tion and the development of vulnerable plaques. Rittersma et al.44 recently showed 
that plaque instability in the form of successive silent thrombi frequently occurs 
days or weeks prior to occlusive thrombus formation, which suggests that plaque 
disruption may not be the final determining factor in an acute clinical event. In ad-
dition, intraplaque hemorrhage and plaque angiogenesis have been reported to play 
a role in plaque destabilization.37,38 As such, it has been difficult to define vulnerable 
plaques and pinpoint the specific biological conditions that trigger occlusive throm-
bus formation. 
 Atherosclerotic plaque rupture, by its very nature, is difficult to study in hu-
mans.57 Advances in imaging techniques have been able to distinguish plaque char-
acteristics, however, because the occurrence and time point of rupture are unpre-
dictable, it remains difficult to identify vulnerable lesions. What are needed are 
animal models in which the pathophysiology of vulnerable plaques that lead to rup-
ture can be studied. Plaque ruptures have been reported in lesions of the brachio-
cephalic artery in ApoE-/- mice after both long and short periods of high-fat feed-
ing.53,59 However, ruptures were not associated with an occlusive thrombus. Al-
though sudden death occurred in more than half of the mice that were fed a high fat 
diet for a long period of time (up to 59 weeks), this was not attributed to plaque 
rupture.53 Ruptured lesions have also been reported in the aorta of ApoE-/- mice 
treated with biphosphonates, but again, were not associated with an occlusive 
thrombus.60 Luminal thrombi rarely occur in mice and are unorganized and nonoc-
clusive, and it is known that the regulation of coagulation differs in mice and hu-
mans.79 Because blood coagulability in humans is now considered to be an impor-
tant contributing factor in thrombus formation,3 mouse models fail to emulate the 
human condition in this respect. 
 Another important factor that may contribute to plaque vulnerability is intra-
plaque hemorrhage, which has been observed in mouse plaques, albeit infrequent-
ly.67,68,80 The source of intraplaque hemorrhage in humans is thought to occur via 
microvessels that are present in advanced lesions. These vessels mediate plaque 
progression by allowing for the rapid accumulation of cholesterol-rich erythrocyte 
membranes inside the plaque that contribute to enlargement of the lipid core.37 Al-
though intraplaque hemorrhage was observed in mouse studies mentioned above, 
plaque neovascularization was either not reported or not determined.67,68,70 Studies 
by Moulton et al.81,82 in ApoE-/- mice investigated the role of angiogenesis and 
atherosclerosis by the use of angiogenic inhibitors, which significantly reduced 
plaque area and progression. However, the occurrence of intimal vessels was rela-
tively low and whether or not they had a direct effect on plaque development was 
inconclusive. Administration of vascular endothelial growth factor (VEGF), a major 
inducer of angiogenesis, was shown to promote atherosclerosis in mice deficient in 
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ApoE and ApoB100,83 however other studies suggest that VEGF may not play an 
angiogenesis-specific role in plaque development. Antibodies directed against Flk-1, 
the major receptor for VEGF-mediated angiogenesis, reduced plaque growth, but 
this was not attributable to reduced plaque neovascularization.84 Similarly, adenovi-
ral transfer of various VEGF isoforms in LDLR/ApoB48 double knockout mice had 
no effect on plaque growth or neovascularization.85 The role of plaque neovasculari-
zation in mouse atherosclerosis, intraplaque hemorrhage, and plaque vulnerability 
remains unclear. The new concept of angiogenesis as a contributor to plaque vul-
nerability has, therefore, not been reproduced in mouse or other animal models. 
 Attempts to better mimic human cardiovascular disease have recently been 
made in mouse models in which acute coronary events occur. In particular, high fat 
diet-fed SR-BI-deficient hypomorphic ApoER61 mice are hypercholesterolemic and 
develop intraplaque hemorrhage, MI, cardiac dysfunction, and premature death.74 
In this model, hypomorphic ApoER61 mice express reduced levels of an ApoE4-like 
murine ApoE isoform, which has structural and lipoprotein binding characteristics 
that resemble the human ApoE4 isoform.74 Human ApoE4 is associated with higher 
LDL cholesterol levels and an increased risk of cardiovascular disease.86 Other 
mouse models of atherosclerosis have been developed to resemble the human con-
dition by the introduction of human genes. For example, in ApoE2 knockin and 
ApoE3Leiden mice, lipid profiles are comparable to humans, and as such they con-
tinue to be used in atherosclerosis studies, however they do not result in human 
end-stage coronary events. 
Conclusions and Future Directions 
Currently, there is no standard animal model of vulnerable plaque.  Much focus has 
been placed on mouse models, however mice do not develop atherosclerosis with-
out genetic manipulation. Genetically altered mice that have been shown to develop 
plaque rupture have either required mechanical intervention to induce rupture or if 
they occurred spontaneously, were not associated with end-stage atherosclerosis 
such as occlusive thrombi, MI, or death. Focus has also been placed on rupture of 
atherosclerotic plaques, however recent studies have revealed other causes of occlu-
sive thrombus formation such as endothelial erosion and the presence of calcific 
nodules - phenomena that are yet to be described in animal models. The goal of 
most studies of vulnerable plaque has been to induce lesions with a thin fibrous cap, 
large lipid core, and an inflammatory infiltrate, however the phenotype of culprit 
lesions associated with occlusive thrombi in humans has been shown to be varied 
and do not necessarily possess these characteristics. Furthermore, the relatively new 
concept of angiogenesis as a marker of vulnerable plaque and a source of intra-
plaque hemorrhage remains to be reproduced in animal models. Lesions in mouse 
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models in particular lack angiogenesis, and whatever intraplaque hemorrhage that 
has been reported has not been attributed to neovascularization. 
 Animal models have been invaluable in elucidating the pathobiology and com-
plex processes of atherosclerosis, but their use in studying vulnerable plaques and 
end-stage atherosclerosis remains limited. An ideal animal model would possess 
lesions that are histologically identical to human lesions, and their lipid metabolism 
and coagulation would also resemble that in humans.  Lesions in animal models 
should also have the same propensity to disrupt as in humans and result in occlu-
sive thrombus formation.57 This may be too much to ask of an animal model. We 
should perhaps focus our attention on unraveling the mechanisms of occlusive 
thrombus formation as related to plaque disruptions in humans by longitudinal 
imaging studies or identification of genes differentially expressed in human lesions, 
as performed by Faber et al.87 We may also have to accept that only specific aspects 
of the mechanisms of plaque vulnerability can be reproduced in animal models and 
that we may never be able to study the entire picture in one model. 
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Abstract 
Pathological aspects of atherosclerosis are well described, but gene profiles during 
atherosclerotic plaque progression are largely unidentified. Microarray analysis was 
performed on mRNA of aortic arches of ApoE-/- mice fed normal chow (NC) or 
western-type diet (WD) for 3, 4.5, and 6 months. Out of 10176 reporters, 387 were 
differentially (>2×) expressed in at least one group compared to a common reference 
(ApoE-/-, 3-month NC group). The number of differentially expressed genes in-
creased during plaque progression. Time-related expression clustering and func-
tional grouping of differentially expressed genes suggested important functions for 
genes involved in inflammation (especially the small inducible cytokines monocyte 
chemoattractant protein [MCP]-1, MCP-5, macrophage inflammatory protein [MIP]-
1α, MIP-1β, MIP-2, and fractalkine), and matrix degradation (cathepsin S, matrix 
metalloproteinase [MMP]-2, and MMP-12). Validation experiments focused on the 
gene cluster of small inducible cytokines. Real-time PCR revealed a plaque progres-
sion-dependent increase in mRNA levels of MCP-1, MCP-5, MIP-1α, and MIP-1β. 
ELISA for MCP-1 and MCP-5 showed similar results. Immunohistochemistry for 
MCP-1, MCP-5, and MIP-1α located their expression to plaque macrophages. An 
inhibiting antibody for MCP-1 and MCP-5 (11K2) was designed and administered 
to ApoE-/- mice for 12 weeks starting at 5 or 17 weeks of age. 11K2 treatment re-
duced plaque area and macrophage and CD45+ cell content and increased collagen 
content, thereby inducing a stable plaque phenotype. Gene profiling of atheroscle-
rotic plaque progression in ApoE-/- mice revealed upregulation of the gene cluster 
of small inducible cytokines. Further expression and in vivo validation studies 
showed that this gene cluster mediates plaque progression and stability. 
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Introduction 
Although clinical consequences and pathological aspects of atherosclerosis are well 
described, understanding of the precise molecular mechanisms of atherosclerotic 
plaque initiation and progression has been a daunting task for years. However, 
since the 1990s, new techniques have emerged to study gene expression profiles in 
complex disease systems in high-output fashion. In atherosclerosis, numerous high-
output gene expression studies have been performed in atherosclerosis-related cell 
types, revealing differential expression of mediators of inflammation, lipid metabo-
lism, signaling molecules, and extracellular matrix (ECM)-related genes, as well as 
many unknown genes.1-5 Although these studies are technically easy to perform, 
genetic information obtained from cell culture experiments may not accurately re-
flect the molecular events that take place in an atherosclerotic lesion. A more desir-
able approach is the use of whole-mount (atherosclerotic) vascular tissue. 
 In the first whole-mount experiments, gene expression profiles of smooth mus-
cle cell (SMC)-rich components of the vascular wall (aorta, vena cava, and neoin-
tima) were compared on a systematic basis. Comparisons between these different 
SMC origins revealed consistent differential expression of genes encoding matrix 
proteins (collagens) or proteins involved in G-protein signaling (RGS5).6,7 
 In another set of experiments, gene expression profiles of whole-mount human 
atherosclerotic plaques8,9 or macrophages obtained from atherosclerotic plaques by 
laser microdissection microscopy10 were compared with nondiseased arterial wall. 
These studies revealed differential expression of a wide array of genes, the majority 
of which were involved in foam cell formation, inflammation, apoptosis, and 
thrombosis.8-10 
 Most acute clinical complications of atherosclerosis result from rupture of an 
atherosclerotic plaque and superimposed thrombosis.11,12 Identification of genes cor-
related with atherosclerotic plaque rupture is crucial to understand and intervene in 
the disease process. In a recent study we were able to identify genes that were dif-
ferentially expressed between stable and ruptured human atherosclerotic plaques 
using the suppression subtractive hybridization technique.13 Although some clones 
represented known genes, such as perilipin, the majority of genes found in this 
study coded for unknown genes, one of them was named vasculin.13,14 In a microar-
ray study that compared coronary atherectomy specimens from patients with stable 
and patients with unstable angina, differential gene expression was predominantly 
observed in the clusters for thrombosis and inflammation.15 
 The aim of the present study was to obtain a detailed portrait of murine gene 
expression in the different stages of atherosclerosis. For this purpose we chose mi-
croarray analysis (mouse unigene 1, 10176 reporters, Incyte Corporation). To limit 
the effects of genetic heterogeneity and environmental influence, the experiment 
was performed in a well-established mouse model of atherosclerosis, the ApoE-/- 
mouse. A similar study was performed several years ago, but on a much smaller 
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scale, with limited time points and conditions.16 In this study, mRNA of entire aor-
tas of ApoE-/- mice fed a western-type diet for 10 or 20 weeks was hybridized on 
gene filter arrays containing 588 genes. Multiple gene clusters containing >200 genes 
based on expression levels were found.16 In a recent publication, transcripts of aortic 
tissue of atherosclerosis-resistant (C3H/HeJ) and atherosclerosis-prone (C57Bl6) 
mice were analyzed at baseline, during aging, and during exposure to an athero-
genic stimulus (high fat diet) and validated in atherosclerotic lesions of ApoE-/- 
mice, revealing that C57Bl6 mice have an atherosclerosis-prone transcription pro-
file.17 
 In our study, gene expression patterns of atherosclerotic aortic arches of ApoE-
/- mice that were fed normal chow or a western-type diet (0.21% cholesterol) for 3, 
4.5, and 6 months were determined. Time-related expression pattern clustering and 
functional grouping of differentially expressed genes revealed an important role of 
genes involved in inflammation and in protein/matrix degradation. Expression 
studies further highlighted regulation of the small inducible cytokines during dis-
ease development in this murine model. The role of the chemokines MCP-1 and 
MCP-5 was validated using a novel monoclonal antibody, which was shown to at-
tenuate atherosclerotic plaque development and progression and induce plaque 
stabilization in the ApoE-deficient mouse. 
Materials and Methods 
Microarray 
Mice and Experimental Protocols 
All animal experiments were performed in accordance with animal care institu-
tional guidelines. Male ApoE-/- mice were purchased from Iffa Credo (France). Mice 
were fed either NC or WD (0.21% cholesterol, Hope Farms) starting at 5 weeks of 
age. Mice were sacrificed at the age of 3 months (ApoE-/-, NC, n=35; ApoE-/-, WD, 
n=13), 4.5 months (ApoE-/-, NC, n=14; ApoE-/-, WD, n=14) or 6 months (ApoE-/-, 
NC, n=16; ApoE-/-, WD, n=16). 
 After the experimental period, mice were euthanized after an 8-hour fast, and 
blood (±1ml) was drawn from the caval vein for lipoprotein analysis. Mice were 
used for either RNA or protein extraction (n=10 to 31 per group) or histological 
analysis (n=4 per group). For RNA or protein extraction, the aortic arches including 
their main branch points (brachiocephalic artery, left carotid artery, and left sub-
clavian artery) (figure 1) were cleaned from fatty tissue and adventitial tissue, ex-
cised, rinsed in ice-cold phosphate-buffered saline (PBS), snap-frozen in liquid ni-
trogen, and stored at -70°C until further use. For histological analysis, mice were 
perfused with PBS containing 1% nitroprusside followed by perfusion with 1% 
paraformaldehyde as described previously.18 The aortic root and the entire aortic 
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arch including its main branchpoints were cleaned of fatty tissue and fixed over-
night in 1% paraformaldehyde.18 After they were processed, aortic arches were em-
bedded longitudinally, and twenty 4μm sections that represented the central por-
tion of the aortic arch were cut. For frozen sections (6μm), aortic roots were embed-
ded in OCT compound (Tissue-Tek, Sakura Finetek) and stored at -70°C. 
RNA Isolation and Microarray Analysis 
Total RNA was isolated with the use of the RNeasy kit (Qiagen). Per isolation, 3 
aortic arches of ApoE-/- mice were pooled. The mean yield per isolation was 5μg 
total RNA. For microarray analysis, mRNA was amplified with a T7-based tech-
nique.19 
Microarray Processing 
Regulation of gene expression was analyzed with the commercially available com-
plimentary DNA (cDNA) mouse UniGEM array of Incyte Genomics. This array con-
Figure 1. HE-stained sections of aortic arches (arch) of ApoE-/- mice including the brachiocephalic 
artery (BCA), right common carotid artery (RCA), left common carotid artery (LCA), and left 
subclavian artery (LSA). * Per 103 μm2. For full colour figure see page 130. 
BCA
RCA
LCA
LSA
arch
Plaque area: 26 ± 21 μm2* Plaque area: 106 ± 26 μm2* Plaque area: 162 ± 42 μm2*
Plaque area: 668 ± 142 μm2* Plaque area: 712 ± 24 μm2* Plaque area: 1807 ± 188 μm2*
3 NC 3 WD 4.5 NC
4.5 WD 6 NC 6 WD
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tains 10176 reporters representing 9556 genes and 580 controls. Polymerase chain 
reation (PCR) analysis confirmed the identity of 8848 reporters. 
 Cy3-dUTP or Cy5-dUTP (Amersham) was incorporated during reverse tran-
scription of polyadenylated [poly(A)1] RNA, primed by a dT(16) oligomer, resulting 
in Cy3- and Cy5-labeled samples.20 Samples from the experimental groups were 
labeled with the Cy3 fluorescent dye, and the common reference group was labeled 
with the Cy5 fluorescent dye. 
Microarray Hybridization 
cDNA was processed as described previously.20 Briefly, cDNA was applied to the 
microarray under a cover slip, and the slide was placed in a hybridization chamber 
that was subsequently incubated for approximately 8 to 12 hours in a water bath at 
62°C. Subsequently, the slides were washed for 1 minute and dried by centrifuga-
tion at 500 RPM. 
 All samples from the experimental group (3, 4.5, and 6 month NC and WD 
ApoE-/- mice) were hybridized to a cDNA chip and compared to the cohybridized 
common reference. All hybridizations were performed in duplicate; in total 2×5 
chips were hybridized. 
(Statistical) Analysis of Microarray Data 
Chips were scanned to detect hybridization signals. Scanned image output files 
were visually examined for major chip defects and hybridization artifacts and sub-
sequently analyzed with Incyte’s GemToolsTM software. Genes were analyzed if 
both of the readings had a signal-to-background ratio of ≥2.5, a signal intensity of 
>250 U for one or both dyes, and a spot size of ≥40% of the spotted area. Twenty-
five percent of all arrays contained 1 of 10176 reporters that failed the minimal area 
requirement to be included. The mean number of reporters that had a signal below 
the minimal signal-to-backgroud level was 278.7±41.6. The threshold of differential 
expression was set at >2-fold upregulation or downregulation. 
 Subsequently, time-related expression pattern clustering was performed using 
an algorithm. The different groups representing the different stages of atherosclero-
sis were put in sequential order on the basis of plaque area, as follows: 3 month WD 
diet, 4.5 month NC, 4.5 month WD, 6 month NC, and 6 month WD (figure 1 and 
table 1). Every gene at each time point was given a number representing >2-fold 
upregulation (1), no change (0) or >2-fold downregulation (-1) compared with the 
cohybridized common reference. 
 Functional grouping of differentially expressed genes was performed with the 
use of the visualization tool GenMAPP (Gene MicroArray Pathway Profiler; 
http://www.genmapp.org). This is a generally accessible program for viewing and 
analyzing microarray data on microarray pathway profiles (MAPP) representing 
biological pathways or any other functional grouping of genes.21 All MAPPs gener-
ated from the Gene Ontology database (http://www.geneontology.org) as well as 
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Table 1. Time-related expression clustering of gene expression profiles of atherosclerotic aortic 
arches of ApoE-/- mice of 3, 4.5, and 6 months of age, fed a western-type diet (3WD, 4.5WD, 6WD) 
or normal chow diet (4.5NC, 6NC). Dark grey (-1): >2-fold downregulation compared with common 
reference; light grey (1): >2-fold upregulation compared with common reference; white (0): >-2<2-
fold upregulation compared with common reference. 
3 
WD 
4.5 
NC 
4.5 
WD 
6 
NC 
6 
WD 
# 
Genes Example Incyte ID 
Genes downregulated in early atherosclerosis 
-1 0 0 0 0 58 Placental growth factor uh10a05 
Genes downregulated in advanced atherosclerosis 
0 0 -1 -1 -1 1 Integral membrane protein 2 vc21b11 
0 0 -1 0 -1 3 Carbonic anhydrase 3 mm16a05 
0 0 -1 0 0 1 Regulator of G-protein signaling 2 mv53b07 
0 0 0 -1 -1 7 Glutathione S-transferase, alpha 4 ml84g10 
0 0 0 -1 0 2 Pancreatitis-associated protein vo87h09 
0 0 0 0 -1 47 Kruppel like factor 15 mj86e04 
Genes downregulated during atherosclerosis 
-1 0 0 -1 -1 1 Solute carrier family 27 (fatty acid transport) ma79d07 
-1 0 0 -1 0 1 Serine proteinase inhibitor, clade B ub62h11 
-1 0 0 0 -1 1 Lectin, galactose binding vn42h06 
-1 0 -1 -1 -1 1 Protease, serine 16 mu26b07 
0 -1 -1 -1 0 1 ESTs vw59h01 
0 -1 0 -1 -1 1 Retinol binding protein ve71cf1 
0 -1 0 -1 0 1 Amine N-sulfotransferase mi98h07 
Genes upregulated in early atherosclerosis 
1 0 0 0 0 26 MCP-3 RANTES 
vu25f10 
ve78c12 
0 1 0 0 0 1 FMS-like tyrosine kinase 1 mm09f03 
Genes upregulated in advanced atherosclerosis 
0 0 0 0 1 111 
Matrix metalloproteinase 2 
Cathepsin H 
Mouse complement factor H 
vv38e03 
mb61c11 
vl88f12 
0 0 0 1 0 5 Jun oncogene vk45c10 
0 0 0 1 1 55 
MIP-1β 
MIP-1α 
Cathepsin B 
ml14h12 
vb44h05 
mg64b10 
0 0 1 0 0 8 Apolipoprotein A1 vp25g01 
0 0 1 0 1 8 IL-8 like vp23f01 
0 0 1 1 1 15 Fractalkine mb59d08 
Genes upregulated in atherosclerosis 
0 1 0 1 0 1 Hemoglobin mm09g04 
0 1 0 1 1 3 Cathepsin D mb64c01 
0 1 1 1 1 10 Cathepsin L vl60h02 
1 0 0 0 1 2 MCP-1 mp63c06 
1 0 0 1 1 4 MCP-2 mu45A04 
1 0 1 0 0 3 ESTs mn30b09 
1 0 1 0 1 2 Heat shock protein 70 mq49f01 
1 1 1 0 0 1 Fatty acid synthase vv71a07 
1 1 1 1 1 3 Cathepsin S mr05a08 
Genes up and downregulated in atherosclerosis 
1 -1 -1 1 0 2 Immunoglobulin heavy chain 1 mt85d12 
1 -1 0 0 0 1 CCL21b ma74f01 
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local MAPPs generated by the G-protein Coupled Receptor Database 
(http://www.gpcr.org), the KEGG database (http://www.genome.ad.jp/kegg), and 
MAPPs specifically designed for GenMAPP were used. Gene expression data were 
imported into the program and dynamically linked to the MAPPs with the tool 
MAPP Finder. 
Validation 
Quantitative Reverse Transcriptase PCR 
The SMART PCR cDNA synthesis kit (BD Biosciences) was used for the preparation 
of double-stranded cDNA from 1μg template RNA (used from a pool of n=3 aortic 
arches per group). cDNA was diluted to a total volume of 50μl. Primers and FAM-
TAMRA-labeled probes for mouse MCP-1, MCP-5, MIP-1α and MIP-1β were de-
veloped. Samples were amplified in duplicate with the use of the Taqman universal 
PCR master mix and the 7700 sequence detector (Applied Biosystems) using 
300nmol/L of primer and 200nmol/L of probe. Data were analyzed with the use of 
Sequence Detection Software (Applied Biosystems). Relative expression of mRNA 
was calculated by the comparative CT method. To standardize for the amount of 
input RNA, the endogenous cyclophilin gene was included. 
ELISA 
Samples of aortic arch were homogenized in tissue protein extract buffer (Pierce) 
with the use of a Medimachine (BD Biosciences) fitted with 50μm units. Protein ex-
tracts of two pools of n=3 aortic arches of ApoE-/- mice per group (3, 4.5, and 6 
month NC or WD) were filtered with 30μm filters and subjected to an enzyme-
linked immunosorbent assay (ELISA) for MCP-1 and MCP-5 (R&D Systems). 
Immunohistochemistry 
Immunohistochemistry was performed on frozen sections of aortic roots (MCP-1 
and MCP-5) or paraffin-embedded aortic arch sections (MIP-1α) with the use of 
standard procedures. In short, sections were fixed for 15 minutes in 4% paraformal-
dehyde and incubated with anti-MCP-1 antibody (goat polyclonal, 1:30, R&D Sys-
tems), anti-MCP-5 antibody (goat polyclonal, 1:50, R&D Systems), and anti-MIP-1α 
antibody (rabbit polyclonal, 1:100, RDI) or the respective control IgG (negative con-
trol). Subsequently, a suitable biotinylated secondary antibody was applied, fol-
lowed by incubation with an ABCAP kit (DAKO). Immunostaining was visualized 
with an alkaline phosphatase-I kit (Vectastain). 
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Intervention Study 
Generation of 11K2 Monoclonal Antibody 
Murine hybridomas were generated from RBF mice immunized with human MCP-1 
(Garvan Institute) to provide neutralizing monoclonal antibodies. One monoclonal 
antibody (11K2) was selected for its high affinity for human MCP-1 (14 pmol/L) and 
its convenient cross-reactivity to the murine homologues (MCP-1 and MCP-5) al-
lowing studies in murine disease models. The 11K2 hybridoma cell line was sus-
pension adapted and grown in reactors, and the antibody was purified by chroma-
tography on protein A Sepharose and SP Sepharose. 
ELISA 
The wells of a 96-well plate (Maxisorb Nunc) were coated with synthetic murine 
MCP-1, MCP-3, or MCP-5 (Chemicon). Residual non-specific binding sites were 
blocked with bovine serum albumin (BSA). The binding of 11K2 was detected with 
the use of horseradish peroxidase-conjugated goat anti-murine IgG (Jackson Immu-
noresearch), and the colorimetric reaction was done with TMB. 
Kinexa Assay 
The Fab fragment of 11K2 was generated by papain digestion of the antibody and 
purified from the Fc fragment by chromatography on protein A Sepharose. The af-
finity of 11K2 for murine MCPs was measured with a Kinexa instrument (Sapidyne 
Instruments). 11K2 Fab at 20 pmol/L was incubated in PBS, 0.02% azide, 0.1% BSA, 
with various concentrations of murine MCP-1 (Chemicon Inc.) or MCP-5 (Peprotech 
Inc.). The mixtures were allowed to reach equilibrium for 3 hours at room tempera-
ture and applied to a column of huMCP-1-coated polymethylmethacrylate beads 
(98μm). Free Fab bound to the column and was detected with Cy-5-labeled goat 
anti-mouse F(ab’)2. Under these conditions, the signal measured is proportional to 
the concentration of free Fab applied to the column. The data were fit to a quadratic 
curve as described previously.22 
Chemotaxis Assays 
Chemotaxis towards murine MCP-1 (BioSource), MCP-3, or MCP-5 (Cell Sciences) 
was measured with the ChemoTx system (Neuro Probe, Inc.). Murine monocytes, 
WEHI-274.1 (ATCC) or THP-1 cells were separated from the chemokines and the 
antibody by a filter with 5μm pores. The effectiveness of 11K2 in inhibiting mono-
cyte chemotaxis was determined after 4 hours. Migration was quantified using Cell 
Titer dye (Promega). 
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Mouse Experiments 
Male ApoE-/- mice (Iffa Credo) were injected intraperitoneally with the 11K2 anti-
body (200μg/week) or an isotype control antibody (IgG1, MOPC-21) twice a week 
for 12 weeks. Treatment started at the age of 5 weeks (early treatment: n=15 for 11K2, 
n=15 for control) or 17 weeks (delayed treatment: n=15 for 11K2, n=15 for control). 
 Tissue processing was performed as described above, and atherosclerotic le-
sions were analyzed as described previously.18,23 In short, atherosclerotic plaques 
were subdivided into initial lesions (pathological intimal thickening, intimal xan-
thoma) and advanced lesions (fibrous cap atheroma) according to the classification 
by Virmani et al.24 Morphometric analysis with the use of computerized morphome-
try (Leica Quantimet 570), included measuring plaque area (hematoxylin and eosin 
[HE]), collagen content (Sirius Red), α-smooth muscle actin content (αSMA, mouse 
monoclonal 1:3000, Sigma), macrophage content (Mac3, rat monoclonal,1:30, Pharm-
ingen), and CD45+ cell content (CD45, rat monoclonal 1:30, Pharmingen). 
Evaluation of Possible Side Effects 
To evaluate possible side effects of 11K2 treatment, fluorescence-activated cell sort-
ing (FACS) analysis (FACSCalibur, BD Biosciences) with T lymphocyte-specific an-
tibodies was performed on peripheral blood leukocytes, spleen, and lymph nodes of 
n=6 11K2 and n=6 control treated mice of both treatment groups. Antibodies used 
for staining were CD3FITC, CD4Biot, CD8PE53-6.7, and CD25PE (all from Pharmingen). In 
addition, >20 organs were excised and evaluated macroscopically and microscopi-
cally on 4μm sections stained with HE. 
Lipid Profile 
For the assessment of lipid profiles, standard enzymatic techniques were used, 
automated on the Cobas Fara centrifugal analyzer (Hoffmann-La Roche). Total 
plasma cholesterol and high density lipoprotein (HDL) were measured with the use 
of kits 0736635 and 543004 (Hoffmann-La Roche), total glycerol using kit 337-
40A/337-10B (Sigma), and free glycerol using kit 0148270 (Hoffmann-La Roche). 
Precipath (standardized serum) was used as an internal standard. Low density 
lipoprotein (LDL) was calculated as follows: total cholesterol – [(total glycerol – free 
glycerol)/2.2 – HDL)]. 
Statistical Analysis 
All microarrays were analyzed and validated with the use of Gemtools. In the inter-
vention study, data were compared with a non-parametric Mann-Whitney U test. 
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Results 
Microarray 
Analysis 
In total, 387 of 10176 reporters were expressed >2-fold (compared with the cohy-
bridized reference: ApoE-/- mice, 3 month NC) in one or more of the experimental 
groups analyzed. The majority of the differentially expressed genes were upregu-
lated in one or more experimental groups (258 genes upregulated, 127 downregu-
lated, 2 upregulated and downregulated in different experimental groups). Of those 
genes, 289 were known and 98 were expressed sequence tags (ESTs) (including 
RIKEN database). 
 Differential expression levels relative to the cohybridized reference ranged from 
2 to 17.5 and from –2 to –11.1. Five genes showed a >10-fold increase, 15 genes >5 to 
<10-fold, and 240 genes >2 to <5-fold. For the downregulated genes, these numbers 
were 3, 18, and 109. 
 Genes that showed the highest relative expression levels were serine protease 
inhibitor 2-2 (10.5-fold upregulation), CD68 (11.0-fold upregulation), cathepsin S 
(12.6-fold upregulation), lectin galactose binding soluble 3 (12.4-fold upregulation), 
and apoptosis inhibitory 6 (17.5-fold upregulation). Genes with the lowest relative 
expression levels were 3 ESTs (all –10.1-fold downregulation). 
Time-Related Gene Expression Changes During Atherogenesis 
For the detection of time-related expression clustering, we developed the algorithm 
described in the methods section. In theory, 35=243 clusters could be formed, how-
ever only 33 different clusters were observed. From these 33 clusters the majority of 
genes were found in clusters containing genes upregulated in advanced atheroscle-
rosis. Among those genes, many were linked to inflammation and proteolysis (table 
1). 
Functional Grouping of Differentially Expressed Genes 
Functional groups that contained most of the differentially expressed genes were 
those involved in inflammation (acute phase response, chemotaxis, cytokines) and 
protein/matrix degradation (protein degradation, proteolysis and peptidolysis, ca-
tabolism) (table 2). 
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Table 2. Functional grouping of genes using gene ontology databases and time-related expression 
profiles of genes differentially expressed in aortic arches ApoE-deficient mice. 
Category Gene Name Clone ID Cluster* 
Lipid metabolism apolipoprotein A-I 107774 0,0,1,0,0 
 apolipoprotein C-IV 404046 0,0,0,0,0 
 apolipoprotein E 521479 0,0,0,0,0 
 apolipoprotein H 1350386 0,0,0,0,0 
 apolipoprotein B editing complex 1 618120 0,0,0,0,1 
 apolipoprotein B editing complex 2 482571 0,-1,-1,-1,-1 
 fatty acid synthase 1227828 1,1,1,0,0 
 solute carrier family 27 (fatty acid transporter), 2 521620 -1,0,0,-1,-1 
 fatty acid binding protein 1 1277312 0,0,1,01 
 fatty acid binding protein 4 523460 0,0,0,0,-1 
 fatty acid binding protein 5 990152 0,0,0,0,0 
 fatty acid synthase 1227828 1,1,1,0,0 
 LDL receptor related protein 1 407600 0,0,0,0,1 
 phospholipid transfer protein 1001588 0,1,1,1,1 
 phospholipase D3 933757 0,0,0,1,1 
 glycosylphosphatidylinosytol specific phospholipase D1 333314 0,0,0,0,0 
Matrix turnover elastin 372899 0,0,0,0,1 
(protein degradation)  fibulin 5 819734 0,0,0,0,1 
 glypican 1 1065141 -1,0,0,0,0 
 procollagen, type I alpha 1 402270 0,0,1,1,1 
 procollagen, type II alpha 1 669703 0,0,0,0,1 
 procollagen, type XVIII alpha 1 720629 0,0,0,0,1 
 matrix Gla protein 407582 0,0,1,1,1 
 cartilage oligomeric matrix protein 335946 0,0,0,1,1 
 osteoprotegerin 851484 0,0,0,1,1 
 thrombospondin 1 1383744 0,0,0,0,1 
 transglutaminase 2, C polypeptide 536592 0,0,0,0,1 
 transglutaminase 3, E polypeptide 317794 -1,0,0,0,0 
 cathepsin B 437755 0,0,0,1,1 
 cathepsin D 334176 0,1,0,1,1 
 cathepsin H 333908 0,0,0,0,1 
 cathepsin L 976659 0,1,1,1,1 
 cathepsin S 596534 1,1,1,1,1 
 cathepsin Z 539055 0,0,0,0,1 
 MMP-2 1224700 0,0,0,0,1 
 MMP-12 1037661 0,0,0,1,1 
 TIMP 622732 0,0,0,1,0 
 TIMP-3 580753 0,0,0,0,1 
 cysteine protease 1 403755 0,0,1,1,1 
 serine protease 16 640501 -1,0,-1,-1,-1 
 chitinase 3-like 1 313884 0,0,0,0,1 
 serine proteinase inhibitor, clade B 1382373 -1,0,0,-1,0 
 serine proteinase inhibitor, clade E 1002830 0,0,0,0,1 
 serine proteinase inhibitor, clade F 333193 0,0,0,0,0 
 serine proteinase inhibitor, clade H 1077734 0,0,0,0,0 
 serine protease inhibitor 1-1 1077714 0,0,1,0,1 
 serine protease inhibitor 1-2 367239 0,0,0,0,0 
 serine protease inhibitor 1-3 334942 0,0,1,1,1 
 serine protease inhibitor 1-5 331065 0,0,1,0,1 
 serine protease inhibitor 2 related sequence 1 1077424 0,0,0,0,0 
 serine protease inhibitor 2-2 1077628 0,1,1,1,1 
 secretory leukocyte protease inhibitor 1367229 -1,-1,-1,-1,-1 
 extracellular proteinase inhibitor 1195775 0,0,0,1,1 
Cytoskeleton myosin VI 872172 -1,0,0,0,0 
 melanoma X-actin 1005837 0,0,0,0,1 
 actin, gamma, cytoplasmic 1005899 0,0,0,0,1 
 alpha actin cardiac 536543 0,0,0,0,0 
of 
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Category Gene Name Clone ID Cluster* 
 laminin γ 2 335886 -1,0,0,0,0 
Growth factors endothelin 1 1040154 0,0,0,0,1 
 insulin-like growth factor 1 1001007 0,0,0,1,1 
 insulin-like growth factor binding protein 2 1277469 0,0,0,0,1 
 insulin-like growth factor binding protein 4 597004 0,0,0,1,1 
 placental growth factor 1617488 -1,0,0,0,0 
 latent TGFβ binding protein 2 1396864 0,0,0,0,1 
Immune system complement component 1q alpha polypeptide 597157 0,0,0,1,1 
and inflammation complement component 1q beta polypeptide 1430527 0,0,0,1,1 
 complement component 1q c polypeptide 426010 0,0,0,1,1 
 complement component 4 1227418 0,0,1,1,1 
 complement factor H-related protein 681810 0,0,0,0,1 
 Fc receptor, IgG high affinity  576062 0,0,0,1,1 
 Fc receptor, IgG low affinity III 516594 0,0,0,1,1 
 Fc receptor, IgE high affinity 316763 0,0,0,1,1 
 Fc receptor, IgE low affinity II 717625 1,0,0,0,0 
 immunoglobulin heavy chain 1 636695 1,-1,-1,1,0 
 immunoglobulin heavy chain 3 1448206 1,-1,-1,1,-1 
 immunoglobulin heavy chain 6 1179412 1,-1,-1,0,-1 
 immunoglobulin gamma constant 635556 1,-1,-1,1,0 
 immunoglobulin kappa chain variable 28 597591 1,-1,-1,0,-1 
 immunoglobulin kappa chain variable 20 2749406 1,-1,-1,0,-1 
 immunoglobulin joining chain 1277614 0,0,0,0,0 
 IG alpha chain C region 875880 -1,-1,-1,-1,-1 
 immunoglobulin-associated beta 720992 1,0,0,0,0 
 delta-immunoglobulin 831907 1,0,0,0,0 
 histocompatibility 2, Q region locus 7 596447 0,0,0,0,1 
 small inducible cytokine D1 (fractalkine) 333711 0,0,1,1,1 
  small inducible cytokine A2 (MCP-1) 573898 1,0,0,0,1 
 small inducible cytokine A3 (MIP-1α) 751833 0,0,0,1,1 
 small inducible cytokine A4 (MIP-1β) 621095 0,0,0,1,1 
 small inducible cytokine A5 (RANTES) 832342 1,0,0,0,0 
 small inducible cytokine A6 1077529 0,0,1,0,1 
 small inducible cytokine A7 (MCP-3) 1181707 1,0,0,0,0 
 small inducible cytokine A8 (MCP-2) 620243 1,0,0,1,1 
 small inducible cytokine A21a (CCL21a) 335077 1,-1,0,0,0 
 small inducible cytokine A21b (CCL21b) 316441 1,-1,0,-1,-1 
 IL11 receptor alpha chain 1 366999 0,0,0,0,1 
 IL11 receptor alpha chain 2 1349690 0,0,0,0,1 
 IL12b 750641 -1,0,0,0,0 
 IL1 receptor accessory protein 678770 -1,0,0,0,0 
 IL2 receptor gamma chain 2 721711 -1,0,0,0,0 
 TNF superfamily member 11 618692 0,0,0,1,1 
 serum amyloid A3 126951 0,0,0,0,1 
 heat shock protein 70 kDa 1 779196 1,0,1,0,1 
 heat shock protein 70 kDa 3 582093 1,0,1,0,1 
Cell adhesion VCAM-1 635211 0,0,0,0,1 
 syndecan 1 1077399 0,0,0,0,1 
 p-selectin 876033 0,0,0,0,1 
 cadherin 13 482972 0,0,0,0,1 
 glycosylation dependent cell adhesion molecule 1 749605 1,0,0,0,0 
Phosphatases, kinases 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 1511542 0,0,-1,0,-1 
proline-serine-threonine phosphatase-interacting protein 1 1349888 0,0,0,0,1 
 MAPKKKK 1 318867 0,0,0,1,1 
 spleen tyrosine kinase 642318 1,0,0,1,1 
 serum/glucocorticoid regulated kinase 1383570 -1,0,0,0,0 
 esterase 31 747188 0,0,0,0,0 
 protein tyrosine phosphatase, non-receptor type 11  332650 0,0,0,1,0 
 lymphocyte protein tyrosine kinase 1148872 0,0,0,0,0 
 creatine kinase 520908 0,0,0,0,-1 
esterases 
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Category Gene Name Clone ID Cluster* 
 protein tyrosine phosphatase, receptor type, V polypeptide-associated 642720 1,0,0,0,0 
Apoptosis apoptosis inhibitory 6 764624 0,1,1,1,1 
 cell death-inducing DNA fragmentation factor  333124 0,0,0,0,-1 
Differentiation growth differentiation factor 15 8204034 0,0,0,0,1 
Transcription factors paired-like homeodomain transcription factor 3 482871 -1,0,0,0,0 
Cell cycle growth arrest and DNA-inducible 45 alpha 961868 0,1,0,1,1 
 cyclin dependent kinase inhibitor 1 C 1038618 0,0,0,1,0 
Ion channels/receptors potassium intermediate/small conductance calcium acti-
vated channel 642677 0,0,0,0,1 
 nuclear receptor subfamily 2 group H member 2 1092732 0,0,0,0,1 
 nuclear receptor subfamily 4 group A member 1 641865 0,0,0,1,0 
 colony stimulating factor 2 receptor  1148775 0,0,0,1,1 
Oxidative stress metallothionein 2 334351 0,0,0,0,1 
Coagulation GAS 6 537284 0,0,0,0,1 
 coagulation factor XII 318749 0,0,0,0,0 
*Gene expression in aortic arches of ApoE-deficient mice fed a western-type diet (WD) for 3 months 
(m), normal chow diet (NC) for 4.5m, WD for 4.5m, NC for 6m, or WD for 6m. –1 represents down-
regulation, 0 no modulation, and 1 upregulation when gene expression was compared with the 
common reference (ApoE-deficient mice fed a NC diet for 3 months). 
 
 
 
Of special interest within these large gene maps were the subfamilies of small in-
ducible cytokines and the cathepsins. Numerous members of both subfamilies were 
expressed throughout atherogenesis. Members of the small inducible cytokines in-
cluded MCP-1, MCP-3, MCP-5, RANTES (regulated on activation normal T cell ex-
pressed and secreted), fractalkine, MIP-1α, MIP-1β, MIP-2, IL-8-like, and small in-
ducible cytokine 21a and 21b. The expression of the majority of the small inducible 
cytokines was slightly elevated in early atherosclerosis and increased to expression 
levels above the 2-fold threshold level in advanced atherosclerotic plaques (figure 
2A), except for small inducible cytokine 21a and 21b (CCL21a and b) and RANTES, 
which appeared to be downregulated in advanced atherosclerosis. Members of the 
cathepsin subfamily included cathepsin B, D, H, L, S, and Z. Relative expression 
levels of all members increased steadily during plaque progression (figure 2B). Fur-
ther validation experiments were confined to the small inducible cytokine family. 
Validation of Expression Profiles of Small Inducible Cytokines in Atherosclerosis 
Real-time PCR for MCP-1, MCP-5, MIP-1α, and MIP-1β on aortic arches of ApoE-/- 
mice of different age and diet confirmed the increased expression in atherosclerosis 
(figure 3A). ELISA on aortic arch lysates showed that expression of MCP-1 and 
MCP-5 protein was highest in advanced atherosclerotic plaques (figure 3B). Immu-
nohistochemistry for MCP-1, MCP-5 and MIP-1α showed highest expression levels 
in macrophage foam cells of advanced atherosclerotic plaques (figure 3C-E). 
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Figure 2. Microarray expression levels of members of the two most abundant clusters: the small
inducible cytokines (A) and the cathepsins (B). For full colour figure see page 131. 
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Role of Small Inducible Cytokines in Atherosclerosis:  Mouse Study 
11K2:  Specificity and Function 
The binding specificity of 11K2 was measured by ELISA (figure 4A). 11K2 demon-
strated half-saturable binding at approximately 1.5ng/ml (10nmol/L) for both MCP-
1 and MCP-5. In contrast, no specific binding of 11K2 to murine MCP-2 and MCP-3 
could be detected up to 10μg/ml (figure 4A). 
 The Fab form of 11K2 was used to obtain a measure of the intrinsic affinity for 
murine MCP-1 and MCP-5. With the use of Kinexa assay, 11K2 Fab was found to 
bind to solution phase murine MCP-1 with an affinity of 0.3nmol/L, whereas its af-
finity for murine MCP-5 was 1.4nmol/L (figure 4B). As determined by ELISA, no 
binding was observed for murine MCP-2. 
 The ability of 11K2 to block monocyte chemotaxis was analyzed by cell migra-
tion assays. Different ratios of 11K2 and murine MCP-1 or MCP-5 were tested for 
the inhibition of murine monocyte migration across a filter barrier over a 4-hour test 
period. For both murine MCP-1 and MCP-5, a 50% reduction in migration was ob-
served with approximately 20-fold excess of monoclonal antibody (figure 4C). 
Figure 3. Validation experiments. (A) Quantitative PCR and (B) ELISA show that both RNA 
and protein levels of several members of the small inducible cytokine family (MCP-1, MCP-5, 
MIP-1α and MIP-1β) increase with disease progression. Immunohistochemistry for (C) MCP-1, 
(D) MCP-5 and (E) MIP-1α show that these proteins are predominantly expressed in macro-
phages of advanced atherosclerotic lesions (magnification 400X). For full colour figure see page 
132. 
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Role of MCP-1 and MCP-5 in Monocyte Recruitment 
In an in vitro experiment using THP-1 cells, we showed that both MCP-1 and MCP-
5 are strong mediators of monocyte recruitment (figure 4D). These results indicate 
an important role for both MCP-1 and MCP-5 in monocyte recruitment in athero-
sclerotic plaques. 
Mice 
In the early treatment group (5 to 17 weeks of age), survival rates were 100%. In the 
delayed treatment group (17 to 29 weeks of age), survival rates were 93.3% for the 
11K2 treated group and 93.3% for the control treated group. Macroscopic and mi-
croscopic analysis on hematoxylin-eosin-stained sections of >20 organs revealed no 
abnormalities. No differences in total cholesterol, triglycerides, HDL, and LDL were 
observed between 11K2 and control treated ApoE-/- mice (data not shown). 
Figure 4. 11K2 is a binding antagonist of murine MCP-1 and MCP-5. (A) Binding of 11K2 to 
surface coated murine MCP-1, MCP-2, MCP-3, and MCP-5 measured by ELISA. (B) Measure 
of free 11K2 Fab in mixtures of 11K2 Fab and MCP-1 or MCP-5 at various concentrations. (C)
11K2 blocks the chemotaxis of a murine monocytic cell line induced by murine MCP-1 and 
MCP-5. Both MCP-1 and MCP-5 are strong chemotactic agents for monocytes. 
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 FACS analysis on peripheral blood leukocytes, spleen, and lymph nodes re-
vealed no differences in the number of CD3+ cells or in the activation status of T 
cells (CD4+/CD8+ ratio, CD25+ T-cells) between 11K2 and control treated ApoE-/- 
mice (data not shown). 
Plaque Development and Phenotype 
In the early treatment group (treatment age 5 to 17 weeks), 11K2 treatment de-
creased total atherosclerotic plaque area per aortic arch (figure 5A). After this treat-
ment regimen, only initial lesions were present in the aortic arch of 11K2 and con-
trol treated ApoE-/- mice. Although the number of initial lesions per aortic arch did 
not change after 11K2 treatment (2.1±0.2 lesions per aortic arch for 11K2 vs. 2.2±0.4 
for control), these initial lesions were remarkably smaller in 11K2 treated mice than 
in control treated mice (8.803±1.314 μm2 for 11K2 vs. 12.921±1.258 μm2 for control, 
P<0.05). This indicates that 11K2 treatment does not impair lesion initiation, but 
does inhibit lesion growth. 
 In the delayed treatment group (treatment from age 17 to 29 weeks), we also 
observed a significant decrease in total plaque area per aortic arch after 11K2 treat-
Figure 5. Plaque characteristics of ApoE-/- mice treated with 11K2 or control antibody. (A) 11K2 
treatment significantly decreased total plaque area per aortic arch. (B) Macrophage and (C) 
CD45+ cell content significantly decreased in initial and advanced lesions after 11K2 treatment. 
(D) Collagen content significantly increased in initial and advanced lesions after 11K2 treatment. 
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ment (figure 5A). Although individual initial and advanced plaque area did not 
change after 11K2 treatment, the total number of advanced plaques per aortic arch 
significantly decreased (2.6±0.3 for 11K2 vs. 4.0±0.2 for control, P<0.05), whereas the 
number of initial lesions increased (1.9±0.3 for 11K2 vs. 1.1±0.2 for control, P<0.05). 
This indicates that the decrease in total plaque area is due to inhibition of disease 
progression: initial lesions partly fail to progress into advanced atherosclerotic 
plaques. 
 A third observation that stresses the effect of 11K2 treatment on lesion progres-
sion is that the increase in plaque area was retarded from 14.1-fold from week 17 to 
week 29 in the control group to only 8.3-fold in the 11K2 treated group (figure 5A). 
 Analysis of plaque composition showed that early and advanced atherosclerotic 
plaques of ApoE-/- mice treated with the 11K2 antibody were particularly low in 
inflammation. Both initial and advanced atherosclerotic lesions of early and delayed 
treatment groups showed a profound reduction in macrophage and CD45+ cell con-
tent (figure 5B, C, 6A-D). Moreover, plaques exhibited increased fibrosis after 11K2 
treatment, as shown by their collagen content (figure 5D, 6E-F). αSMA content had 
increased in initial plaques after 11K2 treatment (early treatment, 4.4±1.2% for 11K2 
vs. 0.7±0.3% for control, P<0.05; delayed treatment, 3.3±1.0% for 11K2 vs. 0.2±0.1% 
for control, P<0.05). 
Figure 6. The relative amount 
of Mac3+ macrophages (200X) 
is decreased after (A) 11K2 
treatment compared with (B)
control treatment. CD45 stain-
ing (400X) of advanced athero-
sclerotic lesions (shoulder re-
gion) revealed that (C) 11K2 
treatment decreased the per-
centage of CD45+ leukocytes 
(indicated by arrows) com-
pared with (D) control treat-
ment. Sirius Red (SR) staining 
(100X) of advanced atheroscle-
rotic plaques revealed an in-
crease in collagen content after 
(E) 11K2 treatment compared 
with (F) control treatment. For 
full colour figure see page 132. 
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 These data show that 11K2 treatment not only inhibits atherosclerotic plaque 
progression, but also induces a plaque phenotype that is low in inflammation and 
high in fibrosis, which are characteristics of a stable atherosclerotic plaque. 
Discussion 
In the present study, we obtained a detailed gene expression profile of murine 
atherosclerosis. We showed that each stage of atherosclerosis is characterized by a 
unique but complex expression pattern of genes. Time-related expression clustering 
and functional grouping of genes shed some light on these complex patterns. 
 The uniqueness of gene expression profiles during atherosclerosis is reflected 
by the outcome of a similar experiment performed with wild-type mice. In that 
study we analyzed gene profiles of aortic arches of C57Bl6 mice of similar ages and 
diets similar to those of the present study. Remarkably, only 107 genes were differ-
entially expressed, most of them selectively in C57Bl6, and only a few unannotated 
clusters could be identified (data not shown). 
 The two largest clusters/functional gene groups identified during atherogenesis 
were those of inflammation and proteolysis. Within these two groups, two gene 
families in particular were modulated during atherogenesis: the small inducible 
cytokines and the cathepsins. Broad-range inhibitors of both families may therefore 
be considered valuable targets for the treatment of atherosclerosis, especially be-
cause inhibition of individual genes showed promising results. 
 Small inducible cytokines or chemokines are members of a superfamily of small 
secreted proteins (8 to 16 kDa) that mediate migration and activation of inflamma-
tory cells into the tissue.25 Members of the CC chemokine subfamily (MCP-1, MCP-2, 
MCP-5, MIP-1α, MIP-1β, MIP-3α, MIP-3β, RANTES, eotaxin, TECK, and CCL21a+b) 
predominantly chemoattract monocytes and T lymphocytes, but not neutrophils. 
Members of the CXC family (IL-8, SDF-1, MIP-2, and CXCL16) particularly induce 
the migration of neutrophils and not monocytes. Fractalkine, the only CX3C 
chemokine described, not only functions as a chemoattractant, but also acts as an 
adhesion molecule. The XCL chemokine lymphotactin induces T lymphocyte traf-
ficking.25 
 Most of the chemokines reported are present in human atherosclerotic 
plaques.26 Moreover, a subset of the chemokine family has been tested in atheroscle-
rotic animal models and proved an important role for this family in the pathogene-
sis of atherosclerosis. Atherosclerotic mice that functionally lack MCP-127,28, 
RANTES29, or the chemokine receptors CCR230,31, CXCR2,32 and CX3CR133,34 reduced 
atherosclerosis. Moreover, inhibition of most of these chemokines reduced the in-
flammatory cell content in the lesion and induced an increase in ECM content, char-
acteristics of a stable atherosclerotic plaque. An exception is the chemokine receptor 
CCR5, which failed to affect atherosclerosis.35 The recently discovered interferon 
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(IFN)-γ-regulated chemokine CXCL16 was also found to be expressed in atheroscle-
rosis.36 
 In the present study we found that even more members of the small inducible 
cytokine family were present in atherosclerotic lesions. Besides upregulation of 
MCP-1 and fractalkine, we also found upregulation of MCP-3, MCP-5, MIP-1α, 
MIP-1β and IL-8-like. Interestingly, in contrast to an earlier report, 29 we found 
downregulation of RANTES and of CCL21a and CCL21b, especially in the more 
advanced stages of atherosclerosis. Our microarray results stress the importance of 
the entire gene family of small inducible cytokines in atherosclerosis. 
 In a subsequent in vivo experiment, we designed a unique inhibitor (11K2) for 
the small inducible cytokines MCP-1 and MCP-5. MCP-1 and MCP-5 both bind to 
the CCR-2 receptor.37 Administration of 11K2 to ApoE-/- mice in a prevention and a 
regression setting revealed that inhibition of MCP-1 and MCP-5 resulted in reduc-
tion of atherosclerosis. Moreover, atherosclerotic plaques were low in inflammation 
and contained increased amounts of ECM. Inhibition of MCP-1 and MCP-5 induced 
a stable atherosclerotic plaque phenotype. 
 Although our antibody did not distinguish between the individual effects of 
MCP-1 and MCP-5, we showed that both MCP-1 and MCP-5 are potent monocyte 
chemoattractants in vitro, suggesting an important role for both MCP-1 and MCP-5 
in monocyte recruitment in atherosclerotic plaques in vivo. Unfortunately, we could 
not perform comparative experiments in vivo because we would need a humanized 
anti-murine MCP-1 and/or MCP-5 monoclonal antibody for comparison with 11K2, 
neither of which exist at present. The only available monoclonal antibody specifi-
cally against MCP-1 is a hamster anti-rodent antibody (clone 2H5).38 Hamster 
monoclonal antibodies are notoriously antigenic in mice and are therefore not suit-
able for long-term in vivo experiments. 
 Although our mouse data are very promising, caution should be exercised in 
regard to the use of 11K2 as treatment of human atherosclerosis. Atherosclerosis is a 
slowly progressive disease, and therefore long-term treatment is required. One of 
the problems with long-term application of antibodies is the development of “anti-
drug” antibodies. Moreover, antibodies are large proteins, and the risk of nonspe-
cific binding to other epitopes is present. MCP-1 and MCP-5 are also involved in 
combating infections, therefore safety of long-term 11K2 treatment might be ques-
tionable. However, FACS analysis in our mice did not reveal any signs of immuno-
suppression after a 3-month treatment period. Recently, antibody therapy in small 
groups of patients using antibodies against tumour necrosis factor (TNF)-α, CD40 
ligand (CD40L) and interleukin (IL)-12 for Crohn’s disease, rheumatoid arthritis, 
and systemic lupus erythematosus proved effective with only limited side ef-
fects.39,40,41 
 For the cluster subfamily of cathepsins, which are important cysteine proteases, 
we observed that cathepsin B, D, H, L, S, and Z were highly expressed during 
atherogenesis. Cathepsin S was one of the most highly expressed genes of our mi-
Chapter 3 
 
 
54  
croarray in all stages of atherosclerosis. Cathepsin B, D, L, S, and K were previously 
reported to be expressed in atherosclerotic plaques.42,43 Mice deficient in cathepsin S 
and the LDL receptor showed a decrease in plaque area, plaque macrophage, SMC, 
and T lymphocyte content,44 indicating an important role of cathepsin S in athero-
sclerotic plaque progression. 
 Besides the two most abundant functional clusters, functional gene groups like 
blood coagulation (e.g., Gas6), cholesterol metabolism (e.g., fatty acid binding pro-
tein), embryogenesis, and morphogenesis (homeobox genes, dickkopf homolog 3) 
were also significantly activated, reflecting the highly complex nature of atheroscle-
rotic plaque development and progression. 
 Microarrays are becoming more and more integral in unraveling pathways of 
complex diseases. Although they are powerful, caution must be exercised in regard 
to the experimental design and interpretation of results. Before multiple microarray 
measurements can be integrated into a single analysis, measurements of individual 
arrays must be normalized.45 In our study we used a pool of cDNA derived from 
ApoE-/- mice fed NC for 3 months that was used as a reference for all microarrays. 
In each microarray experiment, there is a significant amount of “biological noise” 
that can distort the interpretation of the expression data.45 To avoid misinterpreta-
tion, microarrays were performed in duplicate, and the expression of a subset of 
genes were validated using real-time PCR, ELISA, and immunohistochemistry. 
 Despite our careful analysis and validation experiments, the use of entire aortic 
arches in the analysis implies that both intima and media may contribute to the ob-
served differences in gene expression. However, validation experiments for our 
candidate genes did not show expression in the media. 
 Moreover, in our current setup, differential gene expression of individual cell 
types in the plaque (SMCs, macrophages, endothelial cells, and T lymphocytes) 
could only be distinguished after validation. A method successfully used to identify 
gene expression profiles of individual plaque cell types, macrophages in this case, is 
microdissection of individual cells by laser capture microscopy.10,46 
 Here we show that the use of DNA microarray analysis yielded a detailed data-
base that will improve insight into the pathogenesis of atherosclerosis and will be 
helpful to identify new diagnostic markers and therapeutic targets to monitor and 
intervene in atherosclerotic plaque progression. 
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Abstract 
Neovascularization has been implicated in the development and progression of 
atherosclerotic plaques and is thought to contribute to their destabilization. The ef-
fects of the angiogenesis inhibitor endostatin and a novel anti-angiogenic peptide 
called anginex were investigated in collar-induced atherosclerotic lesions of ApoE-/- 
mice. Anginex, endostatin or control treatment was administered via osmotic mini 
pumps either prior to lesion development (early treatment), or thereafter (delayed 
treatment). Analysis revealed smaller lesions in carotid arteries after early anginex 
and endostatin treatment compared to controls, whereas no effect was found on 
advanced lesions following delayed treatment.  Plaque phenotype was not affected 
by anginex or endostatin treatment. Quantitative real-time PCR analysis revealed a 
trend toward a reduced expression of angiogenic factors in carotid arteries of mice 
receiving anginex treatment compared to controls. Furthermore, neovascularization 
was not observed in lesions as determined by immunohistochemical analysis. 
Treatment with anginex or endostatin appears to reduce early, but not advanced, 
lesions in an angiogenesis-independent manner in collar-induced atherosclerotic 
plaques of ApoE-/- mice. 
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Introduction 
Under  normal,  non‐diseased  conditions,  the  adventitial  layer  of  arteries  contains 
vasa vasorum that function to nurture the outer component of the vessel wall, while 
the  intima  is  supplied with nutrients  from  the  lumen.1 Under pathological  condi‐
tions, when the vessel wall exceeds a critical thickness beyond which oxygen can no 
longer diffuse from the  lumen, the vasa vasorum proliferate, producing a network 
of microvasculature to facilitate transport of nutrients.2 Neovascularization has been 
shown  to occur  in atherosclerotic plaques and  is thought  to contribute  to  their de‐
velopment and progression.3 
  Neovascularization in atherosclerosis has been found to be increased in lesions 
of patients with acute coronary syndromes4 and has been  implicated  in plaque  in‐
stability.5  The  formation  of  immature microvessels  in  lesions may  lead  to  intra‐
plaque hemorrhage, which contributes to lipid core expansion and inflammation by 
the  accumulation  of  free  cholesterol  from  erythrocyte membranes  and  leukocyte 
infiltration, respectively.6 
  Inhibiting angiogenesis  in atherosclerotic plaques may reduce plaque progres‐
sion and increase their stability. It has been demonstrated that the angiogenesis in‐
hibitors endostatin or TNP‐470 (a fumagillin analogue) reduce intimal neovasculari‐
zation and plaque growth in ApoE‐/‐ mice.7 Treatment with the proangiogenic fac‐
tor vascular endothelial growth factor (VEGF) increased plaque area in ApoE/ApoB 
double knockout mice.8 It was later shown by the same group that the angiogenesis 
inhibitor  angiostatin  blocked  VEGF‐mediated  neointima  progression  in  rabbits.9 
VEGF overexpression in collar‐induced atherosclerotic plaques of ApoE‐/‐ mice was 
also reported to increase plaque growth and promote leukocyte recruitment.10 Con‐
versely,  inhibition of  the VEGF receptor Flt‐1 or  transfection with soluble Flt‐1 re‐
duced plaque growth in ApoE‐/‐ mice11 and inhibited neointimal formation and in‐
flammation in hypercholesterolemic mice,12 respectively. 
  The designed peptide  anginex,  also  exhibits  strong  anti‐angiogenic properties 
such as inhibition of endothelial cell (EC) adhesion and migration, ultimately reduc‐
ing proliferation and increasing apoptosis.13 Anginex has been shown to reduce an‐
giogenesis  and  tumour  growth  in mouse  tumour models,14 however  its  effects  in 
atherosclerosis have not yet been studied. In the present study, we investigated the 
effects of anginex or endostatin treatment on atherosclerotic plaque development in 
a collar‐induced mouse model of atherosclerosis. We hypothesized that anginex or 
endostatin treatment would reduce plaque development and progression, as well as 
decrease plaque angiogenesis. 
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Materials and Methods 
Mice 
Male ApoE-/- mice on a 100% C57Bl6 background were used (Charles River). Mice 
were treated in an early and delayed treatment setting with anginex (8 mg/kg/day), 
endostatin (5 mg/kg/day) or phosphate-buffered saline (PBS) administered via mini 
osmotic pumps (Alzet, model 2004, Durect Corporation) inserted subcutaneously. 
In the early treatment setting, mice (anginex n=12, endostatin n=5, PBS n=11; mice 14 
weeks of age) were fed a high fat diet (0.21% cholesterol) for 2 weeks after which 
silastic collars were placed around the left and right carotid arteries as described 
previously.15 Mini pumps were also inserted at this time to begin treatment prior to 
atherosclerotic lesion development. After 4 weeks, approximately 1.0ml of blood 
was drawn from the caval vein for lipoprotein analysis, mice were sacrificed, and 
tissues were harvested.  In the delayed treatment setting, mice (anginex n=12, en-
dostatin n=5, PBS n=12; mice 14 weeks of age) were fed a high fat diet for 2 weeks 
after which collars were placed. After 4 weeks when atherosclerotic plaques had 
developed, mini pumps were inserted to begin treatment. After 4 weeks, mice were 
processed as in the early treatment group. Animal experiments were approved by 
the institutional committee for the care and welfare of laboratory animals of Maas-
tricht University. 
Tissue Harvesting 
The left carotid artery was first removed and either snap-frozen in liquid nitrogen 
for isolation of RNA or frozen in OCT compound (Tissue-Tek, Sakura Finetek) for 
histological analysis. The arterial tree was perfused with PBS containing 0.1mg/ml 
sodium nitroprusside (Sigma) followed by 1% phosphate-buffered paraformalde-
hyde. The right carotid artery and the rest of the aortic tree were excised and pre-
served for 24 hours at 4°C in phosphate-buffered paraformaldehyde, after which 
they were placed in 70% alcohol. 
Histology and Morphometry 
Right carotid arteries including intact collars were embedded in paraffin.  Trans-
verse sections were cut in the caudal direction relative to the carotid bifurcation and 
mounted in order on a parallel series of slides as described previously.15 Sections 
were stained with hematoxylin and eosin (HE) and those exhibiting maximal steno-
sis were used to measure plaque area. Sections adjacent to those with maximal 
stenosis were stained with Sirius Red to determine relative collagen content. Mor-
phometric analysis was performed with the use of computerized morphometry 
(Quantimet 570, Leica). 
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Immunohistochemistry 
Paraffin sections adjacent to those with maximal stenosis were immunolabeled with 
Mac3  rat monoclonal antibody  (1:30, Pharmingen)  to detect macrophages and de‐
termine macrophage content relative  to plaque area. Neovascularization  in  lesions 
was determined by anti‐CD31 antibody (1:200, Pharmingen) staining for the detec‐
tion of ECs. Staining was enhanced by  incubating with a  fluorescein‐labeled  tyra‐
mide amplification reagent (1:50, Tyramide Signal Amplification Fluorescence Sys‐
tems Kit, Perkin Elmer). 
RNA Isolation, cNDA Synthesis and Quantitative Real-Time PCR 
RNA was isolated from left carotid arteries of mice of the delayed treatment group 
using  an RNA  isolation kit  (RNeasy Mini Kit, Qiagen). Frozen  carotid  arteries of 
mice were  pooled  (anginex,  n=4  and  control,  n=6)  to  ensure  sufficient  quality  of 
RNA. The  iScript cDNA Synthesis Kit (Biorad) was used to convert 500ng of RNA 
into  cDNA. Quantitative  real‐time PCR was performed  as previously described.16 
Briefly,  tissues were analyzed  for  the  following angiogenic  factors: VEGF‐A, B, C, 
and D,  basic  fibroblast  growth  factor  (bFGF),  and  angiopoietin  (Ang)‐1,  2,  and  3 
with  primers  (Eurogentec)  specific  for  mouse  transcripts.  The  delta‐delta  CT 
method was used  to compare  the relative RNA expression  levels between anginex 
and control treated tissues. 
Statistical Analysis 
Statistical analysis was performed using the Kruskall‐Wallis test to compare differ‐
ences  between  the  three  independent  groups  (anginex,  endostatin,  and  control 
treatment). Data are expressed as mean±SEM and differences were considered sta‐
tistically significant at P<0.05. 
Results 
Atherosclerotic Plaque Area and Composition 
Both anginex and endostatin  treatment reduced plaque area relative  to controls  in 
collar‐induced atherosclerotic lesions of the early treatment group (figure 1). In the 
delayed treatment group, anginex or endostatin treatment did not have an affect on 
lesion area compared with controls. In addition, the two angiogenesis inhibitors did 
not have an affect on plaque phenotype. As shown in figure 2, there was no change 
in collagen content or macrophage content compared  to controls with either early  
or delayed treatment. 
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Plaque Angiogenesis 
Quantitative  real‐time PCR analysis was performed on  carotid arteries of anginex 
treated and control mice to determine RNA expression levels of factors involved in 
angiogenesis. Because tissue samples from mice in a given treatment group had to 
be pooled to ensure sufficient quality of RNA, statistical analysis could not be per‐
formed. However,  there was an apparent decrease  in  the expression of angiogenic 
factors  in  tissues of mice  treated with anginex  compared with  controls  (figure 3). 
CD31  immunohistochemical  staining  revealed  positive  staining  of  luminal  ECs, 
however microvessels were not evident within the plaque itself (figure 4). 
Figure 1. Reduced plaque area with early anginex or endostatin treatment. (A) Plaques of anginex 
or endostatin‐treated mice of the early treatment group were smaller compared with controls. (B)
No difference  in plaque area between anginex or endostatin treatment compared with controls. 
*P<0.05. Images are representative of carotid artery plaques of the early treatment group. For full 
colour figure see page 133. 
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Figure 2. No change in plaque composition with anginex or endostatin treatment. There was 
no change in macrophage content (mφ) or collagen content (SR, indicating Sirius Red stain-
ing) in either of the (A) early or (B) delayed treatment groups compared with controls. For 
full colour figure see page 134. 
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Figure 3. Fold RNA expression of angiogenic factors in carotid arteries of mice 
treated with anginex relative to controls. 
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Figure 4. CD31 immunostaining of a carotid artery atherosclerotic
plaque reveals positively stained luminal ECs. For full colour 
figure see page 135. 
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Discussion 
In this study we investigated the effects of the designed anti-angiogenesis peptide 
anginex in murine atherosclerotic plaque development. We found that anginex re-
duced plaque area in early atherosclerotic lesions, but did not affect advanced le-
sions. Similar results were found with endostatin treatment. Treatment with angi-
nex and endostatin did not alter the composition of plaques as determined by colla-
gen and macrophage content. This is in contrast to a previous study that reported 
reduced plaque growth in advanced, but not early, stages of atherosclerosis in 
ApoE-/- mice upon treatment with endostatin or the angiogenesis inhibitor TNP-
470.7 Although angiogenesis is commonly reported to be a feature of advanced 
stages of atherosclerosis, studies have observed neovascularization in early human 
atherosclerotic lesions.3 In addition, in the study by Moulton et al.7 plaque area was 
determined in the aortic sinus after prolonged treatment (16 weeks) with anti-
angiogenesis agents, whereas in the present study plaque area was measured in 
collar-induced lesions of carotid arteries after four weeks of treatment. Atherogene-
sis in ApoE-/- mice as a result of perivascular collar placement is rapid and induced, 
thereby differing from lesion development at other aortic sites. It would be interest-
ing to determine the effects of anginex treatment on lesions of the aortic sinus and 
aortic arch - two sites in ApoE-/- mice that are commonly examined for plaque de-
velopment. 
 Neovascularization in atherosclerotic lesions was not observed in the present 
study, be it early or late stage. Previous studies have shown the presence of mi-
crovessels in atherosclerotic plaques of ApoE-/- mice, however these were lesions 
located in the aorta or aortic sinus,7,17 not in collar-induced lesions as in the present 
study. Recently, it was found that focal overexpression of VEGF-A in collar-induced 
advanced atherosclerotic plaques of ApoE-/- mice led to an increase in plaque size 
and induced an unstable phenotype characterized by an increased macrophage and 
lipid content, and decreased collagen content. Surprisingly, VEGF-A overexpression 
did not induce plaque angiogenesis as microvessels were not observed in lesions, 
which suggests that the effects exerted by VEGF-A are independent of angiogene-
sis.10 It appears that neovascularization in atherosclerotic plaques of ApoE-/- mice, 
particularly those induced by collar placement, is a rare event, even with admini-
stration of proangiogenic factors. 
 Although we observed a trend toward reduced RNA expression of proangio-
genic factors with anginex treatment, which would suggest that angiogenesis was 
inhibited, results are preliminary and inconclusive. Furthermore, reduced plaque 
growth and development upon treatment with anti-angiogenesis agents is often 
correlated with a reduced leukocyte infiltrate,10,17 however we did not find differ-
ences in macrophage content in lesions of mice treated with anginex or endostatin 
compared to controls. Interestingly, this is in contrast to the effects of anginex 
treatment in tumours in which it has been found that anginex increases the leuko-
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cyte infiltrate. While anginex inhibits tumour growth and microvessel density, the 
number of infiltrated leukocytes is increased as a result of the upregulation of endo-
thelial adhesion molecules.18 These and our findings suggest not only that angio-
genesis inhibitors such as anginex exert different effects in different tissues, but also 
that their effects on neovascularization and leukocyte infiltration occur independ-
ently of one another. 
 Given these findings, it is possible that the reduced plaque area observed in 
initial plaques may have occurred by an angiogenesis-independent mechanism. In 
fact, in all of the studies mentioned above in which the effects of positive (VEGF-A) 
or negative (endostatin, TNP-470, and VEGFR-1 inhibitors) regulators of angiogene-
sis on lesion development were investigated, changes in plaque growth and pheno-
type could not be attributed to plaque neovascularization. 
 In conclusion, anginex and endostatin treatment reduces early, but not ad-
vanced lesions in collar-induced atherosclerotic plaques of ApoE-/- mice. Prelimi-
nary results indicate that treatment with these angiogenesis inhibitors downregu-
lates proangiogenic factors, suggesting that angiogenesis was inhibited. However, 
neovascularization could not be detected in lesions, therefore, lesion sizes may have 
been reduced by an angiogenesis-independent mechanism. 
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Abstract 
Adhesive interactions between cells and the extracellular matrix play an important 
role in inflammatory diseases like atherosclerosis. We investigated the role of the 
collagen-binding integrin α1β1 in atherosclerosis. ApoE-/- mice were α1-deficient or 
received early and delayed anti-α1 antibody treatment. Deficiency in α1 integrin 
reduced the area of atherosclerotic plaques and altered plaque composition by re-
ducing inflammation and increasing extracellular matrix. In advanced plaques, α1-
deficient mice had a reduced macrophage and CD3+ cell content, collagen and 
smooth muscle cell content increased, lipid core sizes decreased, and cartilaginous 
metaplasia occurred. Anti-α1 antibody treatment reduced the macrophage content 
in initial plaques after early and delayed treatment, decreased the CD3+ cell content 
in advanced plaques after delayed treatment, and increased the collagen content in 
initial and advanced plaques after delayed treatment. Migration assays performed 
on α1-deficient macrophages on collagen I and IV substrata revealed that α1-
deficient cells can migrate on collagen I, but not IV. Anti-α1 antibody treatment of 
ApoE-/- macrophages also inhibited migration of cells on collagen IV. Our results 
suggest that α1β1 integrin is involved in atherosclerosis by mediating the migration 
of leukocytes to lesions by adhesion to collagen IV. Blocking this integrin reduces 
atherosclerosis and induces a more stable plaque phenotype. 
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Introduction 
Inflammatory responses, as in atherosclerosis, involve adhesive interactions be-
tween cells and the extracellular matrix (ECM) that are necessary for cell attachment, 
extravasation and migration into tissues, proliferation, and differentiation. Major 
receptors for ECM ligands are integrins, which are transmembrane heterodimers 
consisting of an α and β subunit. The role of several integrins has previously been 
studied in atherosclerotic development. Integrin α4β1 has been shown to be ex-
pressed on smooth muscle cells (SMC) during pathological neointimal thickening 
and is involved in SMC differentiation.1 
 Furthermore, α4β1 integrin mediates adhesion of monocytes to the vascular 
endothelium and anti-α4 antibody treatment decreases leukocyte entry in mice fed 
an atherogenic diet,2 as well as attenuates neointimal growth following carotid in-
jury in ApoE-/- mice.3 Agonists against αVβ3 integrin were also shown to reduce 
neointima formation after injury4 and it has been suggested that this integrin regu-
lates the maturation of macrophages into foam cells.5 Yet another model of endothe-
lial injury has revealed that α2β1 integrin mediates the adhesion of platelets to col-
lagen in the vessel wall and α2β1-deficient mice exhibit delayed thrombus forma-
tion following injury to the carotid artery.6 
 The role of α1β1 integrin in atherosclerosis has not yet been investigated, but 
has been shown to mediate inflammation in several other illnesses. Integrin α1β1 is 
a major collagen receptor that is highly expressed on activated monocytes7 and T 
lymphocytes, including those found in atherosclerotic plaques.8 The role of α1β1 
integrin has been studied in various models of inflammatory diseases including 
hypersensitivity and arthritis,9 kidney fibrosis,10 and colitis11 in which it has been 
shown that a deficiency or blocking of this integrin using anti-α1 antibodies attenu-
ates the inflammatory response as seen by a reduced leukocyte infiltrate. These 
studies suggest a role for α1β1 integrin in the migration of leukocytes to sites of in-
flammation. 
 Besides its expression on immune cells, α1β1 integrin is also expressed on mes-
enchymal cells, most notably SMCs and fibroblasts. Human aortic SMCs have been 
reported to express α1β1 integrin, which is involved in SMC differentiation.12 It has 
been demonstrated that α1-deficient fibroblasts cannot adhere to or migrate on col-
lagen IV13 and are deficient in collagen-dependent proliferation.14 A major function 
attributed to α1β1 integrin is the regulation of feedback inhibition of collagen syn-
thesis. This was shown by enhanced collagen-dependent downregulation of colla-
gen synthesis upon receptor stimulation,15 and a later study reported an increase in 
collagen synthesis in the dermis of α1-deficient mice.16 
 Given that α1β1 integrin regulates collagen synthesis and mediates the migra-
tion of activated leukocytes during inflammation, we wanted to investigate its role 
in atherosclerosis. To examine the role of α1β1 integrin in plaque inflammation and 
development, we used a murine model of atherosclerosis in which α1 integrin was 
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either knocked out or mice were treated with an α1-blocking antibody. Here we 
report that a deficiency or blocking of α1 integrin attenuates atherosclerosis and 
induces a more stable plaque phenotype. 
Materials and Methods 
Mice 
To study the role of α1 integrin in atherosclerosis, α1-/-/ApoE-/- mice were used. 
ApoE-/- mice on a C57Bl6 background were obtained from Jackson Laboratories 
and were backcrossed 10 times with α1-/- mice, originally on a Balb/c background13 
to generate male and female α1-/-/ApoE-/- (homozygous, n=13), α1+/-/ApoE-/- (het-
erozygous, n=8) and α1+/+/ApoE-/- (wild type, WT, n=12) mice. Mice were fed nor-
mal chow for 27 weeks after which they were sacrificed following an 8-hour fast. 
Approximately 0.5 to 1.0 ml of blood was drawn from the vena cava for lipoprotein 
analysis. To study effects of antibody (Ab) blockade of α1 integrin, ApoE-/- mice on 
a C57Bl6 background were used, obtained from Iffa Credo, and fed normal chow. 
Mice were injected intraperitoneally twice a week with 200μg9 of a murinized ver-
sion of a hamster anti-rodent α1-blocking Ab (muHa31/8) or murine IgG isotype 
control Ab (MOPC-21) (Biogen Idec, Inc.). Mice received treatment for 12 weeks 
beginning at either 5 weeks of age when no atherosclerotic lesions are present in the 
aortic arch (early treatment: anti-α1 Ab, n=13; control, n=14) or 17 weeks of age 
when advanced lesions begin to appear in the aortic arch (delayed treatment: anti-
α1 Ab, n=11; control, n=14). Animal experiments were approved by the institutional 
committee for the care and welfare of laboratory animals of Maastricht University. 
Antibody Infiltration 
To determine whether antibody infiltrated plaques, Ha31/8 mAb was labeled with 
Alexa488 using a protein labeling kit (Molecular Probes), and 200μg were injected 
intraperitoneally into 53-week-old ApoE-/- mice three times in the period of one 
week. Control mice did not receive any antibody. Following treatment, mice were 
sacrificed and the arterial tree was briefly perfused with phosphate-buffered saline 
(PBS). Aortic arches were snap-frozen in OCT compound (Tissue Tek, Sakura Fine-
tek) for histological analysis and carotid arteries and abdominal aortas were placed 
in PBS until analysis by two-photon laser scanning microscopy (TPLSM). Aortic 
arch cryosections were fixed in acetone, counterstained with hematoxylin, mounted 
with Prolong Anti-Fade (Molecular Probes), and viewed with a fluorescence micro-
scope. For analysis by TPLSM, carotid arteries and abdominal aortas were placed in 
perfusion chambers, and glass micropipettes were inserted into their ends so they 
could be kept taut during imaging and facilitate perfusion with PBS. 
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Lipid Profiles 
Lipid profiles were assessed as described previously.17 
Histology and Morphometry 
Histological and morphometrical analyses were performed as described previ-
ously.17 To confirm the presence of cartilaginous metaplasia observed in plaques of 
α1-deficient mice, aortic arch sections were stained with alcian blue and toluidine 
blue. 
Immunohistochemistry 
Aortic arch sections were immunostained with Mac3 rat monoclonal Ab (mAb) (1:30, 
Pharmingen) to detect macrophages, CD3 rabbit polyclonal Ab (1:200, Dako) to de-
tect T lymphocytes, and αSMAFITC mAb (1:500, Sigma) as a marker for α-smooth 
muscle actin (αSMA)-positive vascular SMCs. To determine α1 integrin expression 
in macrophages in atherosclerotic plaques of aortic arches, double immunohisto-
chemistry was performed using Alexa488-conjugated Ha31/8 anti-α1 mAb (Biogen 
Idec, Inc.) and CD11bPE (1:200, Pharmingen). To identify characteristics of cartilagi-
nous metaplasia, sections were stained with antibodies against collagen II (goat 
polyclonal, 1:75, Santa Cruz Biotechnology, Inc.), osteocalcin (OC) (rabbit polyclonal, 
1:50, ANAWA Trading SA), osteonectin (ON) (rabbit polyclonal, 1:2000, Zymed 
Laboratories, Inc.), osteopontin (OPN) (goat polyclonal, 1:25), bone morphogenetic 
protein (BMP)-2 (mouse monoclonal, 1:20, Genetics Institute, Inc.), BMP-4 (goat 
polyclonal, 1:25, Santa Cruz), matrix Gla protein (MGP) (mouse monoclonal, 1:25), 
osteoprotegerin (OPG, 1:100), and osteoprotegerin ligand (OPGL, 1:75). To deter-
mine collagen IV expression in atherosclerotic plaques, mouse aortic arch and hu-
man carotid artery paraffin sections were stained with antibody against collagen IV 
(rabbit polyclonal anti-mouse 1:300, anti-human 1:50). 
Cell Isolation 
Bone marrow-derived macrophages were isolated from the femur and tibia of α1-/-
/ApoE-/- and α1+/+/ApoE-/- mice. Cells were cultured in standard RPMI containing 
L-glutamine, HEPES, 10% fetal calf serum, 100 IU/ml penicillin/streptomycin, and 
15% L929 cell-conditioned medium. 
Migration Assay 
Cell migration was assayed using 24-well Transwell migration chambers (Costar) 
with a pore size of 8μm. Membranes were coated with 110μg/ml of type I collagen 
(isolated as previously described)18 or 50μg/ml of type IV collagen (BD Biosciences) 
and incubated at 37°C for 1 hour until complete gel formation. Membranes were 
allowed to air dry, then 106 cells suspended in serum-free medium were added to 
each chamber. Cells isolated from WT mice were incubated with 100μg/ml of α1-
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blocking Ab or control Ab for 30 minutes prior to addition to chambers. Complete 
medium including 100ng/ml MCP-1 (R&D Systems, Inc.) was added to lower cham-
bers and migration was carried out at 37°C for 4 and 12 hours. Non-migrated cells 
were removed from membranes and migrated cells within the membrane were 
fixed with methanol and stained with toluidine blue. Membranes were cut out of 
inserts and mounted onto slides in immersion oil. The number of migrated cells 
were counted on five randomly chosen microscopic fields of each membrane. 
FACS Analysis 
Fluorescence-activated cell sorting (FACS) analysis (FACSCalibur, Beckton Dickin-
son) was performed on cells isolated from peripheral blood, spleen, and lymph 
nodes, as well as peritoneal macrophages from antibody-treated mice (anti-α1 Ab, 
n=6; control Ab, n=6 of both early and delayed treatment groups). Cells were labeled 
with T lymphocyte-specific antibodies: CD3FITC, CD4Cy-Chrome, CD8PE, and CD25PE, as 
well as antibodies to detect macrophages: Gr1FITC and Mac1PE (all from Pharmingen). 
Statistic  
Statistical analyses were performed using a non-parametric Mann-Whitney U test. 
Data are expressed as mean±SEM and differences were considered statistically sig-
nificant at P<0.05. 
Results 
α1 Deficiency 
Mice 
Body weight did not differ in α1-deficient mice compared with controls and plasma 
total cholesterol, triglycerides, LDL, and HDL levels did not differ between α1-/- 
and α1+/+ mice, but were elevated in α1+/- relative to α1+/+ mice (table 1). Autopsy 
of organs revealed no abnormalities or pathologies. 
Expression of α1 Integrin 
Expression of α1 integrin was present on SMCs and slightly on T lymphocytes (data 
not shown). Expression was also detected on macrophages in atherosclerotic 
plaques. Figure 1 shows CD11b+ macrophages in atherosclerotic plaques that 
stained positive for α1 integrin. 
al Analysis
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Figure 1. Fluorescence immunohistochemical staining showing expression of (A) α1 integrin
(Alexa488-labeled anti-α1 Ab, green, indicated by arrow) in (B) macrophages (PE-CD11b, red, 
indicated by arrow) in an advanced atherosclerotic plaque in the aortic arch of an ApoE-/- mouse. 
(C) Hematoxylin counterstaining of the same plaque showing macrophages (indicated by ar-
rows). For full colour figure see page 135. 
A B CAlexa488-anti-α1 Ab PE-CD11b Hematoxylin
Table 1. Plasma lipid profile and body weight of α1-deficient, antibody-treated, and control mice. 
Mice n 
Average 
body weight
(g) 
Plasma total 
cholesterol 
(mM) 
Plasma total 
triglycerides
(μM) 
Plasma total 
HDL 
(mM) 
Plasma total 
LDL 
(mM) 
       
α1-/-/ApoE-/- 10 26 9.79 ± 0.79 1703.5 ± 112 0.38 ± 0.1 8.6 ± 0.7 
α1+/-/ApoE-/-   9 26 14.9 ± 1.2* 2433.5 ± 166* 0.81 ± 0.1* 12.9 ± 1.1* 
α1+/+/ApoE-/- 12 27 10.7 ± 1.1 1690.4 ± 195 0.33 ± 0.1 9.6 ± 1.0 
       
Early treatment       
anti-α1 Ab 13 28 10.9 ± 0.6 1088.6 ± 106 0.44 ± 0.1† 10.1 ± 0.6 
control Ab 14 28 9.4 ± 0.6 859.2 ± 121 0.28 ± 0.1 8.8 ± 0.5 
       
Delayed treatment       
anti-α1 Ab 11 30 11.2 ± 0.6 1227.9 ± 117 0.32 ± 0.03 10.4 ± 0.6 
control Ab 14 30 11.3 ± 0.6 1419.8 ± 110 0.31 ± 0.03 10.5 ± 0.6 
* P<0.05, α1+/-/ApoE-/- vs. α1+/+/ApoE-/- 
† P<0.05, early treatment, anti-α1 Ab vs. control Ab 
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Extent of Atherosclerosis 
Complete deletion of α1 integrin reduced total plaque area by 42% compared with 
WT mice (figure 2). The decrease in plaque area was due to a 38% decrease in ad-
vanced atherosclerotic plaque area. Absence of one α1 allele was sufficient to sig-
nificantly reduce the total plaque area as seen in heterozygous mice in which total 
plaque area was reduced by 37% and advanced plaque area was reduced by 16% 
compared with WT mice (P<0.05). Plaques representative of the 3 groups of mice are 
shown in figure 2C, which shows that plaque area was significantly reduced in α1 
homozygous and heterozygous mice compared with controls. 
Atherosclerotic Plaque Composition 
To further characterize atherosclerosis, the composition of lesions was analyzed.  
Histological analysis of advanced plaques demonstrated that α1-deficiency resulted 
not only in a decreased size, but also a dramatic alteration in plaque composition. 
Lesions from α1-deficient mice were more fibrotic and less lipid-rich than those of 
WT mice, whereas plaques of α1 heterozygous mice were of an intermediate pheno-
type (figure 3). Analysis of initial lesions in the aortic arch revealed that the relative 
number of CD3+ cells, macrophages, collagen, and αSMA content did not differ in  
Figure 2. Deficiency in α1 integrin reduced plaque area in aortic arches. (A) Total plaque 
area of α1-/- and α1+/- mice was significantly smaller than those of α1+/+ mice. (B) Average 
area of individual advanced plaques of α1-/- mice was smaller compared with those of 
α1+/+ mice. (C) HE-stained sections of representative advanced atherosclerotic plaques of 
α1-/-, α1+/- and α1+/+ mice showing relative area of plaques. *P<0.05. For full colour figure 
see page 136.
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Figure 3. Plaque composition of initial and advanced atherosclerotic plaques in aortic arches
of α1-deficient mice. There were significantly less (A) macrophages (Mac3+, red stained cells) 
and (B) CD3+ cells (arrows) in advanced plaques of α1-/- compared with α1+/+ mice. There 
was a significantly higher (C) collagen content (SR+) and (D) SMC content (αSMA+ cells, 
arrows) in advanced plaques of α1-/- compared with α1+/+ mice. (E) Lipid cores were smaller 
in plaques of α1-/- compared with α1+/+ mice (arrows). *P<0.05. For full colour figure see 
page 137. 
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initial atherosclerotic plaques. Similarly, initial lesions in heterozygous mice were 
not altered compared with those in WT mice. 
 Differences in plaque composition were more pronounced in advanced lesions 
of homozygous and heterozygous mice. Inflammatory cell content significantly de-
creased in homozygous mice, reflected by a decrease in the percentage of macro-
phages and CD3+ cells. Furthermore, lipid cores of plaques were smaller while ECM 
as measured by collagen and αSMA content increased. Atherosclerotic plaques of 
heterozygous mice showed an intermediate plaque phenotype with a significant 
decrease in CD3+ cells and a trend toward a decrease in macrophage content 
(p=0.07) and collagen content (p=0.06). 
 The presence of cartilaginous metaplasia observed in advanced plaques of α1-
deficient mice was confirmed with immunohistochemical staining against collagen 
II, which is the major matrix protein of cartilage tissue, as well as with alcian blue 
and toluidine blue, which stain chondroid tissue (figure 4). To further identify char-
acteristics of cartilaginous metaplasia, we performed immunohistochemistry using 
bone markers. The regulators of bone formation OC, ON, OPN, BMP-2, and BMP-4 
were present in areas of cartilaginous metaplasia (figure 5). MGP, another protein 
involved in bone formation, was only present in plaque macrophages. Two regula-
tors of osteoclastogenesis, OPG and OPGL, did not show expression. 
Antibody Treatment 
Mice 
Average body weight of mice did not differ in the anti-α1 antibody-treated group 
compared to controls in either of the early or delayed treatment groups.  There were 
no differences in plasma total cholesterol, triglycerides, or LDL, however HDL was 
slightly elevated in anti-α1 antibody-treated mice compared with controls in the 
early treatment group (table 1). Autopsy of organs revealed no abnormalities or 
pathologies. 
 To ascertain possible systemic effects of antibody treatment on atherosclerotic 
lesion development, FACS analysis was performed on cells isolated from peripheral 
blood, spleen, and lymph nodes, as well as on peritoneal macrophages of anti-α1 
antibody-treated and control mice. Analysis revealed no differences in the amount 
of Mac1+ macrophages between the two groups in either blood or peritoneum. Simi-
larly, there were no differences in the amount of CD4+ (helper) or CD8+ (cytotoxic) 
T lymphocytes, nor in the activation status of T lymphocytes (reflected by 
CD4+/CD8+ ratio and CD4+CD25+ T lymphocytes) between the two groups in any 
of the tissues. There was however, an increase in the amount of CD3+ T lympho-
cytes (total T lymphocytes) in peripheral blood of anti-α1 antibody-treated mice 
compared with controls in both of the early and delayed treatment groups (figure 
6). 
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Antibody Infiltration 
Figure 4. Cartilaginous metaplasia in 
advanced plaques in aortic arches of α1-
deficient mice. (A) Collagen II is ex-
pressed in matrix (indicated by arrows) 
surrounding chondrocyte-like cells. (B) 
Alcian blue and (C) toluidine blue stain-
ings show chondrocyte-like cells and 
chondroid matrix (indicated by arrows) in 
advanced atherosclerotic plaques of α1-/- 
mice. *P<0.05. For full colour figure see 
page 138.
0
5
10
15
20
25
30
%
Cartilaginous Metaplasia
Initial Advanced
*
*
α1-/-
α1+/-
α1+/+
A CB
A
OC
B
BMP-4
C D
E
MGP
F
OPN
BMP-2
ON
Figure 5. Expression of mediators 
of  bone  formation  in  atheroscle‐
rotic plaques  in  the aortic arch of 
 1‐deficient  mice.  (A-C)  Strong 
expression of OC, ON and BMP‐4 
in  chondrocyte‐like  cells  (indi‐
cated by arrows). Weaker expres‐
sion of (D) BMP‐2 and (E) OPN in 
chondrocyte‐like  cells  (indicated 
by  arrows).  (F)  MGP  only  ex‐
pressed  in  macrophages  (indi‐
cated  by  arrow).  Magnification: 
400X.  For  full  colour  figure  see 
page 138.
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Antibody Infiltration 
Figure 6. FACS analysis of CD3+ cells in blood revealed an in-
creased number of circulating T lymphocytes in blood of anti-α1 
antibody-treated mice compared with controls. *P<0.05. 
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Figure 7. Anti-α1 antibody infiltrated atherosclerotic plaques of ApoE-/- mice. (A) Fluorescence 
and bright field images of atherosclerotic plaques in the aortic arch of ApoE-/- mice injected with 
Alexa488-labeled anti-α1 antibody or not injected with any antibody (control). Antibody appears
as green spots in the plaque and autofluorescence of elastic laminae in the media are shown in 
green. (B) TPLSM 3D image of an atherosclerotic plaque in the carotid artery of an ApoE-/-
mouse injected with Alexa488-labeled anti-α1 antibody. Antibody appears as green spots and 
collagen fibers in the plaque and media are shown in blue. For full colour figure see page 139. 
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Antibody Infiltration 
To ascertain whether anti-α1 antibody infiltrated atherosclerotic plaques, we used 
TPLSM and fluorescence microscopy. Atherosclerotic plaques of mice injected with 
Alexa488-labeled anti-α1 antibody displayed more fluorescence in plaques of aortic 
arches compared with control mice, which were not injected with antibody. Simi-
larly, using TPLSM, which combines 3D resolution and large penetration depth19 
showed a positive signal for antibody labeled with the green fluorescent label Al-
exa488 in atherosclerotic plaques in carotid arteries (figure 7). 
Extent of Atherosclerosis 
There was no significant difference in the individual plaque area between anti-α1 
antibody-treated and control mice in either of the early (initial: 14596±1455 for anti-
α1 mAb vs. 15761±1955 for control, P=0.06; advanced: 49593±8051 for anti-α1 mAb 
vs. 91519±14468 for control, P>0.05) or delayed treatment groups (initial: 45184±9635 
for anti-α1 mAb vs. 31076±5729 for control, P>0.05; advanced: 141300±19809 for 
anti-α1 mAb vs. 120498±10671 for control, P>0.05). 
Atherosclerotic Plaque Composition 
Differences in plaque composition between anti-α1 antibody-treated and control 
mice were less striking than in α1-deficient mice. Significant differences observed 
were a decreased macrophage content in initial atherosclerotic plaques of anti-α1 
antibody-treated mice compared with controls in both of the early and delayed 
treatment groups (figure 8A), a decreased CD3+ cell content in advanced plaques of 
anti-α1 antibody-treated mice of the delayed treatment group compared with con-
trols (figure 8B), and an increased collagen content in initial and advanced plaques 
of anti-α1 antibody-treated mice compared with controls of the delayed treatment 
group (figure 8C). There were no differences in αSMA content in any of the groups 
(early treatment, initial: 3.0±0.6 for anti-α1 Ab vs. 1.8±0.4 for control, P>0.05; early 
treatment, advanced: 1.9±1.1 for anti-α1 Ab vs. 3.7±0.5 for control, P>0.05; delayed 
treatment, initial: 0.7±0.5 for anti-α1 Ab vs. 2.8±1.1 for control, P>0.05; delayed 
treatment, advanced: 3.4±0.6 for anti-α1 Ab vs. 4.5±0.4 for control, P>0.05). 
Cell Migration Assay 
Because we observed a reduced macrophage content in both α1-deficient and anti-
α1 antibody-treated mice, we wanted to test the ability of α1-deficient macrophages 
to migrate on collagen substrata. Cells were allowed to migrate on collagen I and IV 
monolayers as it has previously been reported that α1 integrin binds these types of 
collagen.13 Following 4 and 12 hours of incubation, significantly less α1-/- cells had 
migrated on collagen IV compared to WT cells (figure 9A). There was no significant 
difference in the number of α1-deficient cells migrating on collagen I compared 
with WT cells after 4 or 12 hours of migration (figure 9B). Treatment of WT cells 
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with α1-blocking antibody inhibited migration on collagen IV compared with con-
trol antibody after 4 and 12 hours of migration (figure 9C). 
Collagen IV Expression 
Because α1-deficient macrophages as well as macrophages treated with α1-blocking 
antibody were inhibited from migrating on collagen type IV, the expression of col-
lagen IV was determined in atherosclerotic plaques. Collagen IV is strongly ex-
pressed in the region of endothelial cells (EC) and slightly in areas surrounding cells 
in both mouse and human atherosclerotic plaques (figure 10). 
Figure 8. Plaque composition of initial and advanced atherosclerotic plaques in aortic arches of
antibody-treated mice. There were significantly less (A) macrophages (Mac3+, red stained cells) 
and (B) CD3+ cells (brown stained cells, arrows) and a higher (C) collagen content (SR+ areas 
shown in red) in plaques of anti-α1 antibody-treated compared with control mice (Lu indicates 
lumen). *P<0.05. For full colour figure see page 140. 
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Discussion 
Figure 9. Cells lacking α1 integrin or receiving anti-α1 antibody treatment are deficient in mi-
grating on collagen IV, but not collagen I. (A) Significantly less α1-/- macrophages migrated on 
collagen IV compared with α1+/+ after 4 and 12 hours. (B) No significant difference in the num-
ber of α1-/- compared with α1+/+ macrophages migrated on collagen I after 4 and 12 hours. (C)
Significantly less anti-α1 antibody-treated compared with control antibody-treated macrophages 
migrated on collagen IV after 4 and 12 hours. *P<0.05. 
0
500
1000
1500
2000
2500
3000
3500
0
200
400
600
800
1000
1200
1400
1600
1800
0
200
400
600
800
1000
1200
1400
1600
# 
M
ig
ra
te
d 
C
el
ls
# 
M
ig
ra
te
d 
C
el
ls
# 
M
ig
ra
te
d 
C
el
ls
Collagen IV Collagen I Collagen IV
CA B
*
*
*
*
4 hours 12 hours 4 hours 12 hours 4 hours 12 hours
α1-/- Control Abα1+/+ Anti-α1 Abα1-/- α1+/+
Figure 10. Collagen IV expression in mouse and human atherosclerotic plaques. (A) Advanced 
atherosclerotic plaque in a human carotid artery expressing collagen IV in the region of endothe-
lial cells (indicated by arrow, magnification 10X) and (B) shown at higher magnification (40X). (C)
Advanced atherosclerotic plaque in a mouse aortic arch showing collagen IV expression in the 
region of endothelial cells and somewhat surrounding cells within the plaque (indicated by arrow,
magnification 40X). For full colour figure see page 140. 
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Discussion 
To investigate the role of α1β1 integrin in atherosclerosis we have used α1 integrin, 
ApoE double knockout mice as well as administered an α1-blocking antibody to 
normal ApoE knockout mice in an early and delayed treatment setting.  Deficiency 
in α1 integrin did not prevent the initiation of lesion formation, but did reduce the 
size of advanced atherosclerotic plaques and induced a more stable plaque pheno-
type as characterized by decreased inflammation and increased ECM content. In 
both of the early and delayed anti-α1 antibody treatment groups, macrophage con-
tent was decreased in initial plaques while collagen content increased in advanced 
plaques. Furthermore, the CD3+ cell content was decreased in advanced plaques 
after delayed treatment. 
 Antibody treatment against α1 integrin was less effective in attenuating athero-
sclerosis compared to complete genetic deletion, however, the consequences of anti-
body intervention do not necessarily correlate with the phenotype of corresponding 
null animals. Knockout animals are deficient in a particular protein from birth, 
whereas antibody-treated mice receive treatment against the already existing pro-
tein beginning at a later time point for a limited period of time. Furthermore, in the 
present study we sacrificed α1-deficient mice after 26 weeks of age, whereas in the 
antibody intervention study, mice were sacrificed after 17 or 29 weeks of age in the 
early and delayed treatment groups, respectively. Previous studies have also dem-
onstrated differences between the effects of using knockout mice and antibody in-
tervention. For instance, complete genetic deletion of CD154 (CD40 ligand) in 
ApoE-/- mice resulted in smaller advanced plaques,20 whereas with anti-CD40 
ligand antibody treatment, advanced plaque area was not reduced compared to 
controls.21 
 Despite differences in the effects of α1-deficiency and anti-α1 antibody treat-
ment, plaque phenotype was altered in both experiments to a more stable pheno-
type in two important ways, by reducing the macrophage content and increasing 
the collagen content. Indeed, the two major functions of α1β1 integrin are the regu-
lation of collagen synthesis and mediating the migration of activated leukocytes into 
inflamed tissues.7,16 In the course of inflammation, leukocytes migrate through the 
subendothelial basement membrane,7 which is rich in collagen type IV.22 Central to 
the migration of cells into inflammatory sites are adhesive interactions between cells 
and ECM proteins that are widely mediated by the integrin family of adhesion 
molecules.23 α1β1 is a major collagen-binding integrin with a preference for collagen 
IV and is expressed on activated leukocytes. It has been demonstrated in vitro that 
lipopolysaccharide-activated monocytes highly express α1β1 integrin.24 Activated T 
lymphocytes also express α1β1 and it has been shown in vivo to be involved in the 
migration and retention of leukocytes in tissues.25 
 T lymphocytes found in atherosclerotic plaques express α1β1 integrin8 and we 
have demonstrated here that macrophages in normal mouse atherosclerotic plaques 
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also express this integrin. However, the role of α1β1 integrin in lesion development 
has not yet been determined. Our study revealed a reduced inflammatory cell con-
tent particularly in lesions of α1-deficient, but also in anti-α1 antibody treated mice, 
suggesting a role for α1β1 integrin in the accumulation of leukocytes in atheroscle-
rotic plaques. To shed light on the mechanism by which this occurs we performed 
migration assays, which demonstrated that α1-deficient and anti-α1 antibody-
treated macrophages are inhibited from migrating on collagen IV. The subendothe-
lial basement membrane of vessel walls consists largely of collagen IV, through 
which leukocytes must migrate to enter the intima during atherogenesis.26 In the 
present study, we have also shown by immunohistochemical staining that collagen 
IV is expressed in the region of ECs in both human and mouse atherosclerotic 
plaques. It appears therefore, that α1β1 integrin is necessary for the infiltration of 
leukocytes during atherogenesis.  Results of the migration assays also suggest that 
antibody treatment against α1β1 integrin was successful in blocking its function in 
vivo. 
 Furthermore, there was an increase in the level of CD3+ T lymphocytes in the 
peripheral blood of anti-α1 antibody-treated mice as determined by FACS analysis 
as well as a significantly reduced CD3+ cell content in advanced plaques after de-
layed anti-α1 antibody treatment. These findings are consistent with a role of α1β1 
in the migration and/or retention of activated T lymphocytes in collagen-rich tis-
sues.27 By preventing migration and localization of α1β1-positive T lymphocytes in 
tissues such as the vessel wall, antibody treatment against α1β1 results in an in-
creased circulating T lymphocyte population. 
 Our findings are consistent with previous studies on α1β1 integrin in various 
models of inflammatory diseases. Monocyte accumulation and activation was found 
to be reduced in mouse models of colitis in which α1 integrin was deleted or 
blocked by antibody treatment.11 A decrease in macrophage accumulation was also 
observed in a model of kidney fibrosis in which α1 integrin was deleted.10 A defi-
ciency in α1β1 integrin as well as anti-α1 antibody treatment was reported to be 
protective against experimental murine arthritis, delayed-type hypersensitivity, and 
contact hypersensitivity as shown by a reduced leukocyte infiltrate.9 In addition, in 
vitro α1-blocking antibody treatment attenuated the proliferation of T lymphocytes 
isolated from draining lymph nodes of arthritic rats28 and inhibited T lymphocytes 
cultured from peripheral blood of arthritic patients from migrating on collagen IV.29 
 Besides its role in mediating activated leukocyte migration to sites of inflamma-
tion, α1β1 integrin regulates collagen synthesis by negative feedback inhibition. 
This was demonstrated in α1-deficient mice in which steady state collagen synthesis 
was observed in normal and wounded dermis.16 Furthermore, receptor stimulation 
has been shown to enhance the downregulation of collagen synthesis.15 In our study 
we found an increased collagen content in atherosclerotic plaques of both α1-
deficient and anti-α1 antibody-treated mice. This was particularly evident in ad-
vanced plaques, which is to be expected given that initial plaques consist of little or 
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no collagen. An increased collagen content in atherosclerotic lesions contributes to 
their stability as does a thick fibrous cap, which we also observed in α1-deficient 
mice. Atherosclerotic lesions consist primarily of collagen types I and III and al-
though α1β1 prefers to bind collagen IV, it is also a receptor for collagen I. It has 
been reported that α1β1 integrin downregulates collagen I mRNA levels in cells 
suspended in collagen gels30 and collagen I synthesis was increased in the dermis of 
α1-deficient mice due to elevated collagen I mRNA levels.16 This suggests that nega-
tive feedback inhibition of collagen synthesis mediated by α1β1 integrin occurs in 
atherosclerosis. 
 In addition to an increased collagen content, we found an increase in SMC con-
tent as revealed by αSMA-positive cells in advanced atherosclerotic plaques of α1-
deficient mice. SMCs are ECM-producing cells that are responsible for the collagens 
present in atherosclerotic plaques and are particularly involved in the formation of 
fibrous caps. The abundance of SMCs in atherosclerotic plaques is therefore impor-
tant to plaque stability, however the role of α1β1 integrin in SMC proliferation and 
accumulation in atherosclerotic plaques is unclear. 
 Along with a change in plaque composition to a more stable plaque phenotype, 
cartilaginous metaplasia was observed in plaques of α1-deficient mice. Cartilagi-
nous metaplasia may be a pathway by which calcification develops in atheroscle-
rotic lesions,31 and increasing morphological and molecular evidence suggests that 
atherosclerotic calcification shares similarities with bone formation. Several proteins 
involved in osteogenesis have been identified in human atherosclerotic lesions such 
as OC, ON, OPN, BMP-2, BMP-4, and MGP and are associated with calcification.32 
OC is an osteoblast-specific protein that can also be expressed by macrophages, 
whereas ON is a non-collagenous protein that accumulates in the ECM of bone tis-
sue. BMP-2 and BMP-4 are osteogenic factors that trigger osteoblast differentiation. 
OPG, a member of the TNF receptor superfamily, is expressed on osteoblast-like 
cells and inhibits their differentiation. 
 In our study, we observed the expression of all of these bone markers to various 
degrees in areas of cartilaginous metaplasia, which suggests that the cartilaginous 
tissue found in these lesions may be a precursor to calcification. It is important to 
note that although cartilaginous metaplasia was more extensive in lesions of α1-
deficient mice relative to controls, there was no gross difference in the expression 
pattern of cartilage and bone markers between the two groups. The role of α1β1 
integrin in cartilaginous metaplasia is unknown, however, its occurrence in athero-
sclerotic plaques may be an indirect effect of α1-deficiency. It has been reported that 
two of the matrix components known to be important in bone formation, fibronectin 
and collagen I, are also important in promoting mineralization of vascular cells.33 
Because collagen type I is abundantly present in atherosclerotic plaques and an in-
creased collagen content was observed in plaques of α1-deficient mice, this may 
have lead to the formation of cartilaginous metaplasia observed in these plaques. 
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 These results indicate a role of α1β1 integrin in atherosclerosis and emphasize 
the importance of integrin-mediated adhesive interactions in this inflammatory dis-
ease. Complete deletion of this integrin was not only able to reduce plaque area, but 
also altered plaque composition by reducing inflammation and increasing the ECM 
content, which are crucial features of a stable atherosclerotic plaque. Antibody in-
tervention against α1 integrin, although less effective in attenuating atherosclerosis 
compared with complete genetic deletion, modulated plaque characteristics in two 
very important respects by decreasing the leukocyte content and increasing collagen 
content. It appears that α1β1 integrin is involved in the inflammatory process of 
atherosclerosis by mediating the migration of leukocytes to lesions. 
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CHAPTER 6 
TWEAK inhibition reduces fibrosis and 
alters the macrophage phenotype in 
atherosclerotic plaques of ApoE-/- mice 
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Abstract 
TWEAK is a multifunctional cytokine belonging to the tumour necrosis factor su-
perfamily and binds to the receptor Fn14. Both TWEAK and Fn14 are expressed in 
atherosclerotic plaques in areas rich in macrophages and foam cells.  We investi-
gated the role of TWEAK/Fn14 interactions in ApoE-/- mice. ApoE-/- mice were 
treated with TWEAK-inhibiting fusion protein, Fn14:Fc, in an early (5 to 17 weeks of 
age) and delayed (17 to 29 weeks of age) setting. In the aortic arch, Fn14:Fc resulted 
in smaller advanced plaques after early treatment.  Fn14:Fc also resulted in a low 
fibrotic content in advanced plaques of both early and delayed treatment groups. 
Advanced plaques of the delayed treatment group exhibited an increased macro-
phage content and smaller macrophage size.  ApoE-/- bone marrow-derived macro-
phages and foam cells treated with Fn14:Fc and other TWEAK-blocking reagents 
did not induce apoptosis, but blocking TWEAK results in less uptake of modified 
lipids. While TWEAK inhibition did not prevent initiation of lesions, both early and 
delayed treatment reduced fibrosis in atherosclerotic plaques of ApoE-/- mice. De-
layed treatment also induced advanced plaques with a unique macrophage pheno-
type. These findings suggest that TWEAK/Fn14 interactions play a role in athero-
sclerosis and may mediate lipid metabolism in macrophages. 
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Introduction 
TNF-like weak inducer of apoptosis (TWEAK) is a recently identified cytokine be-
longing to the TNF ligand family. It is synthesized as a transmembrane protein with 
its N-terminus residing in the cytoplasm (type II), that can be cleaved into a soluble 
form.1 Using recombinant soluble TWEAK, a novel receptor for TWEAK was identi-
fied and named TWEAKR.2 This was found to be identical to the previously de-
scribed fibroblast growth factor (FGF)-inducible 14 (Fn14), a small type I plasma 
membrane protein discovered during a search for growth factor-inducible genes.3,4 
 As its name suggests, TWEAK was initially described as a weak inducer of 
apoptosis.1 TWEAK expression on human peripheral blood monocytes induced by 
IFNγ have been shown to contribute to monocyte cytotoxicity against tumor cells.5 
Studies investigating the molecular mechanism of TWEAK-mediated cell death re-
ported that TWEAK indirectly induces apoptosis in several tumor cell lines via en-
dogenous TNF.5,6 Further studies by Nakayama et al. described additional cell-type 
specific pathways of TWEAK-induced cell death including caspase-dependent 
apoptosis and cathepsin B-dependent necrosis.7,8 
 These multiple pathways of TWEAK-induced cell death are solely mediated by 
Fn14,8, however the signaling pathway remains to be defined.  Studies have shown 
that binding of TWEAK to Fn14 activates the NFκB pathway, which regulates genes 
involved in inflammation, and that this occurs via TNF receptor associated factors 
(TRAF).9 TWEAK/Fn14 interaction is therefore capable of regulating a variety of 
cellular processes besides apoptosis, many of which are important in atherosclerosis. 
TWEAK has been implicated in angiogenesis as it induces the proliferation and mi-
gration of ECs and aortic SMCs in vitro and neovascularization when implanted in 
rat corneas.10,11 It has also been shown that TWEAK potentiates the mitogenic activ-
ity of FGF-2 and VEGF-A.12 In addition, TWEAK can stimulate the expression of 
proinflammatory cytokines in several cell types, including ECs13 and mesangial 
cells.14 
 Recently, analysis of human atherosclerotic plaques showed that TWEAK and 
Fn14 are expressed in areas rich in macrophages and foam cells and TWEAK in-
duces production of proatherogenic mediators such as MCP-1, IL-6, IL-8, MMP-9,15 
and HMGB116 by a human macrophage-like cell line, however the effects of TWEAK 
on atherogenic development have not been determined. In the present study, using 
a TWEAK-blocking protein in a mouse model of atherosclerosis we report that 
blocking TWEAK inhibits fibrosis and induces a macrophage-rich plaque pheno-
type with smaller macrophages in vivo and decreases lipid uptake by macrophages 
in vitro. 
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ethods 
Mice 
To study the role of TWEAK/Fn14 interactions in atherosclerosis, male ApoE-/- mice 
on a 100% C57Bl6 background were used (obtained from Iffa Credo) and fed normal 
chow. Mice were injected intraperitoneally twice a week with 100μg of murine 
Fn14:Fc fusion protein (Fn14:Fc) as previously described14 or murine IgG isotype 
control Ab (P1.17) (American Type Culture Collection). Mice received treatment for 
12 weeks beginning at either 5 weeks of age when no atherosclerotic lesions were 
present in the aortic arch (early treatment: Fn14:Fc, n=15; control, n=15) or 17 weeks 
of age when advanced lesions began to appear in the aortic arch (delayed treatment: 
Fn14:Fc, n=14; control, n=14). This dose level was designed to achieve at least a 
20μg/ml serum level of Fn14:Fc, a level sufficient to inhibit TWEAK based on com-
plete inhibition of TWEAK-induced signaling by 2μg/ml Fn14:Fc in vitro.14 Mice 
were sacrificed following an 8-hour fast. Approximately 1.0ml blood was drawn 
from the caval vein for lipoprotein analysis. Animal experiments were approved by 
the institutional committee for the care and welfare of laboratory animals of Maas-
tricht University. 
Lipid Profiles 
For the assessment of lipid profiles standard enzymatic techniques were used as 
described previously.17 
Histology and Morphometry 
The arterial tree was perfused with PBS containing 0.1mg/ml sodium nitroprusside 
(Sigma) followed by 1% phosphate-buffered paraformaldehyde. Major organs of 
each mouse were excised and analyzed for abnormalities on 4μm-thick paraffin sec-
tions stained with HE. The aortic arch was processed and cut as described previ-
ously.17,18 Atherosclerotic lesions were classified as initial (AHA type II/III: fatty 
streaks containing macrophage-derived foam cells) or advanced (AHA type IV/V: 
containing extracellular lipid, a lipid core, and/or a fibrous cap). Morphometric 
analysis was performed as described previously.17,18 
Immunohistochemistry 
Sections were immunolabeled to detect macrophages, T lymphocytes, and SMCs, as 
described previously.17,18 TUNEL (terminal deoxynucleotidyl transferase biotin-
dUTP nick end labeling) staining was performed with the use of the ApopTag kit 
(Oncor) for the detection of apoptotic cells in vivo. 
Materials and M
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Cell Isolation 
Bone marrow-derived macrophages were isolated from the femur and tibia of 
ApoE-/- mice and cultured as described previously.18 
Lipoprotein Isolation and Modification 
Low density lipoprotein (LDL) was isolated from fresh human plasma by density 
gradient ultracentrifugation. LDL was oxidized with CuSO4 by incubating over-
night at 37°C followed by dialysis against PBS+10μM EDTA. Modification of LDL to 
oxidized LDL (oxLDL) was confirmed by gel electrophoresis.  The concentration of 
lipoprotein samples was determined by the Bradford protein assay. 
Fn14 Expression on Macrophages and Foam Cells 
Bone marrow-derived macrophages were incubated on glass cover slips in 24-well 
plates at approximately 200,000 cells per well and were loaded with 25μg/ml oxLDL 
for 24 or 48 hours to generate foam cells. Cells were fixed with acetone and blocked 
with 4% normal goat serum in PBS for 30 minutes. Non-specific binding of 
avidin/biotin reagents was blocked using a blocking kit (Vector Labs, SP-2001) ac-
cording to the manufacturer’s instructions. Cells were incubated overnight at 4°C 
with 4μg/ml (in PBS) of a purified Ig fraction of rabbit polyclonal anti-mouse Fn14 
(Biogen Idec, Inc.) or normal rabbit Ig as a negative control. Biotinylated goat anti-
rabbit Ig (Vector Labs, BA-1000) at 1:200 dilution in 4% NGS in PBS was added for 
30 minutes followed by addition of 10μg/ml (in PBS) of streptavidin Alexa488 (Mo-
lecular Probes, S-11223) and incubated in the dark for 30 minutes. Nuclei were 
counterstained with 4’,6-Diamidino-2-phenylindole, dihydrochloride (DAPI). 
Lipid Uptake 
Bone marrow-derived ApoE-/- macrophages were treated overnight with 100ng/ml 
Fc-TWEAK prepared as previously described,14 10μg/ml TWEAK-blocking proteins 
Fn14:Fc or murine anti-TWEAK mAb P2D10,14 10μg/ml Fn14-specific blocking mAb 
P2D3, 10μg/ml MOPC-21 (murine IgG1 isotype control Ab for anti-Fn14 mAb), or 
10μg/ml P1.17 (murine IgG2a isotype control Ab for Fc-TWEAK, Fn14:Fc, and anti-
TWEAK mAb) (both isotype controls were from American Type Culture Collection). 
To demonstrate the specificity of the stimulatory effect of Fc-TWEAK, 100ng/ml Fc-
TWEAK previously determined to be an optimal dose in various assays14 was pre-
mixed for 30 minutes with 10X excess of TWEAK-blocking agents Fn14:Fc, anti-Fn14 
mAb, or anti-TWEAK mAb prior to addition to cells. OxLDL was labeled with the 
fluorescent dye 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate 
(DiI) (Molecular Probes). Cells (2x106 per sample) were loaded with 25μg/ml DiI-
labeled oxLDL for 10 or 30 minutes. OxLDL uptake by macrophages was assessed 
by fluorescence-activated cell sorting (FACS) analysis (FACSCalibur, BD Biosciences) 
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and analyzed with CellQuest software (BD Biosciences). DiI-labeled oxLDL uptake 
was determined for a total of 104 cells per sample and expressed as geomeans. 
Apoptosis Assay 
Bone marrow-derived ApoE-/- macrophages or foam cells (prepared by loading 
macrophages with 25μg/ml oxLDL for 24 hours) were treated overnight with the 
same reagents used for the lipid uptake assay: 100ng/ml Fc-TWEAK, 10μg/ml 
Fn14:Fc, 10μg/ml anti-TWEAK mAb, 10μg/ml anti-Fn14 mAb, 10μg/ml MOPC-21, 
10μg/ml P1.17, or 20μg/ml cycloheximide (CHX) (Sigma), which was used as a posi-
tive control for apoptosis. To determine the TWEAK-blocking ability of each reagent, 
100ng/ml Fc-TWEAK was premixed for 30 minutes with 10× excess of TWEAK-
blocking agents Fn14:Fc, anti-Fn14 mAb, or anti-TWEAK mAb prior to addition to 
cells. Apoptosis was determined by FACS analysis using an annexin VFITC apop-
tosis detection kit (BD Biosciences). Briefly, following antibody treatment, cells were 
washed with PBS and labeled with annexin VFITC (which stains apoptotic and ne-
crotic cells) and propidium iodide (which stains necrotic cells). Cells that were an-
nexin V-positive and propidium iodide-negative were considered apoptotic. 
Statistical Analysis 
Statistical analyses of both the in vivo and in vitro studies were performed using a 
non-parametric Mann-Whitney U test. Data are expressed as mean±SEM and differ-
ences were considered statistically significant at P<0.05. 
Results 
General 
Average body weight of mice did not differ in Fn14:Fc-treated mice compared with 
controls in either of the early or delayed treatment groups. There were no differ-
ences in plasma total cholesterol, triglycerides, or LDL, however HDL was slightly 
elevated in Fn14:Fc-treated mice compared with controls in the early treatment 
group (table 1). Autopsy of organs revealed no abnormalities or pathologies. 
Extent of Atherosclerosis 
Fn14:Fc treatment resulted in smaller advanced plaques compared with control an-
tibody treatment in the early treatment group as shown in figure 1A. The number of 
initial and advanced plaques in the early treatment group did not differ between 
Fn14:Fc-treated and control mice. In the delayed treatment group, however, there 
were more initial plaques and fewer advanced plaques in Fn14:Fc-treated mice 
compared with controls, as shown in figure 1B. Thus, blocking TWEAK starting at 5  
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weeks of age, prior to establishment of atherosclerotic lesions, did not inhibit the 
occurrence of plaques but did significantly limit the size of advanced lesions. Block-
ing TWEAK at 17 weeks of age, after lesions had begun to appear, resulted in fewer 
advanced plaques suggesting that plaque progression from the initial to advanced 
stage as qualified by AHA criteria was inhibited. 
 
 
 
Table 1. Plasma lipid profile and body weight of  
Treatment n 
Average 
body weight
(g) 
Plasma total 
cholesterol 
(mM) 
Plasma total 
triglycerides
(μM) 
Plasma total 
HDL 
(mM) 
Plasma total 
LDL 
(mM) 
Early       
Fn14:Fc 15 30 10.7 ± 0.7 997 ± 78 0.45 ± 0.05* 9.96 ± 0.6 
Control Ab 14 28 9.4 ± 0.6 859 ± 121 0.28 ± 0.05 8.84 ± 0.5 
       
Delayed       
Fn14:Fc 15 30 12.8 ± 0.8 1581 ± 104 0.29 ± 0.04 11.9 ± 0.7 
Control Ab 14 30 11.3 ± 0.6 1420 ± 110 0.31 ± 0.03 10.5 ± 0.6 
* P<0.05
 
 
Figure 1. Smaller advanced plaques with early 
Fn14:Fc treatment and fewer advanced plaques with 
delayed treatment. (A) Early Fn14:Fc treatment re-
sulted in smaller plaque areas compared with control 
mice. (B) Delayed Fn14:Fc treatment resulted in more 
initial plaques and fewer advanced plaques. *P<0.05. 
For full colour figure see page 141. 
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Atherosclerotic Plaque Composition 
Although Fn14:Fc treatment did not affect plaque size to a great extent, the compo-
sition of lesions was altered. Fn14:Fc treatment resulted in less fibrous plaques due 
to a reduced αSMA content in both initial and advanced lesions compared with con-
trol antibody treatment in the delayed treatment group (figure 2A), as well as a re-
duced collagen content in advanced plaques of Fn14:Fc-treated mice in both the 
early and delayed treatment groups (figure 2B). Interestingly, there was an in-
creased macrophage content in advanced plaques of the delayed treatment group of 
Fn14:Fc-treated mice compared with controls (figure 2C). CD45+ cell content was 
decreased in initial plaques following delayed treatment (data not shown). Lipid 
core sizes in advanced plaques did not differ between Fn14:Fc-treated mice and con-
trols in the delayed treatment group (figure 2D). No lipid cores were observed in 
the early treatment group. Thus, both early and delayed anti-TWEAK treatment 
inhibited fibrosis. Delayed treatment also induced a macrophage-rich plaque phe-
notype in advanced lesions, but did not change the size of lipid cores. 
Lipid Uptake by Macrophages 
In addition to inducing macrophage-rich advanced plaques with delayed Fn14:Fc 
treatment, the size of macrophage foam cells in vivo was determined and it was 
found that macrophages in plaques of Fn14:Fc-treated mice were smaller than in 
controls as shown in figure 3A. This suggests that TWEAK inhibition might reduce 
lipid uptake thereby limiting the size of macrophages.  This possibility was directly 
tested in vitro. Bone marrow-derived ApoE-/- macrophages pretreated with 
TWEAK-blocking reagents took up less DiI-labeled oxLDL compared with cells 
treated with control antibody after both 10 and 30 minutes of lipid loading. Figure 
3B shows results after 30 minutes of lipid loading. Conversely, addition of TWEAK 
to the culture did not further enhance lipid uptake (data not shown), suggesting 
there is already sufficient endogenous TWEAK in the culture system. These data 
indicate that endogenous TWEAK/Fn14 interactions regulate lipid uptake in cul-
tured macrophages and may thereby affect the size of macrophages in vivo. 
Fn14 Expression on Macrophages and Foam Cells 
To ascertain whether the receptor is expressed by macrophages and foam cells, 
immunolabeling of Fn14 was performed on ApoE-/- bone marrow-derived macro-
phages and foam cells generated by treatment with oxLDL. Immunofluorescence 
images of macrophages (figure 4A) and foam cells treated with oxLDL for 48 hours 
(figure 4B) show staining with Alexa488-labeled anti-Fn14 Ig as compared with con-
trol Ig indicating the expression of Fn14 on these cells. Foam cells generated by 
treatment with oxLDL for 24 hours showed similar results to those treated with 
oxLDL for 48 hours (data not shown). 
 
Fn14 
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Apoptosis of Macrophages and Foam Cells in vivo and in vitro 
The increased macrophage numbers might be due to a reduction in apoptosis dur-
ing Fn14:Fc treatment. Therefore, apoptosis was determined in macrophages  and 
foam cells in vitro after treatment with TWEAK. Since endogenous TWEAK might 
be affecting the baseline apoptosis under these culture conditions, the effects on 
apoptosis of various reagents that block TWEAK/Fn14 interactions, including 
Fn14:Fc, anti-Fn14 antibody, and anti-TWEAK antibody were determined. As 
Figure 2. Plaque composition of initial and advanced atherosclerotic plaques. Fibrotic content
of atherosclerotic plaques was significantly lower with Fn14:Fc treatment due to (A) a re-
duced αSMA content in initial and advanced plaques of mice that received delayed Fn14:Fc 
treatment and (B) a reduced collagen content as shown by SR staining in advanced plaques
following both early and delayed Fn14:Fc treatment compared with controls. (C) Macrophage 
content as shown by Mac3 immunohistochemical staining increased in advanced plaques of
Fn14:Fc-treated mice compared with controls. (D) Lipid core content (indicated by arrow) as 
shown by HE staining in advanced plaques did not differ between Fn14:Fc-treated mice and 
controls in the delayed treatment group. *P<0.05. For full colour figure see page 142. 
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shown in figure 5A, it was found that neither TWEAK nor TWEAK-blocking shown 
Figure 3. (A) Macrophages in initial and advanced plaques of Fn14:Fc-treated mice were smaller 
than in controls. Total refers to all macrophages regardless of whether present in initial or ad-
vanced plaques. (B) Bone marrow-derived macrophages treated with TWEAK-inhibiting re-
agents (Fn14:Fc, anti-Fn14 mAb, and anti-TWEAK mAb) took up less DiI-labeled oxLDL after 
30 minutes of lipid loading compared with control antibody treatment.  Black bars refer to 
TWEAK-inhibiting reagents and white bars refer to respective control antibodies. *P<0.05. 
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Figure 4. Fn14 is expressed on bone marrow-derived macrophages and foam cells as detected 
by immunohistochemistry using anti-Fn14 Ab. Fn14 is expressed on (A) macrophages and (B)
foam cells treated with oxLDL for 48 hours. Nuclei were counterstained with DAPI. Control
cells were stained with Ig isotype Ab. For full colour figure see page 143. 
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shown in figure 5A, it was found that neither TWEAK nor TWEAK-blocking re-
agents had an effect on apoptosis of macrophages and foam cells. To further ascer-
tain the effects of Fn14:Fc on macrophage apoptosis, TUNEL staining was per-
formed in vivo on aortic arch sections containing atherosclerotic plaques. It was 
found that the number of TUNEL+ cells in Fn14:Fc-treated mice did not differ from 
those in control mice in neither the early nor delayed treatment groups as shown in 
figure 5B. These data suggest that TWEAK/Fn14 interactions do not mediate apop-
tosis of macrophage foam cells in murine atherosclerotic plaques. 
 
Figure 5. (A) There were no differ-
ences in macrophage or foam cell 
apoptosis between  treatment with 
Fc-TWEAK and TWEAK-blocking 
reagents (Fn14:Fc, anti-Fn14 mAb, 
anti- TWEAK mAb). CHX refers to 
positive control. (B) The number of 
TUNEL+ cells in Fn14:Fc-treated 
mice did not differ significantly 
from those in control mice in either 
of the early or delayed treatment 
groups. 
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Discussion 
TWEAK is a multifunctional cytokine involved in processes that are important in 
atherosclerosis such as cell proliferation, migration, apoptosis, angiogenesis, and the 
induction of inflammatory cytokines. In the present study we investigated the ef-
fects of blocking TWEAK/Fn14 interactions on lesion development and progression 
in a mouse model of atherosclerosis.  Our novel findings reveal a role for TWEAK in 
atherosclerosis. TWEAK does not play a role in plaque initiation but regulates 
atherosclerosis at later stages as evidenced by smaller advanced plaques after early 
treatment with the TWEAK-blocking fusion protein, Fn14:Fc, and the reduced 
number of advanced plaques after delayed treatment with Fn14:Fc. TWEAK pro-
motes fibrous plaques, as shown by reduced collagen content in advanced plaques 
with either early or delayed Fn14:Fc treatment. To our knowledge, this is the first 
demonstration that blocking TWEAK inhibits fibrosis. Treatment with Fn14:Fc also 
resulted in a unique macrophage-rich advanced plaque phenotype with delayed 
treatment. Not only were macrophages in lesions of mice treated with Fn14:Fc more 
abundant, they were smaller compared with those in lesions of control mice, and 
took up less modified lipids in vitro. Thus, TWEAK may be involved in regulating 
macrophage lipid metabolism. 
 We demonstrate that macrophages and foam cells express Fn14. TWEAK and 
Fn14 expression have previously been shown in atherosclerotic plaques, particularly 
in regions rich in macrophages and foam cells,15 and TWEAK stimulation of a hu-
man monocyte cell line induced the expression of pro-inflammatory mediators such 
as MMP-9, IL-6, IL-8, and MCP-1 suggesting that TWEAK plays a proatherogenic 
role in atherosclerosis. Treatment with TWEAK has also been shown to induce pro-
liferation11 and migration of SMCs, an effect that was blocked by treatment with 
Fn14:Fc.19 In the present study we found a significantly reduced SMC content in 
lesions of Fn14:Fc-treated mice of the delayed treatment group suggesting that 
TWEAK/Fn14 interactions mediate SMC proliferation and migration in atheroscle-
rosis. TWEAK-expressing macrophages may regulate SMC proliferation and migra-
tion via autocrine or paracrine-mediated signals since both cell types express the 
Fn14 receptor. Interestingly, high level expression of Fn14 has been associated with 
fibroblasts that are induced by mechanical stress to assume a proliferating and syn-
thetic phenotype.20 Further investigations are warranted to determine whether 
TWEAK/Fn14 signaling also promotes collagen synthesis by SMCs. 
 Blocking the TWEAK/Fn14 pathway may have reduced apoptosis of macro-
phage foam cells in lesions resulting in their accumulation. TWEAK is known for its 
ability to induce apoptosis and, therefore, we investigated whether ApoE-/- bone 
marrow-derived macrophages would undergo apoptosis upon treatment with 
TWEAK or would be inhibited from undergoing apoptosis by treatment with 
TWEAK-blocking reagents. Interestingly, neither TWEAK nor TWEAK-blocking 
reagents had a significant effect on apoptosis in macrophages and foam cells in vi-
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tro. In addition, no differences in the number of apoptotic cells were observed in 
vivo between FN14:Fc-treated compared with control mice as revealed by TUNEL 
staining of aortic arch sections. It is also interesting to note that the size of necrotic 
cores did not differ between Fn14:Fc-treated mice and controls, since lipid core size 
is determined by the extent of macrophage cell death occurring in an atherosclerotic 
lesion. As plaques progress, macrophages continue to take up modified lipids until 
they undergo cell death and release their contents thereby contributing to the for-
mation of a necrotic lipid core. In our mice, no differences in lipid cores sizes were 
found between Fn14:Fc-treated mice and controls, lending further support to the 
suggestion that macrophage apoptosis is not altered by blocking TWEAK/Fn14 in-
teractions. Had TWEAK inhibition by Fn14:Fc treatment resulted in reduced apop-
tosis of macrophages, smaller lipid cores would be expected in lesions of Fn14:Fc-
treated mice, which was not the case. Taken together, these observations suggest 
that TWEAK does not mediate macrophage apoptosis in murine atherosclerotic le-
sions. 
 In the majority of studies that have reported TWEAK-mediated apoptosis, cell 
death occurred indirectly or required co-incubation with sensitization agents.21 
TWEAK was shown to induce cell death in Kym-1 rhabdomyosarcoma cells indi-
rectly via endogenous TNF.6 This was later confirmed by Nakayama et al.7 who fur-
ther characterized mechanisms of TWEAK-induced cell death in various tumour 
cell lines and found that HT-29 colon carcinoma cells and KATO-III gastric adeno-
carcinoma cells are sensitive to TWEAK, but only in the presence of IFNγ. Direct 
induction of apoptosis by TWEAK only occurred in HSC3 oral squamous carcinoma 
cells.7 In addition, monocyte apoptosis in systemic lupus erythematosus was shown 
to occur via increased TWEAK expression in activated T cells.22 These findings indi-
cate that TWEAK does possess proapoptotic activity, but its effects may be indirect 
and cell-type dependent. In the context of atherosclerosis, TWEAK does not appear 
to induce apoptosis in macrophages and foam cells. 
 Having ruled out the possibility of inhibiting macrophage apoptosis by Fn14:Fc 
treatment, the increased macrophage content observed in lesions of Fn14:Fc-treated 
mice, and in particular the smaller size of these cells, lead us to investigate the ef-
fects of TWEAK on lipid uptake by macrophages. Blocking the TWEAK/Fn14 path-
way with the reagents Fn14:Fc, anti-Fn14 antibody, and anti-TWEAK antibody re-
sulted in decreased oxLDL uptake compared with control antibody treatment.  This 
suggests that TWEAK/Fn14 interactions modulate lipid uptake and/or efflux in 
macrophages. Since TWEAK/Fn14 interactions regulate innate immune responses in 
macrophages, including cytokine and chemokine production, we speculate that 
they may also regulate lipid uptake through expression of scavenger receptors. In 
addition, it is plausible that, as in the case of apoptosis, TWEAK regulation of lipo-
protein metabolism may require stimulation with another mediator. 
 The advanced plaque phenotype induced by delayed treatment with the 
TWEAK-blocking agent is fairly unique. Like delayed treatment with Fn14:Fc, de-
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layed treatment with a TGFβ inhibitor resulted in less fibrous plaques with in-
creased inflammatory cells compared with controls.17 However, in the case of TGFβ 
inhibition, the plaques exhibited an increased CD3+ cell content, as well as macro-
phage content, and larger lipid cores; macrophage size was not reported to be 
smaller and there was no difference in the number of αSMA+ cells. Thus, inhibition 
of TGFβ appears to increase plaque instability.  Whether or not TWEAK may be a 
useful therapeutic target in atherosclerosis remains to be determined. Though 
TWEAK inhibition reduces the number of advanced AHA lesions, the consequences 
of a macrophage-rich plaque phenotype, albeit small macrophages with reduced 
lipid uptake, is unknown. Regardless, inhibition of fibrosis by TWEAK blockade in 
other disease contexts may be of therapeutic value. 
 In summary, we have demonstrated that TWEAK inhibition in ApoE-/- mice 
induces plaques with reduced SMC and collagen content. Thus, TWEAK may in-
duce SMC proliferation and migration in atherosclerotic lesions.  Amongst the ad-
vanced lesions, which are reduced in number by delayed Fn14:Fc as compared with 
control treatment, TWEAK inhibition also induces a macrophage-rich phenotype. 
TWEAK may regulate lipid metabolism in macrophages since Fn14:Fc treatment 
resulted in smaller macrophages in vivo and TWEAK-blocking reagents resulted in 
less lipid uptake by macrophages in vitro. Given these findings, TWEAK/Fn14 in-
teractions play a role in atherosclerosis, however the mechanisms by which they 
exert their effects remain to be elucidated. 
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CHAPTER 7 
General discussion 
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In this thesis the role of several mediators involved in plaque development and 
progression in mouse models of atherosclerosis are described. Identification of me-
diators at various stages of atherosclerosis is key to gaining insight into the athero-
genic process. Once mediators are identified, they can be manipulated in animal 
models of atherosclerosis such that their effects are inhibited or enhanced in order 
to demonstrate their specific role in the disease and/or evaluate their therapeutic 
potential. 
 We hypothesized that in a mouse model of atherosclerosis, the ApoE-/- mouse, 
the various stages of atherogenesis are accompanied by a specific expression pattern 
of genes. To test this hypothesis, microarray technology was used to analyze gene 
expression in the various stages of atherosclerosis in ApoE-/- mice (chapter 3). The 
gene expression profile during plaque progression revealed upregulation of genes 
involved in inflammation, namely the small inducible cytokines, as well as genes 
involved in protein and matrix degradation.  These findings were validated by in-
hibiting the small inducible cytokines MCP-1 and MCP-5 in an early and delayed 
treatment setting and it was found that atherosclerotic lesions were attenuated and 
exhibited a stable phenotype. 
 Using a different approach to stabilize lesions, the effects of inhibiting neovas-
cularization using angiogenesis inhibitors was determined in a collar-induced 
mouse model of atherosclerosis. It was found that atherosclerotic lesion size was 
reduced with early, but not delayed treatment with the angiogenesis inhibitors an-
ginex and endostatin (chapter 4). 
 The role of a novel mediator not previously described in atherosclerosis, VLA-1, 
and a mediator gaining attention in the field of atherosclerosis, TWEAK, was inves-
tigated in apoE-/- mice in an early and delayed treatment setting. Inhibition of VLA-
1 by antibody blockade, and by complete genetic deletion in particular, attenuated 
atherosclerosis and induced stable lesions characterized by a reduced leukocyte 
content and increased ECM. In addition, a role for this integrin in the extravasation 
of leukocytes to lesions was revealed (chapter 5). Blocking the cytokine TWEAK re-
sulted in lesions rich in macrophages and a reduced ECM content (chapter 6). 
Targeting Macrophages 
While the composition of human atherosclerotic plaques prone to thrombus forma-
tion is continually being defined (chapter 2), it has been established that inflamma-
tion is detrimental to atherosclerosis. Central to inflammatory processes occurring 
in atherosclerotic plaques are leukocytes. Monocyte-derived macrophages in par-
ticular play a prominent role throughout the life of a lesion, exerting pro-
inflammatory effects at all stages of atherogenesis.1 In the present thesis we showed 
that treatment against the cytokines MCP-1 and MCP-5 and the integrin VLA-1 
changed the composition of lesions to a more stable phenotype characterized by a 
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reduced macrophage content. Inhibiting TWEAK/Fn14 interactions also altered 
plaque phenotype, notably the number of macrophages, which was increased. It is, 
therefore, apparent that intervention against diverse targets, whether they are 
chemokines, cytokines, or adhesion molecules, affects macrophage content in 
atherosclerotic lesions. 
Chemokines 
Indeed, given their significant role in atherosclerotic plaque development and pro-
gression, monocyte-derived macrophages are emerging as targets of therapeutic 
strategies and various approaches to suppress macrophage accumulation and func-
tion have been explored.2 Common targets in the initial stages of atherosclerosis are 
the proinflammatory chemokines.  Well-described chemokines that are largely re-
sponsible for the recruitment of monocytes to the vessel wall are MCP-1 and 
RANTES.3 Inhibition of RANTES by administration of an antagonist to its receptor 
reduced macrophage infiltration, reduced the number of atherosclerotic lesions and 
induced a more stable plaque phenotype in ApoE-/- mice.4 A deficiency in MCP-15-7 
or its receptor CCR-2,8 which is highly expressed on monocytes,9 has been shown to 
reduce the macrophage infiltrate thereby reducing atherosclerosis. In the present 
thesis we used a novel approach to target MCP-1, which was to use an inhibiting 
antibody. Treatment with this antibody reduced the macrophage content in both 
early and advanced lesions and reduced the overall atherosclerotic burden. 
Adhesion Molecules 
Beyond monocyte recruitment to the vessel wall, options for intervention include 
inhibiting the adhesion of monocytes to the endothelium or their infiltration 
through the subendothelial basement membrane. Leukocyte adhesion and transmi-
gration into tissue are mediated by integrins and members of the immunoglobulin 
superfamily.10 For instance, antibody blockade of vascular cell adhesion molecule-1 
(VCAM-1), an immunoglobulin highly expressed on activated ECs that bind mono-
cytes through the integrin VLA-4,11 was shown to attenuate atherosclerosis in ApoE-
/- mice by reducing the leukocyte infiltrate.12, 13 Similar effects were achieved by 
blocking VLA-4 in animal models of atherosclerosis.14,15 
 In this thesis, we showed that antibody blockade of VLA-1 integrin reduced the 
macrophage content in initial lesions. VLA-1 binds collagen IV, which is abundantly 
present in the subendothelial basement membrane.16 Activated monocytes are 
known to express VLA-117 and we showed that macrophages in atherosclerotic 
plaques of ApoE-/- mice also express this integrin.  Furthermore, we found that 
macrophages deficient in VLA-1 or treated with an anti-α1 antibody do not migrate 
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on collagen IV. Given these findings we suggest that VLA-1 mediates the extravasa-
tion of monocyte-derived macrophages to atherosclerotic lesions. VLA-1 may, there-
fore, be considered among the various adhesion molecules that play a role in 
atherosclerosis as a novel potential therapeutic target. 
Angiogenesis 
Among the potential targets in the accumulation of macrophages, neovasculariza-
tion has gained increasing attention. Neovascularization has been implicated in the 
progression of atherosclerosis by providing a pathway for leukocyte entry into le-
sions.18,19 Inhibition of neovascularization by endostatin treatment has been reported 
to reduce macrophage accumulation and reduce advanced atherosclerotic lesion 
progression in ApoE-/- mice.20 This is in contrast to our study in which we found a 
reduced size of initial, but not advanced, lesions in ApoE-/- mice upon treatment 
with the angiogenesis inhibitors endostatin and anginex, and this was not accompa-
nied by a reduction in macrophage content. Our findings are also in contrast to the 
effects of anti-angiogenesis therapy in the treatment of cancer, particularly with re-
spect to leukocyte infiltraton. Treatment with several anti-angiogenesis agents in-
cluding endostatin, anginex and angiostatin has been shown to not only reduce mi-
crovessel density in tumours, but to increase the leukocyte infiltrate.21 There is an 
apparent discrepancy in the effects of endostatin and anginex treatment in cancer 
and atherosclerosis. Nevertheless, anginex, which has not previously been studied 
in atherosclerosis, appears to be as effective in reducing atherosclerosis progression 
as endostatin. 
Cytokines 
Instrumental to the progression of atherosclerosis are cytokines that have also been 
explored as potential targets of intervention. Cytokines differentially mediate 
atherogenesis in that some exert pro-inflammatory processes whereas others play 
an anti-inflammatory role. Among the cytokines that perpetuate inflammation in 
atherosclerosis, members of the TNF superfamily such as TNFα and CD40L are well 
described. Blocking CD40L in ApoE-/- mice by administration of an inhibiting anti-
body induced a stable plaque phenotype, which included a reduced macrophage 
content.22 In this thesis we showed that blocking the cytokine TWEAK, a member of 
the TNF superfamily, increased macrophage accumulation in plaques of ApoE-/- 
mice. These results along with those of a previous study in which it was shown that 
TWEAK and its receptor Fn14 are expressed in atherosclerotic lesions23 suggest a 
role for TWEAK/Fn14 interactions in atherosclerosis. 
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 However, these findings are too preliminary to consider TWEAK a potential 
therapeutic target in the treatment of atherosclerosis. Because TWEAK inhibition 
increased macrophage accumulation in plaques, it would be interesting to deter-
mine the effects of TWEAK overexpression and whether the number of macro-
phages would be reduced. Furthermore, recent studies suggest a pro-inflammatory 
role for TWEAK as it has been shown to induce the expression of inflammatory me-
diators such as MCP-1, IL-6, IL-8, and MMP-9.23 Because we observed an unfavour-
able plaque phenotype characterized by an increased macrophage content and de-
creased fibrosis upon TWEAK inhibition, it does not appear likely that inflamma-
tion was reduced. In addition, TWEAK inhibition resulted in smaller macrophages 
in vivo and a reduced lipid uptake by macrophages in vitro suggesting that 
TWEAK may mediate lipid metabolism. To lend further support to this possibility, 
the effects of TWEAK on lipid uptake and efflux, as well as on the expression of 
mediators involved in lipid metabolism would need to be determined.  
 Although additional studies are required to shed more light on the role of 
TWEAK in atherosclerosis before it can be considered a potential target of interven-
tion, information thus far warrants further investigation. A recent study identified 
reduced levels of TWEAK in the plasma of atherosclerosis patients compared to 
healthy subjects and it was suggested that TWEAK may serve as a biomarker for 
subclinical atherosclerosis.24 
Targeting Atherosclerosis 
Atherosclerosis is a complex multifactorial disease, and as such, a multitude of me-
diators play a role that is not unique to atherosclerosis. This presents the challenge 
of developing therapies that target atherosclerotic lesions without affecting other 
organ systems and essential biological processes. None of the targets described in 
this thesis are specific to atherosclerosis. Both MCP-1 and VLA-1 mediate immune 
mechanisms, therefore inhibition of leukocyte recruitment, adhesion and/or migra-
tion should occur specifically in atherosclerotic lesions without the side-effect of 
general immunosuppression. Similarly, angiogenesis is essential to processes such 
as wound healing, therefore when inhibiting neovascularization it is important to 
target the intended vascular bed. However, as mentioned above, anti-angiogenesis 
therapy exerts opposite yet favourable effects in terms of leukocyte infiltration in 
tumours and atherosclerotic lesions. The increased leukocyte infiltration in tumours 
as a result of anti-angiogenesis agents is beneficial in the treatment of cancer, 
whereas the same treatment reduces macrophage infiltration in lesions, which is 
beneficial in the treatment of atherosclerosis. This suggests that targeting a particu-
lar mediator may not necessarily produce the same effect in different tissues. With 
respect to TWEAK, given that it is a multifunctional cytokine inducing various 
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processes from cell proliferation to apoptosis, a large number of side effects could 
potentially arise from targeting this cytokine. 
 The quest for atherosclerosis-specific mediators is ongoing and the use of tech-
nologies such as microarrays has allowed for the identification of genes involved in 
atherogenesis. Techniques such as laser capture microdissection is being applied to 
isolate cells from atherosclerotic plaques to determine their unique atherosclerosis-
specific gene expression profile as compared to the same cell types in other organ 
systems. Recently, the transcription factor TWIST1, not previously linked to athero-
sclerosis, was found to be highly expressed in macrophage foam cells microdis-
sected from human atherosclerotic plaques compared to macrophages in non-
atherosclerotic tissues such as spleen25 and is a potential atherosclerosis-specific tar-
get of intervention. Although it is unclear whether TWIST regulates atherosclerosis 
or is simply a marker of the disease, it has been shown that TWIST reduces the ex-
pression of proinflammatory cytokines by inhibiting NFκB activity,26 suppresses 
apoptosis,27 and induces cell migration and differentiation.28 Given that TWIST is 
upregulated in macrophage foam cells of atherosclerotic plaques and mediates 
processes important in atherosclerosis, this transcription factor is a promising 
atherosclerosis-specific target. 
 Until mediators specific to atherosclerosis are identified, local drug delivery in 
the treatment of atherosclerosis is ideal. Examples of local treatment modalities are 
percutaneous coronary intervention, drug-eluting stents and viral gene transfer to 
target specific cell types.3 A novel drug delivery system currently being explored is 
nanoparticle technology in which a therapeutic agent is conjugated with a carrier 
that specifically binds to the site of interest. Originally applied to imaging tech-
niques, nanoparticles conjugated to the angiogenesis inhibitor fumagillin have been 
shown to reduce angiogenesis in atherosclerotic rabbits.29 However, currently ap-
plied therapies do not necessarily target atherosclerosis directly.  Statins for instance 
are widely used as therapy for atherosclerosis and they exhibit pleiotropic effects. 
The clinical benefits of statin therapy were originally attributed to its lipid-lowering 
effects, however, a decade ago it was found that statins possess anti-inflammatory 
and anti-oxidant properties, decrease the propensity for thrombosis, reduce SMC 
proliferation and inhibit angiogenesis.30 
Atherosclerosis Prevention or Regression? 
Besides identifying and selecting mediators to target atherosclerosis, it is important 
to consider whether therapy should be aimed at the prevention or regression of the 
disease. In the present thesis, intervention studies in mice were performed in both 
early and delayed treatment settings to investigate whether treatment would pre-
vent the development of atherosclerotic lesions or reduce the extent of pre-existing 
lesions, respectively. 
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 Because chemokines and adhesion molecules play a large role in early athero-
genesis, inhibition of MCP-1 and VLA-1 would be expected to prevent lesion devel-
opment. Microarray results revealed that MCP-1 is expressed throughout athero-
genesis and inhibiting this chemokine reduced the size of initial and advanced le-
sions as well as induced a stable phenotype with both early and delayed treatment. 
This suggests that therapy against MCP-1 may be applied to prevent and regress 
atherosclerotic lesions. 
 Although complete genetic deletion of VLA-1 attenuated atherosclerosis at all 
stages, antibody inhibition was only able to induce a stable plaque phenotype. 
However, inhibition of VLA-1 did reduce the macrophage content of initial lesions, 
which is important given that VLA-1 is involved in the migration of macrophages 
through the subendothelial basement membrane. This suggests that VLA-1 may 
serve as a therapeutic target in atherosclerosis prevention. 
 With respect to angiogenesis, it is generally considered to occur in advanced 
stages of atherosclerosis, however, some studies revealed that neovascularization is 
also associated with early lesions.31,32 Neovascularization was shown in early carotid 
artery lesions of human subjects undergoing endarterectomy32 as well as in coro-
nary arteries of pigs within the first weeks of experimental hypercholesterolemia.31 
Using angiogenesis inhibitors, we found reduced lesion sizes with early treatment 
suggesting that anti-angiogenesis therapy may also be used against atherosclerotic 
lesion prevention. 
 Because TWEAK inhibition produced an unfavourable phenotype rich in 
macrophages and a reduced fibrotic content, it is unclear whether targeting this cy-
tokine should be aimed at atherosclerosis prevention or regression. The role of 
TWEAK in atherosclerosis would need to be further elucidated such as by determin-
ing the effects of TWEAK overexpression. 
 Of the treatments that had a positive effect on atherosclerosis (inhibition of 
MCP-1 and VLA-1; anginex and endostatin treatment), none prevented the devel-
opment of atherosclerotic lesions. At best, lesion sizes were reduced and acquired a 
more stable phenotype. It appears that atherogenesis is inevitable regardless of the 
treatment and that the aim of potential therapeutic strategies should be to prevent 
the progression of atherosclerosis and/or stabilize lesions. The only currently effec-
tive therapeutic strategy to prevent atherosclerosis appears to be non-
pharmacological intervention such as diet and exercise.33 Because atherosclerosis 
develops silently over a long period of time before it is clinically manifest, most 
treatment options focus on lesion regression, and some therapeutic strategies have 
shown promising results. For instance, because HDL is inversely associated with 
cardiovascular disease as it mediates reverse cholesterol transport, increasing HDL 
levels by manipulating its metabolism is gaining attention as potential therapy in 
atherosclerosis.34,35 Upon administration of ApoA-I, a major protein component of 
HDL, plaque resorption and significantly reduced atheromas were shown in animal 
models of atherosclerosis.36-38 Currently, clinical trials are being conducted to test the 
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therapeutic potential of ApoA-I peptide mimetics in the treatment of atherosclerosis 
patients.39 Statin therapy has also been shown to regress atherosclerotic lesions, 
which was attributed to its HDL-elevating properties.40 
Concluding Remarks 
While mouse models of atherosclerosis do not reflect the human condition in its 
entirety, they are invaluable tools in intervention studies in which regulators of 
atherosclerosis and potential therapies can be studied. In the present thesis we in-
vestigated the role of several mediators of atherosclerosis in mouse models. The 
chemokine MCP-1, known to play a central role in the recruitment of leukocytes to 
lesions, was found to be expressed throughout all stages of atherogenesis in ApoE-/- 
mice. Inhibiting this chemokine reduced atherosclerosis and stabilized lesions. Defi-
ciency of the integrin VLA-1, a novel mediator not previously linked to atheroscle-
rosis, attenuated lesions and induced a stable plaque phenotype. Antibody inhibi-
tion of VLA-1 produced similar results, particularly with respect to lesion stabiliza-
tion, confirming this integrin to be a potential therapeutic target. VLA-1 was further 
found to mediate the migration of monocyte-derived macrophages to lesions by 
adhesion to collagen IV, which is highly expressed in the subendothelial basement 
membrane. The process of angiogenesis, which is involved in the progression of 
atherosclerosis, was targeted by administration of angiogenesis inhibitors in ApoE-
/- mice and it was found that the size of initial atherosclerotic lesions was reduced. 
Inhibition of the multifunctional cytokine TWEAK, previously shown to be ex-
pressed in human atherosclerotic lesions, induced a macrophage-rich plaque pheno-
type and reduced fibrosis. 
 The mechanism of action of VLA-1 and TWEAK would need to be further elu-
cidated, as well as investigated in human atherosclerosis, however, our intervention 
studies in mice reveal that these mediators, along with MCP-1 and angiogenesis, 
play a role in atherosclerosis. As such, they may be considered potential therapeutic 
targets. Despite having an affect on the content of macrophages – the very cells that 
play a central role in atherosclerotic lesions – these targets are not specific to athero-
sclerosis. Therapeutic targeting of these mediators would have to be applied locally 
in lesions in order to prevent adverse side effects. On the other hand, the pleiotropic 
effects of statins suggest that drug efficacy in atherosclerosis may not be related to 
target and/or lesion specificity. 
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Summary 
Atherosclerosis continues to be the leading cause of illness and death in western 
society. It is a progressive inflammatory disease of the large and medium-sized ar-
teries in which lipids, cells, and extracellular matrix accumulate in the inner lining 
of the vessel wall leading to the formation of an atherosclerotic plaque. Plaque pro-
gression may cause arterial stenosis, however clinical complications such as myo-
cardial infarction or stroke mostly occur as a result of plaque rupture and subse-
quent thrombus formation. Although the exact triggers of plaque rupture and 
thrombosis are unknown, it is thought that the composition of an atherosclerotic 
plaque is important to its stability: the more stable, the less likely it is to disrupt. 
Stable plaques are generally considered to be fibrotic, have a low inflammatory in-
filtrate, and a small necrotic lipid core. 
 In this thesis, key players in atherosclerotic development and progression were 
identified and investigated in mouse models to gain further insight into the patho-
genesis of atherosclerosis as well as to determine their therapeutic potential in the 
stabilization of plaques. The primary hypothesis was that the various stages of 
atherogenesis in the ApoE-/- mouse model exhibit a unique expression pattern of 
genes. Once key regulators were identified, they were validated in ApoE-/- mice to 
determine their effects on atherosclerotic plaque composition and stability. 
 The various animal models used to study plaque stability or vulnerability are 
described in chapter 2. The definition of a vulnerable plaque prone to rupture and 
thrombus formation is highly disputed as the characteristic composition of such 
plaques is unclear. The current concepts and generally accepted features of vulner-
able plaques that are thought to contribute to clinical complications are described. 
Studies that have reported vulnerable plaque characteristics such as plaque rupture 
and thrombosis in animal models of atherosclerosis are summarized and evaluated 
based on their ability to represent the human condition. Although animal models 
are invaluable in elucidating the mechanisms of atherogenesis, their use in studying 
vulnerable plaques remains limited as there is currently no standard animal model 
of plaque rupture. 
 In chapter 3, the gene expression profile of the various stages of atherosclerosis 
in ApoE-/- mice as determined by microarray analysis is described. The gene ex-
pression profile during plaque progression revealed upregulation of genes involved 
in inflammation, such as the small inducible cytokines MCP-1 and MCP-5, as well 
as genes involved in matrix degradation. MCP-1 in particular is a well-known 
chemokine that mediates the migration of monocytes to inflamed tissue and is 
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known to promote atherosclerotic plaque progression. The role of MCP-1 and MCP-
5 was validated using a novel monoclonal antibody against these cytokines, which 
was found to attenuate atherogenesis and induce plaque stability in ApoE-/- mice. 
More specifically, antibody treatment resulted in smaller atherosclerotic plaques 
with a reduced macrophage and T cell content, and increased fibrosis as character-
ized by a reduced collagen and SMC content. Given the positive effects of blocking 
MCP-1 on atherosclerotic lesion development and progression, this chemokine may 
be a potential therapeutic target in the treatment of atherosclerosis.  
 Angiogenesis has been implicated in the development and progression of 
atherosclerotic plaques and is thought to contribute to their destabilization. In chap-
ter 4, preliminary studies are described in which the role of angiogenesis was inves-
tigated in atherogenesis using a collar-induced model of atherosclerosis in ApoE-/- 
mice. Mice were treated with the angiogenesis inhibitors anginex or endostatin, 
both of which were found to reduce the development of initial atherosclerotic le-
sions, whereas no effects were found on advanced lesions. Histological analysis re-
vealed that plaque phenotype was not affected by anginex or endostatin treatment, 
and neovascularization was not observed in lesions. Treatment with anginex or en-
dostatin appears to reduce early, but not advanced lesions in collar-induced athero-
sclerotic plaques of ApoE-/- mice, partly via an angiogenesis-independent manner. 
 Among the factors involved in atherosclerotic plaque stability, adhesive interac-
tions between cells and extracellular matrix components play an important role. 
Chapter 5 focuses on the collagen-binding integrin α1β1 or VLA-1, which was either 
genetically deleted or inhibited using an α1-blocking antibody in ApoE-/- mice. 
Mice deficient in this integrin in particular, as well as those receiving antibody 
treatment exhibited stable plaques characterized by an increased collagen content 
and a reduced macrophage infiltrate. Further investigation revealed that VLA-1 
integrin is expressed on macrophages and binds to collagen IV - a type of collagen 
abundantly expressed in the basement membrane of the vessel wall through which 
leukocytes must migrate to enter atherosclerotic plaques. Macrophages deficient in 
α1 integrin are inhibited from migrating on collagen IV substrata, which suggests 
that this integrin mediates the migration of macrophages to lesions. This study indi-
cates a role for VLA-1 in atherosclerosis and inhibiting this integrin may be consid-
ered an approach in the treatment of atherosclerosis. 
 Investigation of the role of a recently discovered cytokine, TWEAK, in athero-
sclerosis is described in chapter 6. TWEAK is a multifunctional cytokine that medi-
ates various processes important  atherosclerosis such as cell proliferation, migra-
tion, apoptosis, and neovascularization, and has recently been identified along with 
its receptor, Fn14, in atherosclerotic plaques. Treatment of ApoE-/- mice with a 
TWEAK-blocking fusion protein, Fn14:Fc, resulted in a macrophage-rich advanced 
plaque phenotype and reduced fibrosis. In addition, macrophages treated with re-
agents that block TWEAK/Fn14 interactions were found to take up less modified 
in
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lipids. These data suggest that TWEAK plays a role in atherosclerosis that may in-
volve lipid metabolism in macrophages. 
 In chapter 7, the findings of this thesis are discussed. Because atherosclerosis is a 
complex, multifactorial disease, the various processes and regulators that may po-
tentially be targeted in the treatment of atherosclerosis are considered. Macrophage 
content in particular is often affected in atherosclerotic plaques by intervention 
studies whether they target chemokines, cytokines, or adhesion molecules. The me-
diators investigated in this thesis are evaluated based on their potential as therapeu-
tic targets. Based on the findings in this thesis, we conclude that MCP-1 is the most 
promising therapeutic target as its role has been well-documented in the field of 
atherosclerosis, and blocking this chemokine as reported in the present thesis re-
sulted in a stable plaque phenotype. Given that a deficiency in or blocking of VLA-1 
also resulted in a more stable plaque phenotype, this integrin may be considered a 
potential target, however, the mechanism of action of this integrin in atherosclerosis 
would need to be further elucidated. Although the role of TWEAK and the process 
of angiogenesis in atherosclerosis are as yet unclear, the findings in this thesis sug-
gest a role for these mediators in atherosclerosis that warrants further investigation. 
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Samenvatting 
Atherosclerose is de belangrijkste doodsoorzaak in de westerse samenleving. Het is 
een progressieve inflammatoire ziekte van de grote slagaders waarbij lipiden, cellen 
en extracellulaire matrix in de vaatwand ophopen en uiteindelijk leidt tot de vor-
ming van een atherosclerotische plaque. De progressie van een plaque kan stenose 
van het vat veroorzaken, echter clinische complicaties zoals hart- en herseninfarcten 
onstaan meestal door het openscheuren van een plaque (plaque ruptuur) en de 
hierop volgende vorming van een bloedstolsel (thrombose). Alhoewel de precieze 
aanleiding voor de ruptuur van een plaque niet bekend is, denkt men dat de samen-
stelling van een atherosclerotische plaque een belangrijke factor is in het wel of niet 
ruptureren van een plaque. Over het algemeen wordt aangenomen dat een plaque 
die weinig kans heeft op ruptuur (ook wel genoemd een stabiele plaque) een dikke 
overliggende bindweefsel laag heeft, een kleine kern van weefsel-debris (necroti-
sche kern) en weinig ontsteking. Een plaque die een hoog risico heeft op ruptureren 
heeft een dunne overliggende bindweefsellaag, veel ontsteking en een grote necroti-
sche kern. 
 In dit proefschrift zijn een aantal belangrijke regulerende processen in de ont-
wikkeling en progressie van atherosclerotische plaques nader onderzocht in mui-
zenmodellen. Dit is gedaan om meer inzicht te krijgen in de mechanismen die ten 
grondslag liggen aan ontstaan en ontwikkeling van atherosclerotische plaques. Ook 
is gekeken of door het ingrijpen in deze regulerende processen een mogelijke be-
handeling bewerkstelligd kon worden. Nadat de belangrijkste regulerende proces-
sen waren vastgesteld, is in een serie experimenten onderzocht in hoeverre door in 
te grijpen in deze processen de samenstelling van atherosclerotische plaques of te 
wel de plaque stabiliteit beinvloed kon worden. 
 De verschillende muizenmodellen die gebruikt worden voor het bestuderen 
van plaque stabiliteit zijn in hoofdstuk 2 beschreven. De definitie van een ruptuur-
gevoelige oftewel instabiele plaque met hoge kans tot ruptuur en thrombusvorming 
is onderwerp van discussie, omdat de precieze samenstelling en eigenschappen van 
deze plaques niet bekend zijn. De huidige gedachten en in het algemeen geaccep-
teerde kenmerken van een instabiele plaque waarvan men denkt dat die leiden tot 
clinische complicaties zoals hart en herseninfarcten worden beschreven. Ook wor-
den studies waarin melding werd gemaakt van plaque ruptuur en thrombose in 
muizenmodellen voor atherosclerose samengevat en geëvalueerd op hun bruik-
baarheid als voorspeller voor de humane situatie. Alhoewel dierenmodellen van 
onschatbare waarde zijn voor het onderzoeken van de onderliggende mechanismen 
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van atherosclerose, is de toepasbaarheid voor het bestuderen van instabiele plaques 
beperkt, omdat er op dit moment geen gestandaardiseerd diermodel van instabiele 
plaques bestaat. 
 In hoofdstuk 3, werd tijdens de verschillende stadia van atherosclerose verande-
ringen in gen-expressie van de atherosclerotische vaten van Apolipoprotein E 
knockout muizen (ApoE-/-) bepaald. Dit profiel werd bepaald door het gebruik van 
microarray. Veranderingen in het genexpressieprofiel tijdens plaque progressie liet 
zin dat genen die te maken hebben met inflammatie verhoogd tot expressie kwa-
men. Opvallend hierin waren de bepaalde ontstekingsmediatoren (“small inducible 
cytokines” MCP-1 en MCP-5), en ook genen betrokken bij afbraak van het bind-
weefsel (de extracellulaire matrix). Met name het bekende chemokine MCP-1 is een 
regulator in het proces van transport van bepaalde ontstekingscellen (monocyten) 
naar ontstoken weefsels en dit zou zo de ontwikkeling van atherosclerotische pla-
ques kunnen bevorderen. De rol van MCP-1 en MCP-5 in de ontwikkeling van pla-
ques in een muizenmodel is bevestigd door gebruik van een antilichaam tegen 
MCP-1/5. Dit antilichaan blokkeert de werking van MCP-1/5. In het muizenmodel 
verminderde het antilichaam de ontwikkeling en progressie van plaques en zorgde 
voor stabielere plaques met minder ontstekingscellen en meer bindweefsel. Gezien 
de positieve aspecten van het blokkeren van MCP-1, is deze chemokine een potenti-
eel therapie-doel in de behandeling van atherosclerose. 
 Angiogenese is het proces waarbij nieuwe, kleine bloedvaten worden gevormd, 
die groeiend/actief weefsel voorzien van zuurstof en voedingsstoffen. Angiogenese 
wordt gezien als en mogelijk bijdrage aan de ontwikkeling and progressie van 
atherosclerotische plaques en men denkt dat het bijdraagt aan het minder stabiel 
worden van de plaque. In hoofdstuk 4, werden preliminaire studies beschreven naar 
de rol van angiogenese in atherosclerose. Met gebruik van ApoE-/- muizen werd de 
ontwikkeling van atherosclerotische plaques versneld door een plastic buisje (collar) 
om beide carotiden te plaatsen. De muizen werden vervolgens behandeld met 2 
angiogeneseremmers (anginex en endostatin). Beide remmers bleken de ontwikke-
ling van vroege plaques te verminderen, maar er waren geen effecten te zien als de 
behandeling werd gestart als vergevorderde plaques zich al gevormd hadden. His-
tologische analyse toonde aan dat het samenstelling van de plaque (qua ontsteking 
en bindweefsel) niet was veranderd door behandeling met anginex of endostatin. 
Ook kon er geen vorming van nieuwe bloedvaatjes in de plaque aangetoond wor-
den. Behandeling met anginex of endostatin in collar-geïnduceerde ApoE-/- muizen 
blijkt vroege plaques te reduceren in grootte, maar heeft geen effect op vergevor-
derde plaques. Dit lijkt te gebeuren op een wijze die onafhankelijk is van angioge-
nese. 
 Een van de relevante factoren voor de stabiliteit van atherosclerotiche plaques is 
de adhesie tussen cellen en componenten van de extracellulaire matrix. Integrines 
zijn structuren op cellen die ervoor zorgen dat cellen in weefsels verbinding met 
elkaar houden. Hoofdstuk 5 richt zich op integrine α1β1 (ook bekend als VLA-1) dat 
Samenvatting 
 
 
127
zich bindt aan collageen. Dit integrine werd genetisch uitgeschakeld dan wel ge-
remd door het toedienen van een α1-blokkerende antilichaam in ApoE-/- muizen. 
Zowel in muizen die deficient waren voor dit integrine als in muizen die behandeld 
waren met het antilichaam werden stabielere plaques aangetoond met een ver-
hoogde hoeveelheid collageen (bindweefsel) en verminderd aantal macrofagen. 
Verder werd aangetoond dat VLA-1 aanwezig is op macrofagen en zich bindt aan 
collageen IV. Collageen IV is een belangrijke bestanddeel van de vaatwand en een 
barriere die monocyten moeten overbruggen om atherosclerotische plaques binnen 
te kunnen komen. Macrofagen die deficient zijn voor α1-integrin kunnen zich niet 
voortbewegen op een ondergrond van collageen IV, wat suggereert dat dit integrine 
een rol speelt in de voortbeweging van macrofagen in en naar plaques. Deze studie 
laat zien dat VLA-1 een rol speelt in atherosclerose en de inhibitie ervan zou een 
strategie kunnen zijn om atherosclerose te behandelen. 
 De rol van het recent ontdekte ontstekingsmediator of cytokine TWEAK in 
atherosclerose is beschreven in hoofdstuk 6. TWEAK is een multifunctioneel cytokine 
die een rol speelt in meerdere processen die belangrijk zijn in atherosclerose, zoals 
celdeling,voortbeweging van cellen, celdood en het vormen van nieuwe vaatjes. 
Bovendien werd TWEAK en zijn receptor Fn14 onlangs aangetoond in menselijke 
atherosclerotische plaques. Behandeling van ApoE-/- muizen met een eiwit dat 
TWEAK remt (Fn14:Fc) resulteerde in vergevorderde plaques die rijk waren aan 
macrofagen en weinig bindweefsel hadden. Verder was er minder vet opgenomen 
door macrofagen die behandeld waren met stoffen die de interactie tussen TWEAK 
en Fn14 blokkeren. Deze data suggereren dat de manier waarop TWEAK een rol 
speelt in atherosclerose te maken heeft met het vet metabolisme in macrofagen. 
 De bevindingen in dit proefschrift werden in hoofdstuk 7 bediscussiëerd. Omdat 
atherosclerose een complexe ziekte is, zijn de verschillende processen en regulato-
ren overwogen die mogelijk een aangrijpingspunt kunnen zijn in het behandelen 
van atherosclerose. De hoeveelheid macrofagen in atherosclerotische plaques kan 
beïnvloed worden door in te grijpen in processen waarbij ontstekingsmediatoren en 
matrix-cel interacties betrokken zijn. De mediatoren bestudeerd in dit proefschrift 
werden geëvalueerd op basis van hun mogelijke therapeutische waarde. Gebaseerd 
op de bevindingen in dit proefschrift, concluderen we dat MCP-1 het meest veelbe-
lovende aangrijpingspunt is, omdat de rol van deze chemokine goed bekend is in 
atherosclerose, en blokkeren ervan zoals beschreven in dit proefschrift resulteerde 
in stabielere plaques. VLA-1 kan ook een mogelijk aangrijp ngspunt zijn in het be-
handelen van atherosclerose, omdat een deficiëntie of het blokkeren van deze inte-
grine tot stabielere plaques leidde, hoewel het mechanisme van dit proces in 
atherosclerose verder onderzocht moet worden. Alhoewel zowel de rol van TWEAK 
als het proces van angiogenese in atherosclerose tot nu toe nog niet duidelijk zijn, 
suggereren de bevindingen in dit proefschrift een rol voor deze mediatoren in 
atherosclerose. 
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Full colour figures 
A B
C D
Figure 1. Human atherosclerotic lesions with intraplaque hemorrhage or non‐occlusive luminal 
thrombus.  (A) Hematoxylin  and  eosin  (HE)‐stained  section of  a  carotid  artery  atherosclerotic 
plaque with intraplaque hemorrhage. (B) Martius, scarlet and blue (MSB)‐stained section of the 
same plaque as  in A, with  fibrin deposition shown  in red.  (C) HE‐stained section of a carotid 
artery atherosclerotic plaque associated with a nonocclusive luminal thrombus. (D) MSB‐stained 
section  of  the  same  plaque  as  in C  showing  fibrin  deposits  in  red  and  components  of  fresh
thrombus (erythrocytes) shown in yellow.               
Full colour figures 
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Figure 2. Mouse atherosclerotic lesion with intraplaque hemorrhage. (A) HE-stained section of 
an aortic arch atherosclerotic plaque with intraplaque hemorrhage. (B) MSB-stained section of 
the same plaque as in A showing fibrin deposition in red. 
A B
Figure 1. HE-stained sections of aortic arches (arch) of ApoE-/- mice including the brachio-
cephalic artery (BCA), right common carotid artery (RCA), left common carotid artery (LCA),
and left subclavian artery (LSA). * Per 103 μm2 
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Figure 2. Microarray expression levels of members of the two most abundant clusters: the small
inducible cytokines (A) and the cathepsins (B). 
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Figure 3. Validation experiments. (A) Quantitative PCR and (B) ELISA show that both RNA 
and protein levels of several members of the small inducible cytokine family (MCP-1, MCP-5, 
MIP-1α, and MIP-1β) increase with disease progression. Immunohistochemistry for (C) MCP-1, 
(D) MCP-5 and (E) MIP-1α show that these proteins are predominantly expressed in macro-
phages of advanced atherosclerotic lesions (magnification 400X). 
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Figure 6. The relative amount 
of Mac3+ macrophages (200X) 
is decreased after (A) 11K2 
treatment compared with (B)
control treatment. CD45 stain-
ing (400X) of advanced athero-
sclerotic lesions (shoulder re-
gion) revealed that (C) 11K2 
treatment decreased the per-
centage of CD45+ leukocytes 
(indicated by arrows) com-
pared with (D) control treat-
ment. Sirius Red (SR) staining 
(100X) of advanced atheroscle-
rotic plaques revealed an in-
crease in collagen content after 
(E) 11K2 treatment compared 
with (F) control treatment. 
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Figure 1. Reduced plaque area with early anginex or endostatin treatment. (A) Plaques of anginex 
or endostatin‐treated mice of the early treatment group were smaller compared with controls. (B)
No difference  in plaque area between anginex or endostatin treatment compared with controls. 
*P<0.05. Images are representative of carotid artery plaques of the early treatment group. 
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Figure 2. No change in plaque composition with anginex or endostatin treatment. There was 
no change in macrophage content (mφ) or collagen content (SR, indicating Sirius Red stain-
ing) in either of the (A) early or (B) delayed treatment groups compared with controls. 
Full colour figures 
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Figure 4. CD31 immunostaining of a carotid artery atherosclerotic
plaque reveals positively stained luminal ECs. 
 
Figure 1. Fluorescence immunohistochemical staining showing expression of (A) α1 integrin 
(Alexa488-labeled anti-α1 Ab, green, indicated by arrow) in (B) macrophages (PE-CD11b, red, 
indicated by arrow) in an advanced atherosclerotic plaque in the aortic arch of an ApoE-/- mouse. 
(C) Hematoxylin counterstaining of the same plaque showing macrophages (indicated by ar-
rows). 
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Figure 2. Deficiency in α1 integrin reduced plaque area in aortic arches. (A) Total plaque 
area of α1-/- and α1+/- mice was significantly smaller than those of α1+/+ mice. (B) Average 
area of individual advanced plaques of α1-/- mice was smaller compared with those of 
α1+/+ mice. (C) HE-stained sections of representative advanced atherosclerotic plaques of 
α1-/-, α1+/- and α1+/+ mice showing relative area of plaques. *P<0.05. 
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Figure 3. Plaque composition of initial and advanced atherosclerotic plaques in aortic arches
of α1-deficient mice. There were significantly less (A) macrophages (Mac3+, red stained cells) 
and (B) CD3+ cells (arrows) in advanced plaques of α1-/- compared with α1+/+ mice. There 
was a significantly higher (C) collagen content (SR+) and (D) SMC content (αSMA+ cells, 
arrows) in advanced plaques of α1-/- compared with α1+/+ mice. (E) Lipid cores were smaller 
in plaques of α1-/- compared with α1+/+ mice (arrows). *P<0.05. 
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Figure 4. Cartilaginous metaplasia in 
advanced plaques in aortic arches of α1-
deficient mice. (A) Collagen II is ex-
pressed in matrix (indicated by arrows) 
surrounding chondrocyte-like cells. (B) 
Alcian blue and (C) toluidine blue stain-
ings show chondrocyte-like cells and 
chondroid matrix (indicated by arrows) in 
advanced atherosclerotic plaques of α1-/- 
mice. *P<0.05. 
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Figure 5. Expression of mediators 
of  bone  formation  in  atheroscle‐
rotic plaques  in  the aortic arch of 
 1‐deficient  mice.  (A-C)  Strong 
expression of OC, ON and BMP‐4 
in  chondrocyte‐like  cells  (indi‐
cated by arrows). Weaker expres‐
sion of (D) BMP‐2 and (E) OPN in 
chondrocyte‐like  cells  (indicated 
by  arrows).  (F)  MGP  only  ex‐
pressed  in  macrophages  (indi‐
cated  by  arrow).  Magnification: 
400X. 
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Figure 7. Anti-α1 antibody infiltrated atherosclerotic plaques of ApoE-/- mice. (A) Fluorescence 
and bright field images of atherosclerotic plaques in the aortic arch of ApoE-/- mice injected with 
Alexa488-labeled anti-α1 antibody or not injected with any antibody (control). Antibody appears 
as green spots in the plaque and autofluorescence of elastic laminae in the media are shown in
green. (B) TPLSM 3D image of an atherosclerotic plaque in the carotid artery of an ApoE-/-
mouse injected with Alexa488-labeled anti-α1 antibody. Antibody appears as green spots and 
collagen fibers in the plaque and media are shown in blue. 
Alexa488-anti-α1 Ab
A
Control
B
Alexa488-anti-α1 Ab
Control
Full colour figures 
 
 
140  
Figure 8. Plaque composition of initial and advanced atherosclerotic plaques in aortic arches of
antibody-treated mice. There were significantly less (A) macrophages (Mac3+, red stained cells) 
and (B) CD3+ cells (brown stained cells, arrows) and a higher (C) collagen content (SR+ areas 
shown in red) in plaques of anti-α1 antibody-treated compared with control mice (Lu indicates 
lumen). *P<0.05. 
0
10
20
30
40
50
60
%
0
10
20
30
40
50
60
70
80
90
%
Mac3 Mac3
Anti-α1 Ab Control Ab
CD3
SR SR
CD3
A
B
C
*
Initial Advanced
Anti-α1 Ab
Control Ab
Lu
Initial Advanced
Early Treatment Delayed Treatment
*
0
0.1
0.2
0.3
0.4
%
Initial Advanced Initial Advanced
Early Treatment Delayed Treatment
Anti-α1 Ab
Control Ab
Initial Advanced Initial Advanced
Early Treatment  Treatment
Anti-α1 Ab
Control Ab
*
*
*
Figure 10. Collagen IV expression in mouse and human atherosclerotic plaques. (A) Advanced 
atherosclerotic plaque in a human carotid artery expressing collagen IV in the region of endothe-
lial cells (indicated by arrow, magnification 10X) and (B) shown at higher magnification (40X). (C)
Advanced atherosclerotic plaque in a mouse aortic arch showing collagen IV expression in the
region of endothelial cells and somewhat surrounding cells within the plaque (indicated by arrow,
magnification 40X). 
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Figure 1. Smaller advanced plaques with early 
Fn14:Fc treatment and fewer advanced plaques with 
delayed treatment. (A) Early Fn14:Fc treatment re-
sulted in smaller plaque areas compared with control 
mice. (B) Delayed Fn14:Fc treatment resulted in more 
initial plaques and fewer advanced plaques. *P<0.05. 
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Figure 2. Plaque composition of initial and advanced atherosclerotic plaques. Fibrotic content
of atherosclerotic plaques was significantly lower with Fn14:Fc treatment due to (A) a re-
duced αSMA content in initial and advanced plaques of mice that received delayed Fn14:Fc
treatment and (B) a reduced collagen content as shown by SR staining in advanced plaques
following both early and delayed Fn14:Fc treatment compared with controls. (C) Macrophage 
content as shown by Mac3 immunohistochemical staining increased in advanced plaques of 
Fn14:Fc-treated mice compared with controls. (D) Lipid core content (indicated by arrow) as 
shown by HE staining in advanced plaques did not differ between Fn14:Fc-treated mice and 
controls in the delayed treatment group. *P<0.05.
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Figure 4. Fn14 is expressed on bone marrow-derived macrophages and foam cells as detected 
by immunohistochemistry using anti-Fn14 Ab. Fn14 was expressed on (A) macrophages and (B)
foam cells treated with oxLDL for 48 hours. Nuclei were counterstained with DAPI.  Control
cells were stained with Ig isotype Ab. 
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